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Abstract

Epilepsy is a common chronic neurological disorder accompanied by cognitive
impairment. Available antiepileptic drugs (AEDs) have not been reported to have
ameliorative effects on epilepsy-associated memory impairment. The potential of
histamine H3 receptors (H3R) in several neuropsychiatric diseases, including epilepsy
and Alzheimer’s disease, is well recognized. In this study, a series of H3R antagonists
(1-16) were screened for their in vivo anticonvulsant effect in several acute-induced
seizures in rats. Moreover, the procognitive effect of the most promising H3R
antagonist was investigated in dizocilpine (DIZ)-induced amnesic effect applying
several behavioral memory tests. Furthermore, the most promising H3R antagonist
was assessed for its simultaneous anticonvulsant and procognitive effect and its
modulatory effect on levels of oxidative stress markers, several hippocampal
neurotransmitters, and c-fos protein expression in PTZ model. Finally, the promising
H3R antagonist was examined for its anticonvulsant effect in PLC-induced SE and its
ability to mitigate SE incidence.
The Observed results indicated that H3R antagonist 4 (10 mg/kg i.p.) significantly
exhibited high protection in maximum electroshock

(MES)-induced seizures

facilitated through histaminergic neurotransmission and activation of post-synaptically
located H1R and full protection in the PTZ-acute induced seizures, . Moreover, H3R
antagonist 4 (5 mg/kg i.p.) showed a procognitive effect that was abrogated with RAM
co-injection in all behavioral memory tests. Additionally, treatment with H3R
antagonist 4 showed a simultaneous anticonvulsant and procognitive effect in addition
to antioxidant effect in PTZ- acute and -chronic models. Furthermore, chronic
treatment with H3R antagonist 4 (5 mg/kg i.p.) modified histamine, acetylcholine, and
glutamate release, and reduced hippocampal c-fos activation. In addition, RAM
administration reversed the protective effects provided by H3R antagonist 4 in PTZchronic model. Moreover, and in PLC-induced SE, systemic administration of H3R
antagonist 4 (10 mg/kg i.p.) mitigated severity of SE and exhibited antioxidant effect
in the hippocampus of the treated rats, facilitated through the histaminergic
neurotransmission. The observed findings recommend that the newly developed H3R
antagonist 4 provides antiepileptic, memory-enhancing, and antioxidant properties in

viii
a PTZ-induced kindling model of epilepsy and provides neuroprotection in a
preclinical PLC-induced SE in rats, highlighting the histaminergic system as a
potential therapeutic target for the management of epilepsy with accompanied memory
deficits.
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H3
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Pentylenetetrazol, Pilocarpine, Oxidative stress, c-fos, Memory impairment, Status
epilepticus.
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)Title and Abstract (in Arabic

دراسة الفعالية المضادة للصرع والمحسنة للذاكرة لعدد من مثبطات مستقبالت
الهستامين H3-المستخلقة حديثًا في نماذج فئران بحثية مختلفة
الملخص

مرض الصرع هو مرض عصبي مزمن شاثع يصاحبه ضعف اإلدراك .لم يتم اإلبالغ عن العقاقير
المتاحة المضادة للصرع ليكون لها آثار تحسين على ضعف الذاكرة المرتبطة بالصرع .إن إمكانية
استخدام مستقبالت الهستامين ( (H3Rفي العديد من األمراض العصبية والنفسية  ،بما في ذلك
مرضي الصرع والزهايمر  ،معروفة جيدًا .في هذه الدراسة تم فحص التأثير المضاد للتشنج لعدد
من المركبات الجديدة من مثبطات مستقبالت الهيستامين (H3R (3باستخدام نماذج بحثية مختلفة
للصرع .عالوة على ذلك  ،تم التحقق من التأثير المقوي للذاكرة لمثبط مستقبالت الهستامين األكثر
فعالية في فقدان الذاكرة الناتج عن استخدام  DIZمن خالل تطبيق اختبارات الذاكرة السلوكية.
إضافة إلى ذلك ،تم التحقيق من تأثيره المضاد للتشنج والمقوي للذاكرة في وقت واحد باإلضافة
إلى تأثيره المضاد لألكسدة في النماذج الحادة والمزمنة من  PTZو نموذج  PLCالذي يسبب الحالة
الصرعية  .SEأيضا ،تم تقييم تأثير المركب في الحصين على مستويات الناقالت العصبية وعلى
مستوى  c-fosمن خالل تقنية اللمعان المناعي في نموذج .PTZ

أظهرت النتائج أن بعض المركبات كانت فعالة في تخفيف نوبات الصرع الناتجة عن الصدمات
الكهربائية  ،MESو فعالة أيضا في الحماية من نوبات الصرع الناتجة عن استخدام ) (PTZمثل
مثبط مستقبالت الهيستامين H3و رقمه  ،4وقد تم إبطال هذا المفعول باستخدام منشط مستقبالت
الهيستامين  (RAM) H3وهذا فقط في نموذج نوبات الصرع الناتجة عن الصدمات الكهربائية.
عالوة على ذلك  ،أظهر مثبط مستقبالت الهيستامين  H3رقم  10( 4ملغ /كغ) تأثيرًا مقوي للذاكرة
تم إلغاؤه باستخدام حقن  RAMالمشترك في جميع اختبارات الذاكرة السلوكية .باإلضافة إلى ذلك
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 ،أظهر مثبط مستقبالت الهيستامين  H3رقم  4تأثيرًا مضادًا للتشنج و لفقدان الذاكرة في وقت
واحد وتأثيرًا مضادًا لألكسدة في نماذج  -PTZالحادة والمزمنة .من ناحية أخرى ،فإن العالج
المزمن بمثبط مستقبالت الهيستامين  3رقم  4قد عدل تحرير الهيستامين واألستيل كولين
والغلوتامات  ،وقلل من تنشيط  c-fosفي الحصين .وأدى حقن  RAMإلى عكس اآلثار الوقائية التي
يوفرها مثبط  H3Rرقم  5( 4ملغ  /كغ ) في نموذج  PTZالمزمن .إلى جانب ذلك  ،فإن العالج
المضاد ل  H3Rالحاد ( 10ملغ /كغ) قد خفّض الحالة الصرعية  SEالتي يسببها  PLCوأظهر تأثيراً
مضاداً لألكسدة في الحصين ،وأدى استخدام  RAMإلى عكس التأثير الوقائي.

توصي نتائجنا بأن مضادات  H3Rالمشيدة حديثًا قادرة على توفير خصائص مضادة للصرع ،
معززة للذاكرة  ،ومضادة لألكسدة في نموذج تأجيج الصرع الناجم عن  PTZوتوفر الحماية
العصبية في فئران الحالة العصبية التي يسببها  PLCفي الفئران  ،مما يسلط الضوء على نظام
الهيستامين كعالج محتمل لإلدارة العالجية للصرع.
مفاهيم البحث الرئيسية :الصرع  ،نماذج الفئران  ،مثبطات مستقبالت الهستامين  ، H3ضعف
الذاكرة  ،االلتهاب العصبي  ،اإلجهاد التأكسدي  ،الحصين.
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Chapter 1: Introduction
1.1 Epilepsy
1.1.1 Epilepsy Definition
Epilepsy is considered one of the most common neurologic diseases, affecting around
65 million people worldwide1, and it is a complicated cluster of neurological disorders,
characterized mainly by chronic persistent and unprovoked interruptions of the normal
brain function, known as epileptic seizures. An epileptic seizure is the momentary
incidence of signs caused by abnormal excessive or synchronous neuronal activity in
the brain2. Epilepsy affects around 5-8 per 1000 inhabitants in high-income countries3,
whereas the prevalence is 10 per 1000 in low-income countries, and an even higher
percentage has been documented in rural areas4. Epilepsy is not a singular disorder
existence but a group of disorders manifesting underlying brain dysfunction that might
result from various triggers.
The conceptual description of epilepsy, as proposed by the International League
Against Epilepsy (ILAE) in 2005, is defined as a brain disorder characterized by an
enduring predisposition to generate epileptic seizures, which necessitates at least two
unprovoked seizures >24 h apart2. However, in 2014 ILAE formulated a practical
definition with the addition of time limitation, which is more useful in both diagnosis
and treatment of epilepsy. Epilepsy is a brain disorder that meets any of the following
conditions that include experience a minimum of two unprovoked seizures taking
place >24 h apart, experience of one unprovoked seizure with probability of
experiencing additional seizures comparable to general recurrence risk (at least 60%)
after two unprovoked seizures, and taking place over the next ten years, and diagnosis
of the epilepsy syndrome5. Furthermore, patients are considered to be free of epilepsy

2
if they have not experienced any seizures during the last ten years with no antiepileptic
drugs (AEDs) administered over the last five years, or for age-dependent patients that
have now passed applicable epilepsy.
1.1.2 Epilepsy Classification
ILAE Commission on classification and terminology in 2010 has revised the attempts
previously proposed for the classification of epileptic seizures in 1981 and 19896-8.
ILAE identified two types of epileptic seizures, namely generalized and focal seizure.
Accordingly, generalized epileptic seizures are seizures originating from large parts of
the cortex in both hemispheres (not necessarily the entire cortex), which can involve
cortical and subcortical structures. These seizures include several subtypes, e.g.
absence, generalized tonic-clonic (GTC), myoclonic, and atonic seizures. On the other
hand, focal (partial) epileptic seizures originate from a small specific part of the cortex
in one hemisphere8.
Another ILAE classification of epilepsy is based according to the underlying cause,
which are as follows:
1) Genetic: genetic defect(s), where seizures are the main symptom of the disease
examples: childhood absence epilepsy and Dravet syndrome,
2) Structural/metabolic: structural or metabolic condition or disease which has been
demonstrated to be associated with an increased risk of developing epilepsy in
appropriately designed studies. Examples: trauma, stroke, and some infections, and
3) Unknown: nature of the underlying cause is yet not known9.
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1.1.3 Pathophysiology of Epilepsy
An epileptic seizure is due to temporary irregular synchronization of brain neurons
that interrupts the usual patterns of neuronal interaction and leads to waning electrical
discharges in the Electroencephalogram (EEG), which causes several signs depending
on the site of seizure’s origin. Within the seizure origin, convulsions are frequently
believed to originate from an imbalance between excitation and inhibition either by
increased excitation or decreased inhibition10,11. The interconnectivity among neuronal
networks permits for harmonization of various missions and behaviors may be the
cause for the wide broad range of comorbidities associated with epilepsy, including
depression, learning disabilities, and autistic features12. Several mechanisms can result
in neuronal excitation; neurotransmitters can be released from synaptic vesicles and
go through the synaptic membrane into the synaptic cleft and immediately activate the
receptors located post-synaptically. In addition, extrasynaptic receptors can be
activated by neurotransmitters leaking directly into the extrasynaptic space. Moreover,
presynaptic neurotransmitters release can be regulated through presynaptic receptors.
On the other hand, inhibitory networks are positioned inside the similar or among
distinct brain regions and contain several cell types with complicated intrinsic
connections.
Under typical physiological environments, the networks are regulated by inhibitory
neurons, granting typical functions to arise, but if these neurons are further inhibited,
the network may become disinhibited, resulting in a seizure. Consequently,
multifactorial inter-neuronal connections among inhibitory or excitatory neurons may
cause a pathological neuronal hypersynchrony and seizures13-15. Also, and as
previously shown by Engel et al., an epileptic seizure is a multifactorial condition
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(Figure 1)16. The seizure threshold is increased by current AEDs, thus decreasing the
tendency of seizure to happen. Epileptogenic abnormalities can be genetic, structural,
or metabolic. Finally, the precipitating factors can contribute to the seizure initiation,
e.g., exposed to light in photosensitive epileptic patients. None of the previous factors
are static and can interchange from one time to another.
From all the above-mentioned indications, epilepsy is considered a condition with
persisting cerebral dysfunction that produces persistent epileptic convulsions without
the need for a direct stimulus to provoke each seizure17.

Figure 1: Multifactorial basis of epilepsy.
Multifactorial basis of epilepsy. (1) dashed line indicates seizure threshold. (2) represents epileptogenic
abnormalities (3) represents different transit factors (precipitating factors). The other panels illustrate how these
three factors interact. Modified from16.
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1.1.4 Antiepileptic Drugs (AEDs)
The precipitous rise in the understanding of neurotransmitters’ mode of action and
synaptic neurophysiology resulted in improvements in epilepsy treatment due to the
development of innovative AEDs. The gained knowledge permitted the development
of wisely targeted treatments to compete with traditional practical approaches. Earlier,
the long-standing clinically valuable anticonvulsant drugs, including phenobarbital
(PB), potassium bromide, and trimethadione were accidentally discovered by
investigating their anticonvulsant effect based on their sedative or hypnotic properties,
as it was known that sedation will result in damping effect of the neuronal activity18.
Afterward, by applying a wide range of animal models, several considerable AEDs
were clinically released into the market before the 1990s and were categorized as firstgeneration AEDs.
Phenobarbital (PB):
PB is one of the oldest AEDs. In 1912, PB was launched as a sedative drug, and then
its antiepileptic effects were accidentally discovered. PB exerts its antiepileptic effect
by enhancing the inhibitory neurotransmission -aminobutyric acid (GABA) through
binding to GABAA receptor19. PB is still widely used in status epilepticus (SE),
although it is effective against almost all types of seizures, excluding absence
seizures20.
Phenytoin (PHT):
PHT was discovered in 1983 by Merritt and Putnam applying electroshock- acute
seizure model in cats21. PHT showed higher efficiency and less sedating effect than
PB22, and it is still one of the most widely used drugs against generalized and partial
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seizures23. PHT was found to mainly block sodium channels, resulting in an inhibition
of neuronal depolarization 24.
Trimethadione (TMD):
TMD was identified in 1944 by Everett and Richard using acute pentylenetetrazol
(PTZ)-induced seizure model. TMD, unlike PHT, is effective against absence
seizures25. However, TMD is no longer used due to its high risk of adverse effects.
Ethosuximide (ETX):
ETX was discovered in 1958, and nowadays it is only indicated for treating typical
childhood absence epilepsy26. ETX was found to block T-calcium channels, resulting
in an inhibition of neuronal depolarization24.
Valproic Acid (VPA):
VPA was introduced to the market in 1960s27. It is one of the most widely used AEDs
around the world not only in epilepsy but also as s mood stabilizer drug, and it is
effective against all types of seizures19. VPA inhibits voltage-gated sodium channels
resulting in an inhibition of neuronal depolarization, increasing GABA
neurotransmission not through direct interaction with the GABA receptors, but
probably by improving glutamate decarboxylase or inhibiting GABA transaminase
enzyme. Also, VPA was found to alter dopaminergic and serotoninergic
transmissions24,27-29.
Benzodiazepines (BZs):
Leo Sternbach was the first to discover the BZs in the USA; however, the first
clinically launched BZ (chlordiazepoxide) was in the UK in 1960, and diazepam
(DZP) followed in 1963. After that, carbamazepine (CBZ) was introduced to the
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market in the 1970s in the USA, and it is effective against generalized seizures30. CBZ
was found to inhibit voltage-gated sodium channels resulting in an inhibition neuronal
depolarization. Moreover, BZs were revealed in their stimulating effects on GABAmediated inhibition by binding to the GABAA receptor binding site.
During the 1990s and the 21st century, additional AEDs were discovered and released
into the market. These AEDs were categorized as second-generation AEDs (new
AEDs). Second-generation AEDs have a broader therapeutic index, fewer side effects,
and fewer drug-drug interactions compared with the traditional first-generation AEDs.
Several new AEDs were, also, approved for epilepsy treatment, including topiramate,
levetiracetam,
oxcarbazepine,

vigabatrin,

lamotrigine,

zonisamide,

pregabalin,

felbamate,

gabapentin,

rufinamide,

and

tiagabine,

lacosamide31.

Eslicarbazepine, stiripentol, pregabalin, rufinamide, lacosamide, and perampanel were
only licensed for adjunctive use32.
Overall, the general mechanisms of the available AEDs are related to reducing
neuronal excitation and raising postsynaptic inhibition or modifying synchronization
of neural networks to reduce the superfluous neuronal excitability associated with
seizure development. Moreover, several AEDs inhibit the neuronal depolarization
through voltage‐dependent ion sodium and calcium channels blockade, e.g., PHT,
CBZ, oxcarbazepine, lamotrigine, topiramate, and VPA; or by enhancing potassium
channel function, e.g., retigabine24. Furthermore, the neuronal depolarization can be
blocked due to glutamate-induced inhibition of excitation, e.g., felbamate. Other AEDs
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work by stimulating GABA-mediated inhibition, e.g., vigabatrin, tiagabine, clobazam,
and PB24 (Figure 2).

Figure 2: Mechanisms of action of selected available AEDs.
NMDA: N-methyl-D-aspartate; AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid.

1.1.4.1 Memory deficits associated with clinical use of AEDs
Epilepsy is a chronic disorder with devastating neurological results on the patients,
necessitating long time therapy with AEDs. Currently available (AEDs) are not
capable of providing the sufficient. seizure control in almost one-third of the patients
and also do not stop the underlying epileptogenic alterations33. Moreover, the
consistent use of one or more AEDs will augment the epilepsy-associated
comorbidities, such as cognitive impairment34. It is stated that AEDs decrease neuronal
irritability; however, it also can damage neuronal excitability, neurotransmitter levels,
several genes, different enzymes, and factors that are required in memory and learning
processing35. It is well documented that apart from the cognitive impairment that
occurs in epileptic patients as epilepsy comorbidities, the traditional AEDs can
additionally produce cognitive disabilities36. Predictably, AEDs should advance
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patients' cognitive functions by regulating the number and severity of epileptic
activities as well as by enhancing the psychosocial environment that affords additional
benefit to cognition. However, it is noted that AEDs treatment induced cognitive
deficits in epileptic patients and healthy individuals as well37. PB is one of the most
AEDs that negatively impacts memory function in epileptic patients, as it was reported
that PB treatment evokes behavioral and cognitive impairment, including modification
in attention vigilance and short-term memory38. Moreover, CBZ treatment also was
reported to be associated with learning and memory deficits39. Furthermore, the French
pharmacovigilance database (FPVD) revealed that VPA, lamotrigine, levetiracetam,
gabapentin, pregabalin, and topiramate treatments were associated with memory
deficits40. On the other hand, earlier studies documented that VPA treatment did not
alter memory function41. Additionally, clinical studies revealed that PB and primidone
were shown to have more cognitive effects than CBZ and PHT in epileptic patients42,43.
Among the new AEDs, topiramate exhibited a strong correlation with memory
impairment, especially short-term memory impairment44,45.
Moreover, several animal experiments also documented the amnesic effect associated
with several AEDs treatments, since in utero exposure of rodents to several AEDs
resulted in anatomical and behavioral alternations46,47. Also, it was shown that PHT
potentiates the memory deficits induced by PTZ-kindling model, while VPA displayed
less memory alternations effect when compared with PHT48. Interestingly, PHT, PB,
and CBZ failed to alter memory deficits associated with PTZ-kindling model, though
VPA attenuates the memory impairment induced by chronic PTZ in male Wistar rats49.
Several interconnected factors produce complex contributions to the associated
cognitive deficits. Oxidative stress is considered as one of the main elements that may
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contribute to AEDs associated with memory impairment. It has been reported that
several AEDs induced a considerable rise in oxidative stress index with chronic
treatment in epileptic patients, which was related to the associated memory
impairment50. Moreover, CBZ and PB treatment induced memory deficits and
alterations of oxidative stress in experimental animal models51. In addition, AED's
chronic treatment was found to affect cognitive functions by suppressing neuronal
excitability or enhancing inhibitory neurotransmission. Therefore, the perfect AED
would decrease neuronal irritability by avoiding influencing the neuronal excitability
and cognitive functions.
1.1.5 Epilepsy Comorbidities
Nowadays, epilepsy is considered to be a spectrum disorder more than periodic
spontaneous seizures. For most of the patients, the burden of epilepsy is mainly caused
by the associated comorbid conditions. Several psychiatric and behavioral features
were documented as epilepsy comorbidities, including depression, memory deficits,
anxiety, autism, attention-deficit hyperactivity disorders (ADHD), and learning
disabilites24. In addition, it was revealed that even one seizure was capable of
modifying the neurodevelopment by altering the receptor distribution and
expression52. Previously, the associated comorbidities were counted as side effects
resulting from AEDs treatment or as a secondary outcome due to uncontrolled
seizures. However, recently the comorbid conditions are considered as a fundamental
part of the epilepsy disorder, and are even usually attributable to an underlying disorder
of neuronal networks53. Likewise, some psychiatric comorbidities were considered as
risk factors for epilepsy development. On the other hand, epilepsy may raise the
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possibilities

for

psychiatric

comorbidities,

indicating

mutual

causes

and

mechanisms54,55.
One or more neurobehavioral comorbidities are regularly associated with chronic
epileptic patients. Cognitive comorbidity is verified in clinical experimental and
psychological studies56-58. Epileptic patients experience several cognitive problems,
including decreased intelligence, attention, language, and memory disabilities59.
Among them all, learning and memory disabilities are considered as one of the most
unbearable neurobehavioral comorbidities of chronic epilepsy60,61, affecting
approximately 30% of epileptic patients62. Cognitive and memory impairments are
usually correlated with poorly controlled seizures, and with a long period of the
disease63; also, they are highly associated with epileptic patients during adult life64.
Besides, memory deficits are highly associated with Temporal Lobe Epilepsy (TLE)
patients65. Moreover, through applying an Intelligence Quotient (IQ) achievement
discrepancy definition, around 50% of epileptic children were classified with memory
disabilities in at least one academic field, while 40% to 60% were classified by using
the low achievement definition66. In addition to the academically recognized defects,
epileptic children suffer from learning and attention disabilities67. Furthermore, both
epileptic adults and children regularly complain of memory disabilites68.
On the other hand, numerous acute and chronic animal models had indicated that the
memory impairment is comorbid with seizures, since acute chemically- and
electrically-induced seizure models were found to induce memory impairment in both
rats and mice69,70. Notably, PTZ kindled rodents were, also, found to exhibit memory
dificits71-73. Moreover, Pilocarpine (PLC)-induced SE was found to be associated with
memory impairments in rodents74,75.
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According to the aforementioned preclinical outcomes in different animal models, it
was stated that overtraining may attenuate the seizures-induced memory impairment76.
Also, it was found that environmental enrichment post-SE seizures might mitigate the
apoptosis and the associated memory deficits77. Interestingly, the cognitive
comorbidity was treated through nonpharmacologic interventions, including cognitive
rehabilitation in adults and specific education in children. However, based on the last
decade's studies, which demonstrated that the nonpharmacologic treatments were not
sufficient in decreasing the associated cognitive comorbidities, pharmacological
treatments were required. Therefore, identification of epilepsy comorbidities and its
underlying mechanisms may suggest several therapeutic choices, especially by
designing opportunities to treat two conditions with a single drug (seizures and
memory deficits).
1.1.5.1 Role of oxidative stress in epilepsy and cognitive function
Reactive oxygen species (ROS), including hydroxyl radical (·OH), superoxide radical
(·O2-), hydrogen peroxide (H2O2), and singlet oxygen (1O2) are produced through
regular cellular metabolism78,79. Scavenging the physiological ROS can be done
through enzymatic antioxidant defense methods, including glutathione reductase
(GR), glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD)
or non-enzymatic antioxidant defense methods, including vitamin E, vitamin C, and a
reduced form of glutathione (GSH). Nevertheless, elevated ROS generation, reduced
antioxidant defense system, or both will cause excessive ROS levels resulting in
oxidative stress80. ROS free radicals will attack several proteins, cell lipids, and also
the DNA, especially in the brain, causing lipids peroxidation81, as the brain consumes
the highest amounts of oxygen compared to other organs, and is full of polyunsaturated
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fatty acids that are susceptible to lipid peroxidation82. Oxidative stress causes
functional cellular interruption and cellular destruction and may result in successive
cell death through oxidation of lipids, proteins, and nucleotides. Moreover, protein
oxidation causes functional alternation and several enzymes deactivation83.
Furthermore, lipid peroxidation results in membrane structure modification, which
disturbs membrane permeability and membrane protein activity84. Therefore, the
assumed function of oxygen radicals and radical-derived ROS in neurodegeneration
disorders (e.g., epilepsy) and cognitive impairment has been well recognized85-87.
Previous experimental results have shown that oxidative stress is strongly implicated
in the pathogenesis of different neurodegenerative diseases and neurologic disorders
like Parkinson’s disease, epilepsy, stroke, and Alzheimer’s disease88,89. It has, also,
been revealed that oxidative stress plays a significant part in the over-excitation status
of the neurons, consequently leading to the death of numerous neuronal cells through
various mechanisms like oxidative damage to membrane proteins, including proteins
for several receptors and/or ion channels83. In epileptic children, high oxidative stress
was documented90, and high MDA levels (an indicator of lipid peroxidation) were
observed in patients diagnosed with refractory TLE 91. Similarly, an elevated oxidative
stress level was documented in epileptic patients when compared with healthy
individuals92. Moreover, preclinical studies in several animal models revealed the
significant role of oxidative stress in the initiation and progression of seizures.
Importantly, hippocampal high oxidative stress was documented post PLC-, Kainic
acid (KA)-, and PTZ-induced seizure models, indicating a neuronal damage81,93,94.
Likewise, high oxidative stress was noted following PTZ-kindling model in the
hippocampus and other brain regions, and it was also noted that treatment with
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antioxidant compounds had a mitigating effect on oxidative stress levels and kindling
procedure95-97.
Moreover and based on previous preclinical observations in rodent models, oxidative
stress was found to originate from repeated seizures, resulting in exacerbation of the
convulsive consequences like the loss of the neuronal cells and cognitive impairment98.
In addition, it was reported that oxidative stress modulated the synaptic plasticity and
cognitive functions86. Furthermore, memory-impairment, in elderly patients was
associated with reduced antioxidant levels in plasma and brain99,100. Likewise, it was
noted that oxidative damage in cortical and hippocampal rat synapse during aging
could be implicated in the deficit of cognitive functions101. Remarkably, the
antioxidant effect of numerous compounds originating from different classes was
associated with a memory-enhancing effect in several animal models75,102-104.
Therefore, oxidative stress is considered as one of the causes of memory
impairment105. Additionally, it was indicated that AEDs treatment elevates the
oxidative stress index, which at least could be partially responsible for the associated
memory impairment105. Accordingly, monotherapy with either PB or CBZ was found
to cause an imbalance in serum oxidant and anti-oxidant status in epileptic children.
However, this imbalance was regulated with the use of VPA monotherapy50.
Moreover, chronic treatment with PB and CBZ in rats resulted in elevated brain
oxidative stress concomitant with memory impairment; however, treatment with
potential anti-oxidant compounds (e.g., curcumin) attenuated both the oxidative stress
and associated memory deficits51. Similarly, chronic PHT treatment worsened memory
deficits and oxidative stress induced by PTZ chronic treatment in mice; nevertheless,
treatment with flavonoid with prospective anti-oxidant effect was found to alleviate
the associated comorbidities

106

. Contrary, VPA was revealed to induce less side
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effects on cognitive function and to attenuate the oxidative stress in both epileptic
patients and several animal models107-109.
1.1.5.2 Role of brain neurotransmitters in epilepsy and associated comorbidities
Simultaneous changes in brain circuitry and chemical signaling are supposed to play
an essential part in epileptogenesis and the learning and memory processes. The vital
role of neurotransmitters in providing normal brain functions is well documented, and
the alternation of several neurotransmitters during a brain insult was noted. The
modification of a wide range of neurotransmitters has been noticed to be closely
correlated with epilepsy110. Numerous central neurotransmitters are known to perform
a significant role in epilepsy and memory, including GABA, glutamate (GLU),
acetylcholine (ACh), and histamine (HA).
1.1.5.2.1 GABA/GLU
Reduced GABAergic and/or improved glutamatergic transmission resulting in an
imbalance between inhibitory and excitatory tone has been recognized as pathological
aspects for the production of seizures, both in humans and in animals models111,112.
Elevated GLU/GABA ratio toward excitation indicates a reduced seizure threshold,
which is considered one of the most critical factors leading to epileptogenesis113.
Several previous findings support the role of GABA in epileptogenesis and treatment
of epilepsy, as GABA is considered the primary inhibitory neurotransmitter in the
brain. Deformities of GABAergic function have been detected in both genetic and
developed animal models of epilepsy114-116. Moreover, the hippocampal GABAinduced inhibition system was appreciated in AEDs development, which led to the
production of clinically useful compounds (e.g., vigabatrin and tiagabine)117.
Likewise, the traditional AEDs (BZs) stimulate GABA-mediated inhibition by binding
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to the GABAA receptor. On the other hand, GABA antagonists’ compounds
characterized by proconvulsant properties, including PTZ and picrotoxin, show the
vital role of GABA in epilepsy118.
GLU is the prevalent excitatory neurotransmitter in the mammalian brain. In epileptic
patients, hippocampal GLU levels were higher than in nonepileptic patients, as found
by using the microdialysis technique. In addition, it was noted that elevated GLU
hippocampal levels were noticed before seizure onset, implying GLU transmission
role in triggering the seizure119. Moreover, Statues epilepticus (SE)-stimulated GLU
release causes overstimulation of non- N-methyl-D-aspartate (NMDA)-type glutamate
receptors , resulting in persistent long-term seizure activity, and brain damage120.
Therefore, the adjustment of glutamatergic neurotransmission at the level of N-methylD-aspartate receptors (NMDARs) plays a crucial role in alleviating SE-evoked brain
damage. Several available AEDs work through modulating the excitation system, e.g.,
topiramate inhibits GLU neurotransmission by mitigating non-NMDA-type glutamate
receptors via blockade of kainate-evoked currents117.
Furthermore, with the massive innervation of GABAergic neurons toward cholinergic
and glutamatergic neurons, it can be suggested that dysfunction of the GABAergic
system may play a role in cognitive impairment in humans. Besides, considerable
declines in GABA concentration were observed in severe cases of Alzheimer’s and
elderly people121.
Furthermore, GLU was noted to be involved in synaptic plasticity underlying learning
and memory, through long term potentiation along with metabotropic and ionotropic
glutamate receptors. On the other hand, NMDA receptors antagonist administration
exhibited a memory impairment effect in rodents122,123. Nevertheless, in pathological
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conditions, e.g., epilepsy or Alzheimer’s disease (AD), elevated extrasynaptic GLU
levels act as a neurotoxic mediator causing depolarization of the neural membranes
and cell death through extrasynaptic NMDA receptors124,125. Consequently, epilepsyinduced elevated brain GLU levels are considered as a causative factor for both the
vulnerability to memory deficit and uncontrolled seizures. In previous preclinical
studies, high brain GLU levels were associated with memory impairment in the PTZkindling model; however, the memory-enhancement effect was facilitated at least
partially through GLU levels normalization126.
1.1.5.2.2 Acetylcholine (ACh)
ACh is a signaling molecule that provokes numerous activities in the Central Nervous
System (CNS) and at the neuromuscular junction. ACh performs a critical role in
alternating brain GLU release and sustaining memory formation127 as low ACh levels
in chronic epilepsy were associated with high GLU levels128. The role of cholinergic
neurons in the incidence and initiation of epilepsy and the interaction with other
nervous systems is well documented. On the other hand, PLC, a cholinergic M receptor
agonist, is extensively used as PLC-induced SE model129.
Moreover, in acute PTZ- and PLC-induced seizure models, elevated ACh levels were
documented in the hippocampus and other brain regions130-132. Also, Maximal
electroshock (MES)-induced seizure model increased brain ACh levels in rodents133.
The elevated ACh levels evoked by seizures provide a convincing indication that
activation of ACh receptors aggravates seizure activity134. In addition, it was
demonstrated that high ACh levels would accumulate and trigger certain
neurobehavioral signs such as convulsion135.
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AChE (acetylcholinesterase) is an essential enzyme that hydrolyzes the ACh,
terminates the cholinergic transmission, leads to normal nervous system function, and
is extensively expressed in the tissues that accept the cholinergic innervations, e.g.,
muscles cells and neurons136. AChE was also documented to be reduced following
electrically and chemically- induced seizure models133,137. Memory impairment
associated with the PLC- and PTZ-induced seizure model has formerly been associated
with alterations in the functionality of the brain cholinergic system133,138. It is also well
documented that the compromised function of AChE is associated with disturbed
cholinergic functions, including learning and memory135,139. AChE plays a significant
role in cholinergic neurotransmission, and reduced levels of AChE generally cause
irregular high levels of ACh in the cholinergic synapses, which result in extreme
motivation and stimulation of muscarinic and nicotinic receptors causing behavior
alternation107,140.
Oppositely, low ACh levels and elevated AChE were noted in chronic epilepsy in
animal models132,141,142. It was thought that the enhancement of GLU-mediated
excitation via kindling could cause overstimulation in NMDA receptors143. Thus, over
stimulation will result in reduced viability and eventually death in cholinergic
neurons144. The AChE overexpression had been remarked to be accompanied by
memory disabilities145,146. Also, it was claimed that elevated AChE concentrations
might be explained as compensatory to cholinergic transmission modulation induced
by PTZ-chronic treatment147. AChE is considered being an important therapeutic
target, as reversible inhibitors of AChE are being used as a memory enhancer in
epileptic patients and other neurodegenerative diseases148.
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Finally, accumulating behavioral and molecular data implies the key role for
cholinergic neurotransmission in the healthy brain function and several models of
seizure generation.
1.1.5.2.3 Brain histamine (HA)
HA as a brain neurotransmitter plays a pivotal role in epilepsy, learning, and memory
149

. It was previously documented that CNS histaminergic system was implicated in a

wide range of physiological and behavioral tasks, including locomotor activity, sleepwake cycle, cognitive functions, appetite control, and stress behavior150. The
participation of brain HA in the regulation of seizure susceptibility is satisfactorily
demonstrated in both clinical and experimental studies that consider HA as an
anticonvulsant neurotransmitter150. Remarkably, children with febrile seizures
exhibited considerably lower histamine concentrations in the cerebrospinal fluid when
compared with febrile children without seizures151. Moreover, several previous clinical
data detected recorded proconvulsant effects of several histamine 1 receptor (H1R)
antagonists administered in clinically relevant doses152-156.
In earlier preclinical studies, intracerebroventricular (i.c.v). HA injection prevented
different types of seizures. In addition, treatment with metoprine, an inhibitor of
histamine N-methyl transferase, a HA catabolizing enzyme, prevented MES-induced
seizures157. Moreover, low HA concentration was associated with both PTZ- and
amygdaloid-kindling seizure models. Furthermore, exogenous HA administration to
kindled animals and endogenous histamine elicited by activation of H3Rs provoked a
kindling mitigating effect158-160. Likewise, histidine and metoprine administration
inhibited the kindling procedure, and both therapies were accompanied by increased
HA levels in the cerebral cortex and hippocampus159,161,162. On the other hand, α-
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fluoromethyl histidine (α-FMH), a selective histidine decarboxylase (HDC) inhibitor,
diminished HA synthesis and increased seizure activity163. Another point is that HDC
knockout (KO) mice were more susceptible to seizures164.
Low levels of HA were observed in the hypothalamus, hippocampus, and temporal
cortex in AD patients165. Also, numerous preclinical studies indicated the role of the
histaminergic system in learning and memory. It was shown that i.c.v. injection of
histamine or histidine had improved the social memory in rats; however, α-FMH and
the H3R agonist had the opposite effect166,167. Moreover, HA or histidine
administration had mitigated scopolamine (SCO)- and dizocilpine (DIZ)-induced
spatial memory impairment168,169. In addition, increasing endogenous HA release by
histidine administration had mitigated seizures and the associated memory impairment
in kindled rats170. On the other hand, decreasing brain HA levels by α-FMH
administration significantly caused spatial memory impairment in rats171.
Furthermore, histamine H1- or H2Rs knockout mice, exhibited impairment of
performance in numerous memory experiments172,173. However, H3Rs knockout mice
showed place recognition enhancement in the Barnes maze test and resistance to SCOinduced memory impairment174,175.
1.1.6 Temporal Lobe Epilepsy (TLE)
TLE is the most predominant type of

refractory symptomatic epilepsy176.

Hippocampal sclerosis (HS) and aberrant mossy fiber sprouting (MFS) are the main
characteristics of TLE. HS is a sever unilateral hippocampal neuronal atrophy in the
hippocampus and parahippocampal gyrus. HS is histopathologically recognized by
segmental neuronal cell loss in the CA1 and CA4 subfields, astrogliosis, granule cell
dispersion, and axonal reorganization177-179. Along with the main feature of seizure
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foci localization in the limbic system, especially in the hippocampus, entorhinal cortex,
and amygdala, TLE has more special features180. A frequent discovery of “early
precipitating damage” leads to the presence of TLE181. Besides, a seizure-free period
after the precipitating damage is known as a “latent period” with a high prevalence of
mesial sclerosis182. Most of these features can be mimicked in TLE chronic animal
models, especially SE animal models or kindling, that are close by being the perfect
homologous of the aforementioned mode113.
1.1.6.1 Animal models for TLE or like-TLE conditions
The potential anticonvulsant activity of the old and new AEDs, except for bromides
and PB, was initially evaluated in acute animal models, e.g. MES- and PTZ-acute
induced seizure models in rodents, indicating that the clinical effect can be predicted
by such straightforward laboratory models183,184. The fact that preclinical tests utilized
for the development of new AEDs, have been formally validated by ‘old’ AEDs may
clarify that none of the new AEDs owns noteworthy features in antiepileptic efficiency
against the old treatments; thus, antiepileptic activity has not been modified to any
considerable extent by the development of new AEDs185. It is not surprising that any
of the AEDs that were detected applying MES or PTZ tests appear to be efficient in
inhibiting or altering epilepsy since MES and PTZ are acute seizure tests instead of
epilepsy models. Thus, models imitating the chronic brain dysfunctions resulting in
epilepsy should be utilized in the search for novel, more effective compounds. In the
following, the acute- seizure model is for models in which a seizure is evoked by
electrical or chemical motivation in naïve non-epileptic healthy rodents. On the other
hand, the chronic model is turning the rodents into epileptic animals by electrical or
chemical kindling or by using the animals with inborn epilepsy. The phrases
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‘anticonvulsant’ and ‘antiepileptic’ are utilized synonymously to imply anti-seizure
compound activity; however, the term ‘antiepileptogenic’ is applied to reveal
inhibiting or modifying epilepsy as epileptogenesis signifies the gradual conversion of
the natural brain to a hyperexcitable epileptic brain149.
Acquired epilepsy models are epilepsy or epilepsy-like conditions, which are
stimulated by electrical or chemical methods in healthy naïve non-epileptic rodents,
mostly in rats. Likewise, TLE or TLE-like conditions can be stimulated by electrical
or chemical kindling, or by models in which recurring unprovoked seizures developed
following SE that is provoked by persistent electrical stimulation of the hippocampus
or by chemical compounds applications.
1.1.6.1.1 PLC-induced SE model
Continuous electrical induction of the hippocampus or amygdala evokes (SE). This
model is categorized by neuropathological changes similar to mesiotemporal sclerosis
(exhibited in several patients with TLE) and by recurring spontaneous seizures
developing after the SE. Comparable to electrical models of TLE, SE can also be
evoked by chemical convulsant application, e.g., PLC and KA186,187. SE is a lifethreatening medical situation and neurologic emergency necessitating immediate
recognition and treatment. SE is generally defined as a prolonged seizure or several
seizures with an incomplete return to consciousness among them188. SE is associated
with high morbidity and mortality189.
PLC is a muscarinic agonist either systemically administered or microinjected focally
into the hippocampus. PLC induces SE by activation of the M1 muscarinic receptor
subtype since M1 receptor knockout rodents lack sensitivity to PLC-induced SE190. In
addition, PLC-induced SE is inhibited by systemic treatment of atropine, a muscarinic
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antagonist191. In-vitro experiments have revealed that PLC produces an imbalance
among excitatory and inhibitory neurotransmission via muscarinic receptors causing
the production of SE192. Moreover, in vivo experiments have shown that PLC provokes
an increase in hippocampal GLU levels after the occurrence of convulsion193,
suggesting that M1 receptors induce the origination of seizures and that they are
maintained via NMDA receptor motivation193,194.
Systemic administration of PLC is associated with high mortality rate. PLC can
instigate SE, and post-SE treated rodents demonstrate neuronal loss in the
hippocampus, particularly in the dentate gyrus. Following a typical latent period,
almost 90% of post-SE rodents exhibit unprovoked, frequent convulsions of Racine
class 3 or more that persist for life195, indicating that PLC-induced SE model is
considered as a commonly accepted model of TLE129.
PLC can trigger both acute and chronic seizures, as PLC-systemic administration
evokes SE in a high percentage of the treated animals, and almost all of the SE animals
exhibited spontaneous recurrent seizures following a latent period of 2–30 days196-199.
Thus, the PLC-model is nowadays widely utilized in several ways depending on the
aims of the experiments, as both the electrical- and chemical-induced SE model may
be utilized as experimental models of SE (TLE-like epilepsy model), to assess
potential compounds for execution of SE, or to generate chronic epilepsy with
persistent unprovoked seizures.
1.1.6.1.1.2 PTZ-kindling model
Kindling is a procedure in which recurrent sub-threshold application of electrical or
chemical agents can cause prolonged seizures, progressively raised in length, and
intensity of the behavioral disorder200,201. The electrical kindling phenomenon was first

24
described by Goddard202, where the application of recurrent low-intensity electrical
incentives into the brain structures produced myoclonic jerks and tonic-clonic seizures
that were generated even 8 weeks after the last stimulation. The PTZ-kindling model
was first described by Mason and Cooper203. It was noticed that an outcome equivalent
to the electrical kindling occurred following sub-convulsant chronic intraperitoneal
(i.p.) injection of the PTZ. Also, it was found that PTZ-induce kindling is a long-term
phenomenon, as once a behavioral symptom of PTZ administration was reached, a
major seizure reaction was displayed on the renewed administration even after months
without utilizing a convulsive stimulus. Behavioral manifestation stated as a bilateral
forelimb clonus or a more severe stage in two or more consecutive applications is taken
as a full kindling state. Ultimately, shifts in the brain’s network in the fully kindled
state resulted in amplified severity of the seizure and the associated behavioral deficits
in reply to a sub-threshold dose of PTZ.
PTZ, a bicyclic tetrazole derivative, was used for the first time as CNS stimulant by
Von Meduna in 1934204. PTZ can stimulate the epileptogenic effect by inhibiting
(GABA)-mediated transmission205. PTZ acts as a potent non-competitive antagonist
of the GABAA receptor by binding to the benzodiazepine (BZ) site of GABAA
complex receptor, which was found to consist of a mixture of allosteric binding sites206208

. The PTZ-kindling model has been applied dynamically for a quick examination of

the epileptogenic processes instead of other expensive and time-consuming chronic
epilepsy models. The model allows for accurate recording of seizures time of start. In
addition, while the first period of the convulsions requires at least 15 days to develop,
dissimilar from acute models, kindling can be employed for recognizing the key
actions triggering the epileptogenesis. In such chemical kindling models, beginning
from early absence to tonic-clonic seizures, a long-lasting development interval
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occurs, which authorizes to explore the detailed activation of seizure activity
distribution203. PTZ-kindling model is characterized by a continual accretion in seizure
liability, neuronal damage, and lack of unprompted repeated convulsions.
Several brain structures were implicated in PTZ-kindling model as described by an
earlier study, in which c-fos, an immediate-early gene, was assessed to visualize the
brain structures involved in each specific stage of the PTZ-kindling model209.
Thalamus and hypothalamus were the first brain structures to be engaged in the early
absence-like phase of kindling. However, with the incidence of clonic and tonic-clonic
seizures post-recurrent sub-convulsive administration of PTZ, sequel engagement in
epileptogenesis of the midbrain, brainstem regions, and almost all of the hippocampal
subfield were observed. Also, in fully kindled rats, c-fos labeling was enhanced in the
dentate gyrus. Moreover, oxidative stress was documented in the hippocampus at the
end of the chemical kindling210.
It was documented that the hippocampus performed a crucial role in the initiation and
propagation of convulsions in humans. Also, (HS) and aberrant (MFS) are frequent
structural irregularities in refractory TLE patients211-213, following 2 to 3 systemic
applications of PTZ hippocampal MFS in the CA3 region and neurogenesis in the
dentate gyrus were evoked214,215. Moreover, a decline in the number of functionally
active neurons in the hippocampal CA1 area was noted following the sixth PTZ
applications216. At the end of the kindling, the susceptibility of the brain to PTZ is
elevated, causing significant destruction of the antiepileptic systems and
hyperactivation of neurons, which triggers chronic epileptization of the brain. The
morphological modifications, evoked by kindling, involve hippocampal progressive
neuronal cell damage.
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It is still debatable whether the post-kindling period of PTZ kindling is considered as
a model of the latent period of epileptogenesis of TLE. In the PTZ model, kindling
was used for the initiation of seizures, which does not reestablish the etiological
aspects for TLE human induction. Precipitating damages in human TLE includes head
trauma, toxins, hypoxia/ischemia, infections (e.g., bacterial meningitis), SE, and birth
trauma. However, the neuropathological alterations seen in the PTZ kindling model
are similar to those reported in PLC-treated animals. Previous morphological
experiments on the PTZ-kindling model offered crucial data concerning the reduction
in the density and quantity of hippocampal neurons. Oppositely, there is a typical
impression that HS does not accompany kindling. Nevertheless, in-vivo Magnetic
Resonance Imaging

(MRI) spectroscopy studies had documented that HS was

detected in the PTZ-kindling model via T2-weighted signal intensity of the PTZ treated
rodents210,217. A few earlier studies documented aberrant MFS following PTZ
treatment218. In addition, comparably to PLC and KA, recurrent PTZ injections may
increase the permeability of the blood-brain barrier, resulting in increased release of
hippocampal GLU that would ultimately facilitate convulsion incidence219,220. All of
the above-mentioned neuropathological features of PTZ-kindled animals imitate a
portion of the phenotypic characterization of the human TLE condition. One of the
advantages of PTZ-kindling model is that PTZ provokes low mortality, and most of
the animals are implicated in convulsion activity. Contrary to KA and PLC models, in
which the initial clonic-tonic convulsion happens after a few hours, in the PTZkindling model, this procedure necessitates quite a few weeks, making it feasible to
examine subtle mechanisms of epileptogenesis210. Models of acquired epilepsy,
including kindling or the evoked SE- epilepsy model, are generally utilized to
investigate the pathophysiology of epilepsy in the pursuit of targets to inhibit epilepsy.
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1.2 Histamine as a neurotransmitter in the central nervous system (CNS)
1.2.1 Synthesis, storage, and release of brain histamine
Brain HA, [2-(4-imidazolyl)-ethylamine), has been widely discussed as a medicinal
substance in the medical literature (Figure 3). It controls a broad spectrum of activities,
including its neurotransmission function221. HA has first detected in ergot fungi
extracts as uterine stimulants in 1910, from which it is subsequently isolated and
extracted from human tissues in 1927222,223. HA was identified before introducing the
first-generation antihistamine, and even prior to the knowledge of H1 or H2 receptors.
The main side effect of antihistamine was the sedation, which implies the central effect
of HA. It was isolated the first time from cortical brain human in 1943, following
several electrophysiological and behavioral studies with (i.c.v.) infusion of HA. It has
been shown as a potential new neurotransmitter to be added to the existing
neurotransmitter systems224.

Figure 3: The chemical structure of histamine [2-(1H-imidazol-4-yl)ethanamine.

Histamine joins the family of biogenic amines (contain one or more amine), which
comprise neurotransmitters, including serotonin and dopamine. Biogenic amines are
mainly produced by decarbo.xylation of amino acids. HA is a monoamine that is not
able to pass the blood-brain barrier; therefore, it is synthesized in a constricted body
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of neurons, sited in the tuberomammillary nucleus (TMN) of the posterior
hypothalamus. (HDC) is an enzyme responsible for catalyzing the amino acid 1histidine to histamine (Figure 4)225. As a result, l-histidine is transferred to histamine
via the oxidative elimination of the carboxyl group by HDC. HA biosynthesis,
therefore, relies on the existence of histidine. At elevated concentrations, histidine may
be a substrate for nonspecific decarboxylase. However, these nonspecific synthesis
routes can be disclosed with alpha-fluoromethyl histidine (α-FMH), a specific HDC
inhibitor226. Once synthesized and via vesicular monoamine transporter-2 (VMAT-2),
the HA is stored in both soma and varicosities vesicles. The release of HA is calciumdependent, and it happens post depolarization of the histaminergic neurons227.
In the brain, HA is stored in two separate compartments, the first one is in vesicles of
neuronal endplates, and the second in the mast cells227. Moreover, it has been
documented that the two compartments are implicated in the given levels of brain HA.
Since 50% of brain HA was found to be lacking in mast cells knockout mice W/WV,
compared to normal mice228. It is noteworthy that central HA biosynthesis and release
is modified through the histamine H3 auto-receptors (H3Rs), and it is Cyclic adenosine
monophosphate/ protein kinase A (cAMP/PKA-dependent)229. Furthermore, other
systems are involved in regulating the activation of central histaminergic neurons and
the release of HA, via its inputs and receptors such as acetylcholine, norepinephrine,
and serotonin177. The re-uptake mechanism is not known for HA, which is different
from the usual aminergic neurotransmitters177. Nevertheless, the central activity of HA
is ceased through the histamine N-methyltransferase (HNMT) in the extracellular
space. Nι-methylhistamine is produced by methylation via HNMT, then degraded by
monoamine oxidase B to Nι-methylimidazole acetic acid (Figure 4)221,224,226.
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Figure 4: Neuronal histamine biosynthesis, release and metabolism in the CNS.
LAAT, L-amino acid transporter; VMT, vesicle monoamine transporter; HNMT, histamine-N-methyl
transferase; MAO, monoamine oxidase. Adopted from 225.

1.2.2 Localization of the histaminergic neurons
Neuronal histaminergic cell bodies are sited only in the tuberomammillary nucleus
(TMN) of the posterior hypothalamus, and TMN is located among the mammillary
bodies and the optic chiasm of the tuber cinereum (Figure 5). Cell bodies of histamine
neurons forward projections to various brain regions without a structural outline of
their projections, as verified by retrograde tracers. One perikaryal may send out
descending and ascending extensions221,224. The heterogeneous histaminergic neurons
have been described, with distinct mechanisms for regulation and innervation of
distinct areas of the brain230,231. The histaminergic neurons provide widespread and
diffuse projections that spread across the basal forebrain practically to the entire brain,
including the thalamus, cortex, hippocampus, striatum, hypothalamus, locus
coeruleus, and spinal cord via its ascending and descending pathways232,233. Through
their expansions, histaminergic neurons seldom create traditional synaptic interaction
with their prospective targets. However, HA is released from varicosities and
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propagates to the nearby regions as a regional hormone that influences neuronal and
non-neuronal components221,224. Two different ascending routes involved ventral
sending projections to hypothalamus and septum, while dorsal sending to the thalamus,
hippocampus, amygdala, and forebrain. The dentate gyrus accepts a considerable
amount of histaminergic fibers via the dorsal pathway. Generally, the descending
pathway to the brain stem, cerebellum, and spinal cord has a minimum fiber density221
(Figure 5) 221.

Figure 5: Projections of TMN histamine neurons.
Two ascending pathways: 1) ventral part to the hypothalamus and septum, 2) dorsal part to the
thalamus, hippocampus, amygdala, and forebrain. One descending pathway to the brain stem,
cerebellum and spinal cord. Adopted from225.

1.2.3 Histamine Receptors
The morphology of the histaminergic neurons, as already mentioned, recognizes the
HA as a neurotransmitter and neuromodulator of a board range of central physiological
functions and behaviors via activation of distinct histamine receptors, including
neuroendocrine, cardiovascular regulator, locomotion, catalepsy, sexual behavior,
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energy homeostasis, drinking and feeding, and learning and memory221,224,234,235.
Histamine neuroreceptor is regarded as one of the main aminergic structures exhibiting
key neurological functions across pharmacologically diverse receptor subtypes. HA
receptors, namely H1-H4R, fit into a board superfamily of G-protein coupled receptors
(GPCRs), recognized by the presence of seven putative transmembrane spanning
domains236-238. H1-3Rs are extremely present in the brain; however, H4Rs in the CNS
have minimal expression

239,240

. Remarkably, all HA receptors with diverging levels

display an active state of confirmation irrespective of any ligand binding241.
1.2.3.1 Histamine H1 receptors (H1R)
H1R is encoded via chromosome 3 sited gene, which encodes a member of the large,
7-transmembrane-spanning, G-protein-associated receptor family242. H1R is activated,
when histamine binds to the receptor, through Gq/11 signaling pathway243. Moreover,
H1R activation may also result in the formation of arachidonic acid (AA) and nitric
oxide (NO)244. Thus, the activation of H1R is probably capable of modifying the
release of the presynaptic transmitter, since AA and NO are considered retrograde
messengers221.
H1Rs are widely distributed in the CNS and are primarily responsible for antihistamine
sedative effects245. Elevated levels of H1Rs are distrusted mainly in brain areas related
to arousal, including thalamus, cortex, aminergic nuclei in the locus corelus and raphe
nuclei, septal nuclei, hippocampus, amygdala, and cholinergic nuclei in the
mesopontine tegmentum and basal forebrain. In addition, H1Rs present in high density
in the nuclei of the cranial nerves, area postrema, nucleus accumbens, molecular layer
of the cerebellum, and nucleus tractus solitaries246.
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Furthermore, H1Rs improve cortical glutamate NMDA-receptor mediated currents247.
Moreover, H1R activation was indicated to result in enhanced expression of the
immediate early-gene (IEG) c-fos in the suprachiasmatic neurons248. H1R knock out
mice normally developed; however, irregular locomotive function, circadian rhythm,
and decreased exploratory behavior were observed in a novel environment249.
1.2.3.2 Histamine H2 receptors (H2Rs)
H2R is encoded via chromosome 5 located gene encoding a member of the large a 7transmembrane domain, G-protein coupled receptor250. H2R was first discovered by
Black ae el as peer the histamine receptor’s distinct pharmacological report, which is
responsible for the promotion of gastric acid secretion251. H2R is Gs-coupled protein,
and is therefore involved in the cAMP/PKA/cAMP response element-binding protein
(CREB) signaling route supplying excitatory impacts252.
H2R, Similar to H1R, is existed in a high density in the brain and spinal cord; however,
as a contrast to H1R, H2R has a low expression in thalamic nuclei, septal areas, and
hypothalamic. H1 and H2 receptors are colocalized in hippocampal pyramidal, granule
cells, and aminergic nuclei (raphe nuclei, substantia nigra, locus coeruleus, and ventral
tegmental area), where they can act synergistically253. H2R knock out mice suffered
from cognitive dysfunction in specific tests associated with corrupted long-term
potentiation in hippocampus172.
1.2.3.3 Histamine H3 receptors
H3R was first described in 1983 as an auto-receptor regulating the release and
synthesis of histamine254. Recently it was cloned, and H3R appeared to be a G-coupled
protein linked to Gi or Go, a member of the GPCR family251,255. As a GPCR family,
H3R transduces via α-subunit of the Gi/o protein (Gi/oα) that is adversely linked to
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adenylate cyclase229,256. Activation of tuberomammillary (TM) located H3Rs causes
inhibition of various high-threshold calcium channels, 257. Nevertheless, unlike other
autoreceptors, there is a lack of evidence of H3Rs to be linked to inwardly-rectifying
potassium channels.
Remarkably, the H3 receptor gene demonstrates a minimal overall homology to all
other biogenic amine receptors255. Several H3R isoforms were acquired via alternative
splicing of the human H3R gene alongside with other species by applying RT-PCR
and genetic information technology of human H3Rs. The obtained isoforms exhibited
heterogeneous pharmacology, signal transduction, and distribution in the CNS256,258.
Interestingly, despite the very low homology observed for the human H3R (hH3R)
protein sequence, (21–22%) in comparison to hH1- and hH2Rs, it showed high
homology compared to hH4R [38–58%)259,260. GPCRs displayed in-vitro constitutive
activity; however, H3Rs showed in-vivo constitutive activity at normal physiological
levels, unlike the other GPCRs261,262. In addition, GPCRs are well known to be present
in equilibrium among their active and inactive conformations, and the level of
constitutive activity of the respective receptor is determined by the amount of the
active conformations and how efficiently they combine to G-protein. Inverse agonists
are compounds that stabilize the inactive status, leading to inhibiting the constitutive
activity.
H3Rs has a predominant, heterogeneous expression in the CNS, despite its
disappearance in the periphery255,263,264. Rats’ H3Rs are highly expressed in the rostral
part of the cerebral cortex, olfactory tubercles, striatum, hippocampus, amygdala,
substantia nigra, nucleus accumbens, cerebellum, and brain stem. However, rat’s H3Rs
are moderately expressed in the hypothalamus and the cell bodies of histamine
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neurons224. On the other hand, humans’ H3Rs are presented primarily in the basal
ganglia, hippocampus, globus pallidus, and cortex246. This aforementioned distribution
is in harmony with their prospective occupation in regulating the synthesis and release
of histamine alongside with other the neurotransmitters, including glutamate,
dopamine, norepinephrine, serotonin, acetylcholine, and GABA265-270. Consequently,
the Gi/oα-facilitated decrease in calcium influx appears to clarify the detected
histamine-induced inhibition of its own, besides other neurotransmitter release221.
H3R knockout mice exhibited an overall decrease of locomotor activity, sleep
restriction, and lack of sensitivity to waking activity of H3R antagonists and to SCOinduced memory deficits175,271.
1.2.3.4 Histamine H4 receptors
H4Rs are receptors coupled to Gi/o protein and are mainly expressed in the periphery,
unlike H3Rs259. According to pharmacological homology among H3 and H4 receptors,
pharmacological similarities were observed among the two receptors, primarily with
imidazole-containing

compounds272.

H4Rs

are

mostly

involved

in

immunomodulation, and they are predominantly expressed in cells and tissues of the
immune system273.
1.3 H3Rs as potential targets in neuropsychiatric diseases
Consistent with the extensive projection of the histaminergic neurons and the
numerous signaling pathways linked to its receptors, neuronal histamine is involved in
multiple CNS actions. Brain histaminergic system alternation has been explained in
numerous brain disorders and could have a considerable part in their
pathophysiology240,274.
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1.3.1 Epilepsy
The connection among the histaminergic system and the pathogenesis of epilepsy,
which is now the matter of extensive evaluation, is still in its early stages, due to the
histamine complex brain neurophysiology224. The histaminergic system implication in
epilepsy pathophysiology and treatment has been described previously in section
1.1.5.2.3. The traditional understanding of epilepsy pathophysiology is regularly
restricted to the conservative theory of imbalance among inhibitory GABAergic and
excitatory glutamatergic neurotransmission in excitotoxic neuronal death275.
The imbalance could be modified by several additional neurotransmitter systems,
including the histaminergic system. H3Rs have been an attractive target in treating
epilepsy by releasing the HA via H3 autoreceptors and, via H3 hetero-receptors, the
release of a broad spectrum of dynamic neurotransmitters, e.g., GABA, glutamate,
acetylcholine, and others in a pathway-dependent manner235. Histamine release is not
only controlled by its H3 auto-receptor system but also by GABA through GABAA
and GABAB receptors and by glutamate via NMDA receptors276-278. Moreover,
bicuculline, a GABAA receptor antagonist, drastically reduced clobenpropit-evoked
mitigation of amygdaloid kindling279. Besides, clobenpropit and iodophenpropit were
noted to exert noncompetitive antagonism in NR1/NR2B subunits of NMDA
receptors280. Furthermore, clobenpropit in cultured cortical neurons blocked NMDAinduced neurotoxicity via enhancing GABA release facilitated by cAMP/PKA281,
which further endorsed the implication of other neurotransmitters in the anticonvulsant
provided effect.
The potential anti-seizure protective effect of pitolisant, a non-imidazole H3R inverse
agonist, was assessed in 14 photosensitive epileptic patients utilizing the standard
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model of photosensitivity and applying 20/40/60 mg dose. Considerable inhibition of
generalized epileptiform discharges was documented in most of the patients282,283.
Unfortunately, despite the present promising experimental animal finding on the
potential effect of pitolisant, the latest phase II trial documented that there were no
clinical effects of pitolisant in human epilepsy284. Furthermore, mounting preclinical,
experimental data from both acute and chronic models of epilepsy signify the efficacy
of H3 receptor antagonists in epilepsy (Table 1).
Several H3R antagonists were observed to protect against experimental convulsions
by boosting brain histamine release, which in turn activates H1 receptors located postsynapticlly162,279,285,286. H1Rs appears to be the key mediators of histamine-induced
increase of seizure threshold besides the clinical evidence mentioned above of the
possible proconvulsant effect of H1R antagonist. Several centrally-acting H1R
antagonists were also shown to induce a proconvulsant effect in several models163,287.
In addition, the H1 receptor antagonist was documented to partially abrogate the
anticonvulsant effect provided by several H3R antagonists in numerous animals
models, indicating histamine participation288,289,158,161. Moreover, the proconvulsant
action of H1R antagonists was mitigated by histidine, not by physostigmine, signifying
the contribution of histaminergic transmission290. Another point is that H1R KO mice
demonstrated quicker reactions to amygdaloid and PTZ-induced kindling291.
From all aforementioned data, it is suggested that the central histaminergic system
applies a potent inhibitory function during epileptic seizure episodes, evidently via an
H3‐dependent mechanism. In agreement with this, H3 receptor antagonists may have
a therapeutic value in epilepsy or at least be a feasible approach that can be combined
with AEDs, particularly in patients who are non‐responsive to conventional therapies.
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Table 1: H3R antagonists tested in several animal models of epilepsy.
Acute
Thioperamide

Clobenpropit
AQ 0145

↓MES- induced
model285,292
↓PTZindced
model 248,293
↓MES- induced
model296,297
↓MES- induced
model 300

Chronic
seizure ↓PTZkindling
seizures162,294
↓Amygdaloid kindled seizures286,295.
seizure
seizure ↓Amygdaloid kindled seizures279,286,298
PTZ- kindling seizures163,299
seizure ↓Amygdaloid kindled seizures 295

Iodophenpropit
ABT-239
↓KA seizure in mice302
ST-1394
↓MES- and PTZ- induced
seizure model303
Pitolisant
↓PTZ- and MES- induced
seizure model304
DL77
↓MES- induced seizure
model305
E159
↓PTZ- and MES- induced
seizure model289

↓Amygdaloid kindled seizures301
NA
NA
NA
NA
NA

NA, not assessed; ↓, anticonvulsant effect.

1.3.2 Cognitive impairment
Cognition is not only about learning and memory; it involves numerous higher brain
functions, such as decision making, attention, and problem-solving. The cognitive
process involves complicated connections between cortical and subcortical neuronal
pathways. Cognitive deficits include one or more aspects of cognition. Memory
impairment is one of the main characteristics of AD disease, and attention is
deteriorated in (ADHD). Likewise, schizophrenia patients experienced deficiency in
executive function, i.e., cognitive inflexibility306. For evaluating the cognitive function
in different brain disorders, several behavioral tests have been developed to investigate
domains of cognition in animals and clinical trials.
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According to the relation of the histaminergic system with several cognitive functions
in section 1.1.5.2.3, H3Rs are nowadays an attractive drug target, as H3Rs modify
several neurotransmitter releases and have unique localization and neurochemistry.
These features make this system uniquely poised to play a role in aspects of learning
and memory. Several preclinical experiments in cognition research have focused on
tests that evaluate the distinct learning and memory domains believed to be the most
altered in diseases such as AD and epilepsy. Other areas, such as attention and
impulsivity, are likely to be of importance in ADHD. H3R antagonists may enhance
HA synthesis and release, and HA is associated with memory improvement.
Additionally, H3R antagonists may enhance the release of other neurotransmitters
implicated in cognition and memory, such as ACh in the prefrontal cortex and
hippocampus307-309 (Figure 6). The mechanism by which H3R antagonists modified
another neurotransmitter release is complicated. It has been hypothesized that
excitation of the neurotransmitter neuron through H1R/H2R, excitation/inhibition of a
“third-party” excitatory or inhibitory neuron which influences other neurotransmitter
releases, or straight rise of the neurotransmitter release via blockade of H3R heteroreceptors might be conceivable mechanistic reasons for the detected modifying result
on neurotransmitter release (Figure 6)230.
Several promising H3R antagonists have been investigated in clinical trials for their
prospective cognitive enhancement effect. Interestingly, GSK-239512, with verified
procognitive effect in several memory experiments in animals, has completed phase 1
clinical trial, and the outcomes indicate a moderate efficacy in mild-moderate AD
patients (ClinicalTrials.gov trial registration number: NCT00675090)310. However,
further grander scale testing is required to clarify its effectiveness311. Moreover,
SAR110894 with documented procognitive effect in rodents312,313, has accomplished
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a phase 2 clinical study for mild-moderate AD, that was tested as an additive to the
standard drug donepezil without disclosing the clinical outcome (ClinicalTrials.gov
trial registration number: NCT01266525). Despite the observed procognitive effect of
ABT-288 in rodents and its outstanding drug-like properties, a clinical phase 2 study
evaluating procognitive effect of ABT-288 in patients with mild-moderate AD
(ClinicalTrials.gov trial registration number: NCT01018875) and schizophrenia
patients with cognitive deficits (ClinicalTrials.gov trial registration number:
NCT01077700) has been accomplished without revealing the clinical results of the
study. Moreover, CEP-26401 is another effective H3R antagonist that has been
demonstrated to enhance social recognition memory in rats314. Remarkably, CEP26401 finished phase 1 of a clinical study focusing on its pharmacokinetics and
pharmacodynamics in healthy subjects for cognition indication with no disclosure of
the results for the clinical trial (ClinicalTrials.gov trial registration number:
NCT01903824). In conclusion, several preclinical and clinical returns have been
remarked for various H3R antagonists in experimental memory models involving their
disease altering properties and capability to attenuate cognitive deterioration
associated with epilepsy in the main.
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Figure 6: Illustration of possible mechanisms by which histamine H3 receptor
antagonists provide various pharmacological effects.
HDC, Histidine decarboxylase; HNMT, Histamine-N-methyltransferase. Modified after230.

1.3.2.1 Role of H3Rs in Long-term memory (LTM)
One essential behavioral test that has been frequently utilized to evaluate long-term
memory (LTM) is the inhibitory avoidance paradigm (IAP). IAP is a fear-motivated
test that depends on the time of treatment and can assess different aspects of memory.
Drugs were administered 30 minutes before the training session (time point 1), directly
after the training (time point 2) or before the test session (time point 3). These three
separate experiments were used to investigate their effect on memory acquisition,
consolidation, or retrieval, respectively. It was indicated that H3R knockout mice were
insensitive to SCO-induced LTM impairment in IAP175. Also, thioperamide mitigated
SCO-induced LTM memory impairment in IAP315, implying that H3R may be acting
through an alternative of cholinergic function in this cognitive domain. Moreover,
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E159 and DL77 attenuated DIZ- induced memory impairment in IAP. Furthermore,
LTM impairment applying IAP was noted in PTZ-kindled rats associated with
hippocampal neuronal death; however, treatment with histidine ameliorated the
memory deficit and decreased neuronal hippocampal damage159. The enhancement
effects of the H3R antagonists could signify an enhanced release of histamine and
other transmitters, e.g., ACh316,317.
1.3.2.2 Role of H3Rs in Recognition memory
Social memory (a type of LTM recognition memory) was one of the earliest domains
investigated with H3Rs. Social recognition memory depends on rodent’s memory
retention, in which an adult rodent utilizes the olfactory cues to recall social contact
with a nonspecific adolescent. Thioperamide enhanced social memory in rats167.
Another type of recognition memory is object recognition. The Novel Object
Recognition (NOR) test was used to calculate both long and short‐term recognition
memory in rodents. In this task, rodents are evaluated for their capability to remember
a familiar vs. an unfamiliar object. It was observed that kindled rats were associated
with recognition memory impairment318,319. Also, GSK207040 and BF2.649 enhanced
recognition memory in naïve rats320,321, while BF2.649 and E159 attenuated SCO- and
DIZ-induced recognition memory deficits, respectively320,322. According to the
previous indication about the role of HA and ACh in recognition memory, it was
suggested that the memory improvement observed with H3R antagonists in the earlier
experiments was via enhanced brain ACh and HA167,323.
1.3.2.3 Role of H3Rs in Spatial memory
Several behavioral animal models were developed for assessing spatial memory
function in rodents, e.g., water maze, elevated plus maze (EPM), barnes maze, and
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radial-arm maze. All of the previous tasks required the rodents to use local information
in navigating around their environment. Spatial memory impairment was documented
in AD patients and epilepsy animal models72,133. Thioperamide and ciproxifan
mitigated SCO-induced spatial memory impairment in rats316,324, but H2R antagonist
administration reversed the thioperamide procognitive effect observed in EPM325.
Most of spatial memory assessment tasks rely on the hippocampus and the septalhippocampal pathway. Moreover, it is suggested that the enhancement in spatial
memory observed with H3R antagonists is via HA and ACh release. H2Rs are also
implicated in the procognitive provided effect306.
1.3.2.4 Role of H3Rs in synaptic plasticity
During memory formation, synaptic plasticity, which is a specific molecular and
cellular change that ensues to compel synapses, is crucial for learning and memory.
Synaptic plasticity encompasses stimulation or blockade of receptors, ion channels,
and proteins, with subsequent modification in the size and quantity of synapses326.
Long-term potentiation (LTP) and long-term depression (LTD) are types of synaptic
plasticity. Among the other brain regions, the hippocampus is a brain area that is
extremely implicated in memory formation.
Interestingly, H1- and H2R knockout mice demonstrated in vitro significant
hippocampal impairment of electrically-induced LTP in CA1 region172. In addition,
HA, lacking any exterior tetanus motivation that is typically utilized in such trials,
induced in vitro hippocampal LTP in CA1 region327.
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1.3.2.5 Histamine in the hippocampus
Various brain areas are probably implicated in the memory modulating actions of
histamine. Many of the tasks for memory assessing are partially or predominantly
dependent on the hippocampal formation. Moreover, HA injection directly into the
ventral hippocampus was found to prevent performance in an active avoidance task by
acting on H1Rs328,329. Furthermore, in vitro experiments on hippocampal neurons tend
to indicate a memory-facilitating role for histamine, which is increased excitability and
facilitation of NMDA receptors and LTP330.
Even though the hippocampal formation accepts only low to moderate histamine
innervation, various well-known effects of histamine have been demonstrated in vitro
and in vivo331. HA affects only one of the main excitatory synaptic paths, which is a
perforant pathway input to the dentate gyrus in rats332-334. At this point, HA inhibits
synaptic transmission by around 30% via presynaptic H3R located on the perforant
path terminals. This effect can also be observed in vivo following i.c.v administration
of an H3R agonist335 or after the motivation of the TM through exploratory behavior336.
Moreover, HA has a dominant impact on hippocampal excitability, as pyramidal and
granule cells are deeply motivated by histamine acting on histamine H2R337-339. H1R
administration raises the incidence of sharp wave-related ripples recorded in the CA1
region, in freely moving rats340. Sharp waves are likely to be essential in the generation
of synaptic plasticity and memory consolidation, suggesting the possible implication
of the histaminergic system in learning and memory formation341,342.
Additionally, it was documented that the hippocampus in humans performs an
essential role in the creation and distribution of seizures, as TLE in humans is
characterized by structural defects like HS211-213. Furthermore, several earlier studies
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have documented the vital role of the hippocampus in memory process in humans343,
where hippocampus removal resulted in an inability to gain new memories in affected
patients344 also patients with bilateral lesions, including the entire CA1 field of the
hippocampus suffered from amnesic effects345. Besides, O'keefe et al. documented the
importance of the hippocampus for the creation and use of spatial memory in
rodenst346, and this was also supported by a recent study that confirmed that the
destruction of the hippocampus or its connections resulted in spatial memory severe
deficit347.
1.3.3 Role of H3Rs in locomotion
Locomotion is a central element of animal activity that can be influenced by several
external and internal inducements such as introduction to a novel atmosphere or
circadian rhythm, respectively348,349. Various disorders are associated with locomotor
deficits, including Parkinson’s disease and hyperactivity syndrome. Centrally acting
compounds may also disturb locomotion that modifies further behavioral parameters,
including memory.
Brain HA is involved in locomotor activity, as HDC knockout mice exhibited low
locomotor activity. In addition, H1R knockout mice displayed locomotion,
exploration, and rearing deficit in a novel atmosphere249. Moreover, in numerous
earlier experiments, brain HA was observed with locomotor activity enhancement, as
α-FMH administration caused brain HA depletion that resulted in spontaneous
locomotor activity reduction350,351. Furthermore, it was noted that high brain HA levels
were accompanied by enhanced locomotion352. Lately, it has been demonstrated that
selective stimulation of HA neurons enhances locomotion353. Several H3R antagonists
were reported to increase HA release and ability to improve locomotion354,355.

45
However, opposing data were documented, with H3R knockout mice exhibiting
lowered spontaneous locomotor activity356. In addition, α-FMH administration at a
higher dose (100 mg/kg) in ICR mice enhanced locomotor activity at nighttime
associated with an 85% reduction in brain GABA levels357. Moreover, thioperamide
was found to reduce amphetamine-apomorphine-cocaine-evoked hyperactivity, and
the effect was reversed by RAM administration358. Furthermore, H1R antagonists
improved locomotor activity with the contribution of an opioid-dependent
mechanism359. Interestingly, HA i.c.v. injection showed a biphasic action in rats: a
temporary augmentation then a decline in locomotion activity224.
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Chapter 2: Aims and objectives

Based on the aforementioned evidences on the potential anticonvulsant and
procognitive effects of several H3R antagonists in animal models, and the observed
findings in the lab regarding targeting H3Rs in numerous neuropsychiatric disorders,
objectives of this research is to target the histaminergic system with novel H3R
antagonists to assess their anticonvulsant and procognitive effect applying different
seizure models in rats.
Aims:
1- Evaluate different novel H3Rs antagonists, namely 1-16 of high in-vitro
affinities for hH3Rs, on their in vivo anticonvulsant effect in MES-, PTZ-, and
STR-induced acute seizure models.
2- Study the dose-dependent protective effect of the most promising H3R
antagonist to validate the specification of the observed effect, and abrogate the
protection provided effect by the most promising H3R antagonist by coadministration with the CNS-penetrant H3R agonist, H1R antagonist, and H2R
antagonist to explain the mechanism behind the observed protective effect.
3- Assess the procognitive effect of the most promising H3R antagonist in
different behavioral memory models, namely IAP and NOR, in the same
animal species.
4- Evaluate the simultaneous anticonvulsant and procognitive effect of the
promising H3R antagonist in both PTZ acute-induced seizure model and PTZ
chronic-kindling model.
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5- Examine the modulating effects of the most promising H3R antagonist on
several hippocampal oxidative stress markers, AChE, levels of several brain
neurotransmitters, and expression of c-fos protein, all of which are associated
with both PTZ acute and chronic models.
6- Assess the anticonvulsant effect of the promising H3R antagonist in the PLCinduce SE model and examine the modulating effects of the most promising
H3R antagonist on hippocampal oxidative stress markers and AChE following
PLC- induced SE model.
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Chapter 3: Materials and Methods

3.1 In vitro screening of H3R antagonists namely from 1-16
All in vitro experiments were conducted in the Department of Technology and
Biotechnology of Drugs, Kraków, Poland.
3.1.1 Human histamine H3 receptor (hH3R) Binding Affinity for tested
Compounds 1–16
The affinity for the human histamine H3R was examined applying radioligand
displacement assays with [3H) Nα-methylhistamine at membrane preparations from
human embryonic kidney (HEK)-293 cells, sturdily expressing the receptor.
Experiments were competed in triplicates with seven different concentrations of the
test compounds 1-16 (Figure 7). The assessment of the data obtained was performed
by the software GraphPad Prism 7 (San Diego, CA, USA), using the “one-site
competition” equation. Ki values were calculated from the 50 percent of inhibitory
concentration (IC50) values according to the Cheng-Prusoff equation360 (Table 2).
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Figure 7: Chemical structures of potential H3R antagonists used in this study.

3.1.2 Human histamine H1 receptor (hH1R) Binding Affinity for Selected
Compounds 4, 7 and 13
Radioligand binding was conducted as mentioned earlier utilizing membranes from
CHO-K1 cells sturdily transfected with the human H1 receptor (PerkinElmer.,
Waltham, MA, USA)361,362. Data were fitted to a one-site curve-fitting equation with
Prism 6 (GraphPad Software, city, state, country) and Ki values were estimated from
the Cheng–Prusoff equation360.
3.1.3 Human histamine H4 receptor (hH4R) Binding Affinity for Selected
Compounds 4, 7 and 13
H4R radioligand displacement tests were conducted with Sf9 cell membrane
preparations, expressing the hH4R, as described previously305,362,363. Tests were
competed in triplicates with four suitable concentrations of the test compound. Data
were analyzed by GraphPad Prism 7, using the “one-site competition” equation.
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Table 2: In vitro hH3R affinities of ligands 1-16.
Ligand

Structure

In-vitro affinity
Ki (hH3R)a in nM
[CI)

1

42.3b
[18.3; 97.4)

2

57.3b
[47.2; 69.7)

3

55.9b
[44.8; 69.7)

4

69.3b
[59.2; 81.1)

5

41.1
[25.6; 66.2)

6

52.8
[31.4; 88.8)

7

40.5
[32.9; 50.0)

8

76.1
[53.5; 108.3)

9

110.2
[61.8; 196.4)

10

69.5
[44.4; 108.8)

11

115.2
[78.4; 169.5)

a[3H]N-Methylhistamine binding assay performed with cell membrane preparations of human
embryonic kidney (HEK) cells stably expressing the human histamine H3R. CI-confidence interval; b
data from364; c data from the literature.
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Table 2: In vitro hH3R affinities of ligands 1-16 (continued).
Ligand

Structure

12

In-vitro affinity
Ki (hH3R)a in nM
[CI)
83.6
[65.8; 106.4)

13

137.2
[60.0; 313.9)

14

36.2
[10.0; 130.3)

15

40.2
[13.5; 119.4)

16

38.5
[10.5; 141.6)

Pitolisant

11.69c

(PIT)

a[3H]N-Methylhistamine binding assay performed with cell membrane preparations of human
embryonic kidney (HEK) cells stably expressing the human histamine H3R. CI-confidence interval; b
data from364; c data from the literature.

3.2 In vivo screening of the H3R antagonists
The in vivo screening in this project consisted of two separate sections. The first section
was for screening the anticonvulsant effect of all the compounds using electricallyand chemically- induced seizure models. The second section was for assessing the
procognitive effect of the promising H3R antagonist applying different behavioral
tests.

52
3.2.1 Animals
Experimental inbred male Wistar rats (Central Animal Facility of UAE University)
were used in this study. All animals were maintained in an air-conditioned animal
facility room with controlled temperature (24°C±2°C) and in humidity (55%±15%)
under a-12 light/dark cycle; all animals had free access to food and water. All
experiments of this study were done between 9:00 am to 1:00 pm, and all procedures
were performed according to the guidelines of the European Communities Council
Directive of November 24, 1986 (86/609/EEC) and was approved for the epilepsy
study by the College of Medicine and Health Sciences/United Arab Emirates
University

(Institutional

Animal

Ethics

Committee,

approval

number:

ERA_2017_5676). All efforts were made to minimize animal suffering and to diminish
the number of animals used. In addition, all animal procedures about convulsion
studies were carried out by the same experimenter and in a blind manner. For the in
vivo anticonvulsant and procognitive screening tests, PTZ- acute seizure model and
PLC- induced seizure model Wistar rats weighing between 180-220 g (6-8 weeks old)
were used in this study, while Wistar rats weighing between 140-160 g (4-6 weeks
old) were used for PTZ- chronic model.
3.2.2 Drugs
The H3R antagonists, namely 1-16, that were assessed in this project are:
(1) 3-methyl-1-(5-(naphthalen-2-yloxy) pentyl)piperidine hydrogen oxalate; (2) 1-(5(naphthalen-2-yloxy)pentyl)

azepane

hydrogen

oxalate;

(3)

3-methyl-1-(6-

(naphthalen-2-yloxy)hexyl) piperidine hydrogen oxalate; (4) 1-(6-(naphthalen-2yloxy)hexyl) azepane hydrogen oxalate; (5) phenyl(4-(6-(piperidin-1-yl) hexyloxy)
phenyl)methanone

hydrogen

oxalate;

(6)

(4-(6-(3-methylpiperidin-1-
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yl)hexyloxy)phenyl)(phenyl)methanone hydrogen oxalate; (7) (4-(6-(azepan-1yl)hexyloxy)phenyl)(phenyl)methanone hydrogen oxalate; (8) phenyl(3-(6(piperidin1-yl)hexyloxy)phenyl)methanone hydrogen oxalate; (9) (3-(6-(3methylpiperidin-1yl)hexyloxy)phenyl)(phenyl)methanone hydrogen oxalate; (10) (3-(6-(azepan-1-yl)
hexyloxy)phenyl) (phenyl)methanone hydrogen oxalate; (11) 1-(6-(4-fluorophenoxy)
hexyl)piperidine

hydrogen

oxalate;

(12)

1-(6-(4-fluorophenoxy)hexyl)-3-

methylpiperidine hydrogen oxalate; (13)1-(6-(4-fluorophenoxy)hexyl) azepane
hydrogen oxalate; (14) phenyl(4-(5-(piperidin-1-yl)pentyloxy) phenyl) methanone
hydrogen oxalate; (15) (4-(5-(3-methylpiperidin-1-yl)pentyloxy) phenyl) (phenyl)
methanone hydrogen oxalate; and (16) (4-(5-(azepan-1-yl)pentyloxy) phenyl) (phenyl)
methanone hydrogen oxalate364. All these compounds were synthesized in the
Department of Technology and Biotechnology of Drugs (Kraków, Poland), according
to the methods described previously304,365. Pentylenetetrazol (PTZ, 60 or 40 mg/kg,
intraperitoneal (i.p.), strychnine (STR, 3.5 mg/kg i.p.), valproic acid (VPA, 300 mg/kg,
i.p.), (PHT, 10 mg/kg, i.p.), (R)-α-methylhistamine dihydrochloride (RAM, 10 mg/kg,
i.p.), pyrilamine (PYR, 10 mg/kg, i.p.), zolantadine dimaleate (ZOL, 10 mg/kg, i.p.),
donepezil hydrochloride (DOZ), dizocilpine hydrogen maleate (DIZ), scopolamine
hydrobromide (SCO), pilocarpine hydrochloride (PLC), and scopolamine methyl
nitrate were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). (DZP) was
manufactured by Gulf Pharmaceutical Industries (Ras Al Khaimah, United Arab
Emirates) and was obtained from Dr. Ameen Al Amaydah (Department of Emergency
Medicine, Emirates International Hospital, Al Ain, United Arab Emirates). All
compounds were dissolved in isotonic saline and administered intraperitoneal (i.p.) at
a volume of 1 mL/kg. All doses of test compounds are expressed in terms of the free
base.
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3.2.3 Screening of the in vivo anticonvulsant effect of all the novel H3R
antagonists (1-16) in different acute-induced seizure models
3.2.3.1 Maximal Electroshock (MES)-Induced Seizure model
MES test was developed by Toman at el in 1946366 and still one of the best-validated
preclinical used models against generalized tonic-clonic seizures (GTCS). Seizures in
the MES test arise from the brain stem upon exposure to auricular excitation through
ear electrodes. MES used to screen the protective effect of the potential compounds,
and their capability to prevent seizures extends through neuronal tissue367. Seizures
were induced as described previously361,289,368, by applying 50 Hz alternating current
of 120 mA intensity for 1 second through ear electrodes to each rat, which provokes
maximal convulsions of their hind limbs, with tonic extension as the endpoint of the
test. Abolition or reduction in the tonic hind limb extension (THLE) time was defined
as protection from MES-induced seizure model.
For the initial screening of the anticonvulsant effect of the H3R antagonists (1-16)
applying MES-induced seizure model, 18 groups were included in this study, and each
group consisted of (n=6-8) rats matched for age and weight (180-220 g) as follows;
group (1): control group injected with (SAL 0.9% i.p.), group (2): positive control
group injected with PHT (10 mg/kg, i.p.) (the dose of PHT as used before is the
minimal dose that protected animals against the spread of MES-induced seizures
without mortality), and groups (3-18): treatment groups injected with the novel H3R
antagonists 1–16 at a dose of (10 mg/kg, i.p.). All H3R antagonists and PHT were
injected 30-45 min before applying the electroshock, and after that, the time of THLE
was recorded.
Furthermore, other MES experiments were done for the dose-dependency study for the
most promising protective compound, in three separate groups of (n=6-8) rats matched
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for age and weight (180-220 g) in each group. The compound with the most promising
protection in MES model was administered at doses of 2.5, 5, or 15 mg/kg, i.p. 30–45
min before the MES challenge.
In addition, abrogative studies were conducted, as the most effective dose of the
promising H3R antagonist was designated for further analysis, in three separate groups
of (n=6-8) rats matched for age and weight, the selected dose of the compound was
co-injected with pyrilamine (PYR) (10 mg/kg, i.p.) a centrally acting H1R antagonist,
zolantadine (ZOL) (10 mg/kg, i.p.) a centrally acting H2R antagonist 30-45 min prior
to MES, or (R)-α-methylhistamine (RAM) (10 mg/kg, i.p.) a centrally acting H3R
agonist 20 min prior to MES to ensure its presence in the CNS, as RAM was described
to show fast metabolism. An additional three groups of (n=6) rats were tested as
follows; SAL was co-injected with PYR, ZOL, or RAM alone (10 mg/kg, i.p.) before
MES to exclude any effect of PYR, ZOL, or RAM on THLE time.
3.2.3.2 Chemically- induced seizure models
In this study and according to earlier protocols, two convulsant chemical agents had
been used for inducing acute seizures. Namely (PTZ 60 mg/kg, i.p.) and (STR 3.5
mg/kg, i.p.)369.
3.2.3.2.1 PTZ- induced seizures model
PTZ is a non-competitive GABAA receptor antagonist, was first synthesized in
1924370. PTZ-induced acute seizure model is widely used as a preclinical chemical
model against GTCS. According to the previous protocols371,372. PTZ (60 mg/kg, i.p.)
was systemically administered to all rats and immediately observed for 30 min.
Average seizure score and percentage of protection against GTCS were recorded to
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assess the protection provided by the potential test compound against seizures. Seizure
score was graded according to Racine scale (stage 0, no change in behavior; stage 1,
stereotype mouthing, eye blinking, and/or mild facial clonus; stage 2, head nodding
and/or severe facial clonus; stage 3, myoclonic jerk in forelimbs; stage 4, clonic
convulsions in the forelimbs with rearing; stage 5, generalized clonic convulsions
associated with loss of balance)373.
For the initial screening of the anticonvulsant effect of the H3R antagonists (1-16)
applying PTZ-induced seizure model, 18 groups were included in this test, and each
group consisted of (n=6-8) rats matched for age and weight (180-220) as follows;
group (1): control group injected with (SAL 0.9% i.p.) + PTZ (60 mg/kg, i.p.), group
(2): positive control group injected with VPA (300 mg/kg, i.p.) + PTZ (60 mg/kg, i.p.)
(the dose of VPA as used before is the minimal dose that protected animals against the
PTZ-induced seizures without mortality)374,375, and groups (3-18): treatment groups
injected with the novel H3R antagonists 1–16 at a dose of (10 mg/kg, i.p.) + PTZ (60
mg/kg, i.p.). All H3R antagonists and VPA were injected 30-45 min before PTZ
injection.
Moreover, other PTZ experiments were done for dose-dependency study for the most
promising protective compound, in three separate groups of (n=6-8) rats, the
compound with the most promising protection in PTZ model was administered at doses
of 2.5, 5, or 15 mg/kg, i.p. 30–45 min before the PTZ injection.
In addition, abrogative studies were conducted, as the most effective dose of the
promising H3R antagonist was designated for further analysis, in three separate groups
of (n=6-8) rats, the selected dose of the compound was co-injected with PYR (10
mg/kg, i.p.) a centrally acting H1R antagonist, ZOL (10 mg/kg, i.p.) a centrally acting
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H2R antagonist 30-45 min before PTZ, or RAM (10 mg/kg, i.p.) a centrally acting
H3R agonist 20 min prior to PTZ to ensure its presence in the CNS, as RAM was
described to show fast metabolism. An additional three groups of (n=6) rats were tested
as follows; PYR, ZOL, or RAM (10 mg/kg, i.p.) were co-injected with SAL + PTZ to
exclude any effect of PYR, ZOL, or RAM on average seizure score.
3.2.3.2.2 STR-induced seizure model
STR is a glycine receptor antagonist, and it is used as a preclinical chemical model
against GTCS. According to the previous protocols371,305 STR (3.5 mg/kg, i.p.) was
systemically administered to all rats and immediately observed for 30 min. Average
seizure score and percentage of protection against GTCS were recorded to assess the
protection provided by the potential test compound against seizures. Seizure score was
graded according to Racine scale (stage 0, no change in behavior; stage 1, stereotype
mouthing, eye blinking, and/or mild facial clonus; stage 2, head nodding and/or severe
facial clonus; stage 3, myoclonic jerk in forelimbs; stage 4, clonic convulsions in the
forelimbs with rearing; stage 5, generalized colonic convulsions associated with loss
of balance)373.
For the initial screening of the anticonvulsant effect of the H3R antagonists (1-16)
applying STR-induced seizure model, 18 groups were included in this test, and each
group consisted of (n=6-8) rats matched for age and weight (180-220) as follows;
group (1): control group injected with (SAL 0.9% i.p.) + STR (3.5 mg/kg, i.p.), group
(2): positive control group injected with VPA (300 mg/kg, i.p.) + STR (3.5 mg/kg, i.p.)
(the dose of VPA as used before is the minimal dose that protected animals against the
PTZ-induced seizures without mortality)374,375, and groups (3-18): treatment groups
injected with the novel H3R antagonists 1–16 at a dose of (10 mg/kg, i.p.) + STR (3.5
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mg/kg, i.p.). All H3R antagonists and VPA were injected 30-45 min before STR
injection.
Furthermore, another STR experiments were done for dose-dependency study for the
most promising protective compound, in three separate groups of (n=6-8) rats, the
compound with the most promising protection in STR model was administered at
doses of 2.5, 5, or 15 mg/kg, i.p. 30–45 min before the STR injection. In addition,
abrogative studies were conducted, as the most effective dose of the promising H3R
antagonist was designated for further analysis, in three separate groups of (n=6-8) rats,
the selected dose of the compound was co-injected with PYR (10 mg/kg, i.p.) a
centrally acting H1R antagonist, ZOL (10 mg/kg, i.p.) a centrally acting H2R
antagonist 30-45 min prior to STR, or RAM (10 mg/kg, i.p.) a centrally acting H3R
agonist 20 min prior to STR to ensure its presence in the CNS, as RAM was described
to show fast metabolism. An additional three groups of (n=6) rats were tested as
follows; PYR, ZOL, or RAM (10 mg/kg, i.p.) were co-injected with SAL + STR to
exclude any effect of PYR, ZOL, or RAM on average seizure score.
3.2.4 Screening of the procognitive effect of the promising H3R antagonist
applying different behavioral tests
In vivo screening of the procognitive effect for the most promising H3R antagonist
(compound 4) was assessed applying four different behavioral tests.
3.2.4.1 Inhibitory Avoidance Paradigm (IAP)
IAP test is a fear-motivated test mainly used to evaluate the effect of chemical
compounds on different types of learning and memory. In this study, retrieval long
term memory was assessed post DIZ- or SCO- induced amnesic effect in male Wistar
rats applying IAP. IAP test was conducted utilizing Passive Avoidance Apparatus
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(Step-through Cage, 7550, Ugo Basile, Comerio, Italy). The apparatus consists of two
similar compartments (51 x 25 x 24 cm each) white and black with a grid floor,
separated by an automated guillotine door (Figure 8). The IAP test was conducted as
previously described376,377,305,378,379,380, to assess the procognitive effect of the
promising compound (compound 4) applying DIZ- and SCO- induced amnesic effect.
The experiment consisted of two trails, two consecutive training days, and the test to
be performed on the third day with 24 hours’ interval. In the first training day, each rat
was placed in the white compartment facing the door after 30 seconds of orientation
time; the door was automatically raised up. Once the rat entered the dark compartment
with his head, and all his four paws the door was lowered, and a foot shock of 0.4 mA
(20 Hz, 8.3 ms) was delivered to the grid floor for a duration of 3 seconds, and the
step-through latency (STL) time was measured. Cut off time of 60 seconds was given
for the rat to cross the door; otherwise, the rat was excluded from the experiment. The
intensity of the foot shock was chosen to minimize pain and reactions, such as jumping
and screaming, in the examined animals. After the foot shock, the respective rat was
immediately transferred to its home cage, and the chambers were cleaned with ethanol
70% in order to eliminate any confounding olfactory cues.
In the second training day (24 hours later), the same protocol was applied except that
the cut off time was increased to 300 seconds, and no foot shock was delivered to the
rat. On both training days, the rats received an injection of saline 30-45 minutes before
starting the experiment. In the test day (24 hours later) same protocol of the second
training day was applied, but animals turned amnesic by the administration of DIZ (0.1
mg/kg, i.p.) or SCO (1 mg/kg, i.p.) 30-45 minutes prior starting the test. The IAP task
was conducted in the morning between 8:00 am and 12:00 noon. In this experiment,
the animals were divided into 7 experimental groups of (n=6-8) rats matched for age
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and weight in each group: All groups in the test day were treated with i.p. injections
30–45 minutes before the test as follows; group (1): control group injected with (SAL
0.9% i.p.), groups (2-3): amnesic groups treated with DIZ (0.1 mg/kg, i.p.) or SCO (1
mg/kg, i.p.) + (SAL 0.9% i.p.), groups (4-5): positive control groups injected with
DOZ (1 mg/kg, i.p.) + DIZ or SCO, and groups (6-7): treatment groups injected with
test compound 4 (10 mg/kg, i.p.) + DIZ or SCO. Moreover, other IAP experiments
were done for a dose-dependency study applying the most promising amnesic
compound (DIZ or SCO) to induced memory impairment in rats. Three separate
groups of (n=6-8) rats were tested as follows; groups 1-3: received DIZ (0.1 mg/kg,
i.p.) + test compound 4 (1.25, 2.5, or 5 mg/kg, i.p.) 30-45 minutes before the test.
Furthermore, the procognitive effect of H3R antagonist 4 was further investigated with
abrogation tests by co-administration of the most effective dose of H3R antagonist 4,
in three separate groups of (n=6-8) rats, the selected dose of the test compound 4 +
DIZ was co-injected with PYR (10 mg/kg, i.p.) a centrally acting H1R antagonist, ZOL
(10 mg/kg, i.p.) a centrally acting H2R antagonist 30-45 min prior the test, or RAM
(10 mg/kg, i.p.) a centrally acting H3R agonist 20 min prior the test to ensure its
presence in the CNS, as RAM was described to show fast metabolism. An additional
three groups of (n=6-8) rats were tested as follows: DIZ + SAL were co-injected with
PYR, ZOL, or RAM (10 mg/kg, i.p.) to excludes any effect of PYR, ZOL, or RAM on
STL time. Doses of PYR, ZOL, and RAM were selected according to the previous
publications305,325,304.
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Figure 8: Passive avoidance apparatus utilized in this study.
In test day all rats were treated with DIZ 30 minutes before the test to induce amnesic effect, test
compound 4 was injected 30-45 minutes, before DIZ treatment. STL time was measured to assess
long-term memory.

3.2.4.2 Novel Object Recognition (NOR) test
NOR test is a behavioral model for testing both short- and long-term recognition
memory. Interestingly the test depends on rodents' natural behavior, as there is no
reward or penalty for the animals in the NOR test. NOR test was conducted according
to the previous protocols322,381 in an open field box 50 cm × 35 cm × 50 cm (Figure
9). The NOR task was conducted in the morning between 8:00 am and 12:00 noon.
On the first day, two habituation sessions with an interval of 1 hour, were conducted.
Each rat was permitted to stay in the box for 3 min habituation time, after that the rat
was returned to its home cage and the box was cleaned with ethanol 70% to eliminate
any confounding olfactory clues. The experimental session on the second day (24
hours later) consisted of T1 (training session) and T2 (test session), which was
conducted after 120 minutes for STM assessment and 24 hours for LTM assessment.
In T1, each rat was introduced to two identical objects (9 cm × 5 cm × 9 cm) wood
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blocks with the same size, shape, and color, which were placed in opposite corners of
the box (30 cm apart) for 3 minutes. The time each rat spent exploring each object was
calculated (exploration of an object defined as touching or snuffing the object, other
behavioral observations, e.g., turning around or sitting on the object was not
considered an experimental behavior). Immediately after training, each rat was
returned to its home cage, and the box and the objects were cleaned with ethanol 70%
in order to remove any confounding olfactory cues. In T2, an identical familiar object
to eliminate any olfactory clues and a novel object (different in shape, size, and color)
were presented to each rat, and the time spent exploring both the old and the novel
objects was calculated. The animals which explored the objects for less than 10
seconds were excluded from the experiment. All rats were treated with DIZ to induce
an amnesic effect to investigate the procognitive effect of the promising compound
(4). In this experiment, the animals were divided into 6 experimental groups of (n=68) rats matched for age and weight in each group: All groups following T1 were
treated with i.p. injections as follows; group (1): control group injected with (SAL
0.9% i.p.), group (2): amnesic group treated with DIZ (0.1 mg/kg, i.p.) + (SAL 0.9%
i.p.), group (3): positive control group injected with DOZ (1 mg/kg, i.p.) + DIZ (0.1
mg/kg, i.p.), and groups (4-6): treatment groups were treated with test compound 4
(2.5, 5, and 10 mg/kg, i.p.) + DIZ (0.1 mg/kg, i.p.). In LTM assessment, test compound
4 was re-injected 30-45 min before T2. Besides, the procognitive effect of the test
compound 4 was further investigated with abrogation tests by co-administration of the
most effective dose of the test compound 4 + DIZ + PYR, ZOL, or RAM (10 mg/kg,
i.p.) following T1, also 30-45 minutes for test compound 4, PYR, and ZOL and 20
minutes for RAM before T2 in LTM assessment.
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PYR, ZOL, and RAM were co-injected with DIZ to eliminate any possible effects of
PYR, ZOL, or RAM on time spent exploring the objects. Doses of the compounds and
the treatment schedule were selected in accordance with previously published studies
that have reported the memory-enhancing effects of H3R antagonists in the NOR
task322,381. The discrimination index (DI) was calculated from the variables N–F/N+F
(where N is the time the rat spent exploring the novel object and F is the time the rat
spent exploring the familiar object in T2).

Figure 9: NOR apparatus utilized in this study.
T1: training session, T2: test session. In T1 all rats were introduced to two identical objects. Novel
object was replaced one of the identical objects in T2 (2 hours or 24 hours) later for STM or LTM
assessment, respectively. Exploration time for each object was measured and DI was calculated. DIZ
and compound 4 were injected post T1, and compound was 4 re-injected 30-45 minutes before T2 in
LTM assessment.

3.2.4.3 Elevated Plus Maze (EPM) test
EPM test is a behavioral model for estimating anxiety-like behaviors in animals. The
EPM apparatus consists of several parts including one central part (8 cm × 8 cm), two
opposing open and closed arms (30 cm × 8 cm), and non-transparent walls (30 cm in
height) illuminated with four 60 V light-emitting diodes (LEDs) (Figure 10). EMP test
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was conducted in the morning between 08:00 am and 12:00 noon, as previously
described322,382. Each rat was placed in the center of the maze (50 cm above the floor)
facing one of the open arms for 5 minutes, the total numbers of entries to both open
and closed arms (with head and forepaws) and the time spent in both open and closed
arms was manually measured. EPM apparatus was cleaned after each rat with 70%
ethanol to remove any confounding olfactory cues. In this experiment, the animals
were divided into 4 experimental groups of (6-8 rats matched for age and weight in
each group): All animals received i.p. injections 30–45 minutes before the test to assess
the anxiety-like parameters and locomotor activity as follows; group (1): control group
injected with (SAL 0.9 % i.p.), group (2): positive control group treated with DZP (10
mg/kg, i.p.), and groups (3-4): treatment groups treated with the test compound 4 (5
and 10 mg/kg, i.p.). The total number of closed arm entries was an indication of
locomotor activity, while the total number of entries and total time spent in open arms
were considered to be an indicator of anxiety level.
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Figure 10: EPM apparatus used in this study.
All rats were placed in the center, total numbers of entries and the total time spent in both open and
closed arms were calculated. Compound 4 was injected 30-45 minutes before the test.

3.2.4.4 Open Field Test (OFT)
Locomotor activity was measured using open field square box 56 × 56 × 56 cm3
(length/width/height) as previously described382,380,379. The test box is open from above
with black polyvinyl chloride walls and was illuminated with four 60 V LEDs. The
floor of the box is divided into 16 equal squares (14 cm in diameter), and the 4 central
squares are regarded as the “center” of the field (Figure 11). The test was conducted
in the morning between 8.00 am to 12.00 noon. In the test day, each rat was placed in
the center of the box and allowed to move freely for 3 minutes, as habituation time,
then the rat was returned to its home cage, and the box was cleaned with ethanol 70%
to avoid any confounding olfactory clues. 30 minutes later, all the animals received
i.p. injection of the tested compound 30-45 minutes before the test session. In the test
session, each rat was placed in the center by its tail and allowed to move freely for 3
minutes, animal activity (distance traveled, and time spent in locomotion) was
recorded by a digital camera placed above the arena. When a rat moved from one
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square to another with its four paws, the one-line crossing is noted, and a distance of
14 cm is recorded. As previously described, the following parameters were manually
scored: the number of lines crossed (defined as at least three paws in a square) and
time spent in the center of the arena and in the periphery during a 3 min. test. Less time
spent in the central area is usually taken as a measure of a higher level of anxiety, while
less distance traveled indicates a deficit in locomotor activity. In this experiment, the
animals were divided into 4 experimental groups (6-8 rats matched for age and weight
in each group): All animals received i.p. injection 30–45 minutes before the test
session to assess the anxiety-like parameters and locomotor activity as follows; group
(1): control group injected with (SAL 0.9% i.p.), group (2): positive control group
injected with DOZ (1 mg/kg, i.p.), and groups (3-4): treatment groups treated with test
compound 4 (5 and 10 mg/kg, i.p.).

Figure 11: OFT apparatus utilized in the study.
All rats were placed in the center, total distant traveled and total time spent in both the center and the
periphery were calculated. Compound 4 was injected 30-45 minutes before the test.
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3.2.5 PTZ model for assessing the simultaneous memory impairment associated
with PTZ- acute and chronic models
3.2.5.1 PTZ- induced acute model
The PTZ- induced seizure model for assessing the simultaneous memory impairment
associated with PTZ- induced seizures protocol was applied as previously
described130,131,133 (Figure 12). On day 1, all animals were injected with PTZ (60
mg/kg, i.p.) after the training session in both IAP and EPM tests. The test session was
conducted 24 hours later to assess the memory impairment associated with PTZinduced seizures. In set of experiments the animals were divided to five experimental
groups (12-16) rats matched for age and weight (180-220 g) in each group) as follows;
group (1): naïve group injected with (SAL 0.9% i.p.), group (2): PTZ group injected
with PTZ (60 mg/kg, i.p.), group (3): positive control group treated with VPA (300
mg/kg, i.p.) + PTZ (60 mg/kg, i.p.), and groups (4-5): treatment groups injected with
test compound 4 (5 and 10 mg/kg, i.p.) + PTZ (60 mg/kg, i.p.). VPA and compound 4
were injected 30-45 minutes before the PTZ injection.
3.2.5.2 PTZ- kindling model
The PTZ- kindling protocol was applied as previously described with slight
modifications383,71,384,318,72,385,141. All animals were injected with a sub-convulsant dose
of PTZ (40 mg/kg, i.p.) three times a week for 12 injections (26 days) (Figure 12). The
PTZ injections were stopped at the end of the 12 injections or when animals are fully
kindled upon the development of seizure score 4 or 5 in three consecutive injections.
All animals were observed for 30 minutes after each PTZ injection, and the average
seizure score for each rat was recorded according to the following Racine scale: (stage
0, no change in behavior; stage 1, stereotype mouthing, eye blinking, and/or mild facial
clonus; stage 2, head nodding and/or severe facial clonus; stage 3, myoclonic jerk in
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forelimbs; stage 4, clonic convulsions in the forelimbs with rearing; stage 5,
generalized clonic convulsions associated with loss of balance373). The kindling
percentage and the survival rates for each group were calculated. Different doses of
PTZ were applied to induce kindling (35, 37.5, and 40 mg/kg), 40 was the most optimal
dose to induce kindling in Wistar rats with less mortality. Inset of experiments the
animals were divided to five experimental groups (n=12-16) rats matched for age and
weight (140-160 g) in each group as follows; group (1): naïve group injected with
(SAL 0.9% i.p.) three times a week, group (2): PTZ group injected with PTZ (40
mg/kg, i.p.) three times a week, group (3): positive control group injected with VPA
(300 mg/kg, i.p.) + PTZ (40 mg/kg, i.p.) three times a week, and groups (4-5):
treatment groups treated with test compound 4 (5 and 10 mg/kg, i.p.) + PTZ (40 mg/kg,
i.p.) three times a week. SAL and PTZ were injected 3 times a week for 12 injections
(26 days), while VPA and test compound 4 were injected 30-45 minutes before each
PTZ injection. The training session in IAP and EPM was performed 24 hours post the
last PTZ injection, followed by the test session (24 hours later). The anticonvulsant
and procognitive effects of H3R antagonist 4, were further investigated with
abrogation tests by co-administration of the most effective dose of H3R antagonist 4
+ (PYR, ZOL, or RAM (10 mg/kg, i.p.) 30-45 minutes before each PTZ injection, only
for RAM 20 minutes before each PTZ injection to ensure its presence in the CNS, as
RAM was described to show fast metabolism. PYR, ZOL, and RAM were co-injected
alone with PTZ or SAL to eliminate any possible effects of PYR, ZOL, or RAM on
the kindling procedure and the memory function.
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Figure 12: Schematic illustration of both PTZ- acute and PTZ- kindling models,
experimental protocol, drug treatments, behavioral studies, and biochemical
assessments.
Male Wistar rats were injected with PTZ (60 mg/kg) in acute- PTZ model, while PTZ (40 mg/kg) was
injected 3 times a week for 12 injections in PTZ-kindling model. Behavioral studies were done (days
1-2 and days 27-28 for PTZ- acute and chronic models, respectively). All animals were sacrificed in
day 2 in PTZ- acute model and 24 hours after the last behavioral assessment (day 29) in PTZ- kindling
model for both biochemical assessments and IHC. PTZ: Pentylenetetrazol, IAP: Inhibitory avoidance
paradigm, EPM: Elevated plus maze, IHC: Immunohistochemistry, AChE: Acetylcholinesterase, NT:
Neurotransmitters, GLU: Glutamate, ACh: Acetylcholine, HA: Histamine.

3.2.5.3 Behavioral tests utilized in both PTZ- acute and chronic models to assess
memory impairment associated with PTZ- induced seizures
The memory impairment associated with PTZ seizures was assessed applying (IAP)
and (EPM). In PTZ- kindling model the tests were conducted 24 hours after the last
PTZ injection. While in PTZ- acute model, the training session was conducted 120
min. before PTZ injection and the test session 24 hours later. Each group consists of
(n= 6-8 animals) and different animals were used in each behavioral test.
3.2.5.3.1 Inhibitory Avoidance Paradigm (IAP)
IAP test is a fear-motivated test mainly used to evaluate the effect of chemical
compounds on learning and memory, and it is the most widely used behavioral test to
investigate memory impairments associated with PTZ acute as well as chronic seizures
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as previously described71,386,387. IAP was conducted as previously described388,389,390,
as it consists of two trails (training and test). In the training day, each rat was placed
in the white compartment, and after 30 seconds habituation time, the door was
automatically raised up. Once the rat with all its four paws and head entered the dark
compartment, the door was closed, and a foot shock of 0.4 mA (20 Hz, 8.3 ms) was
delivered to the grid floor for 3 seconds, and STL time was measured. Immediately
after the foot shock, the rat was returned to its home cage, and the compartments were
cleaned up with ethanol 70%. Cut off time of 60 seconds was given for the rat to cross
the door; otherwise, the rat was excluded from the experiment. In the test session (24
hours later), the same protocol was applied except that the cut off time was increased
to 300 seconds, and no foot shock was delivered to the rat. The reduction of STL time
is used as an indicator of memory impairment.
3.2.5.3.2 EPM
EPM test is usually used to assess anxiety-related behaviors in rodents. However, and
based on the way of experimental conduct, EPM was shown to provide convincing
experimental face validity for the assessment of spatial memory impairments
associated with PTZ seizures in rodents69,391,72,392,393. EPM test for assessing the
memory impairment associated with both PTZ acute and chronic models was
conducted as previously described69,391,72,392 (Figure 13). During the acquisition trial
on the first day, each rat was placed at the distal ending of the open arm facing away
from the central platform. Transfer latency time (TLT), which is the time required for
the rat to enter any of the closed arms with its four paws, was measured. After 10
seconds spent in the closed arm, the animal was returned to its home cage, and the
apparatus was cleaned with ethanol 70%. Cut off time of 60 seconds was given for the
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rat to enter any of the closed arms. Otherwise, the rat was excluded from the
experiment. Subsequently, memory retention was examined 24 hours later, applying
the same protocol of the first day. Prolonged TLT is an indication of memory
impairment of PTZ treated animals131,49.

Figure 13: EPM apparatus used in both PTZ-acute and chronic models for memory
assessment.
All rats were placed in the distal ending of one of the open arms, TLT was measured as an indicator
for memory impairment. TLT: Transfer latency time.

3.2.5.4 Brain collection and tissue preparation for biochemical studies and
immunohistochemistry (IHC)
All the rats were divided into two groups, and each group contains (n = 6-8) rats. On
day 2 one hour after completing the behavioral assessments in PTZ- acute model, and
24 hours after the last behavioral test in PTZ- kindling model, all the rats in the first
half of the animals (n= 6-8 rats) were anesthetized with pentobarbital (40 mg/kg body
weight). Cardiac perfusion was carried out using 0.01 M phosphate-buffered saline
(PBS) at pH 7.4 in order to flush the blood out in rats. Then brains were quickly
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removed and placed on an ice-plate where each brain was cut, and the hippocampus
was removed from the brain and immediately snap-frozen in liquid nitrogen for further
use. For tissue preparation, the hippocampus was weighed and divided into two equal
sections. The first part was homogenized in KCL buffer (Tris–HCl, 10 mM NaCl, 140
mM KCl, 300 mM EDTA, 1 mM Triton-X-100 0.5 %) at pH 8.0 supplemented with
protease and phosphatase inhibitor. The homogenate was centrifuged at 10,000×g for
30 min at 4°C. The clear supernatant was collected for estimation of oxidative stress
markers: MDA, GSH, CAT, and SOD. The second part was homogenized in ice-cold
(0.05 M, pH 8.0) phosphate buffer PB. The homogenate was then centrifuged at
10,000×g for 30 min at 4°C. The clear supernatant was collected for estimation of
AChE and neurochemical estimations of HA, ACh, GLU, and GABA.
For IHC method, the other half of the animals were anesthetized with pentobarbital
(40 mg/kg body weight), 24 hours after the last behavioral test in PTZ- kindling model,
and 2 hours post PTZ injection in PTZ-acute model. Cardiac perfusion was carried out
using 0.01 M phosphate-buffered saline (PBS) at pH 7.4 in order to flush the blood
out, and all the rats were further perfused with Zamboni solution (buffered picric acidparaformaldehyde), and the brains were fixed overnight in Zamboni solution at 4°C
The day after, the brains were dehydrated with graded concentrations of ethanol, then
the ethanol residue was removed by xylene, and lastly, embedded in liquid paraffin
for further use in IHC analysis394. All experimenters who performed the behavioral,
biochemical tests, and IHC analysis were blinded to the experimental groups.
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3.2.5.4.1 Oxidative stress markers
3.2.5.4.1.1 MDA
The levels of lipid peroxidation product, MDA, were measured using the MDA
detection kit (North West Life Science, Vancouver, WA, USA). The protocol of the
assay was followed, as described in the kit datasheet. All the samples and standards
(150 μL) were incubated with thiobarbituric acid TBA (150 μL), in the presence of
acid reagent to expedite the hydrolysis of MDA for 60 min at 60 °C to form MDATBA2 adduct that absorbs significantly at 532 nm. After that, all the samples and
standards were centrifuged for 2 min at 10,000×g. Then all the reaction solutions were
transferred to 96 well plate reader to record the absorbance at 532 nm. The assay used
a standard curve of MDA to calculate the amount of MDA in the samples. The results
are expressed as μM MDA/mg protein.
3.2.5.4.1.2 GSH
The levels of GSH were measured using a commercially available GSH kit (SigmaAldrich Co. St Louis, MO, USA). First, all the samples were deproteinized with 5%
5-sulfosalicylic acid solution; after that, the samples were centrifuged at 10,000×g for
10 min to order to eliminate ant precipitated protein, then the supernatant was used in
this GSH measurement. Incubation of all the samples and standards (10 μL) in 96 well
plates with (150 μL) working reagent (assay buffer + 5, 5′-dithiobis (2-nitrobenzoic
acid) DTNB + GSH reductase) for 5 minutes at room temperature RT, then it was
diluted with NADPH solution (50 μL). The absorbance of the samples and standards
were recorded at 412 nm with the kinetics for 5 minutes by using the microplate reader.
The assay used a standard curve of GSH to calculate the amount of GSH in the
samples. The results are expressed as μM GSH/mg protein.
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3.2.5.4.1.3 CAT
The activity of the antioxidant enzyme, CAT, was estimated using a commercially
available assay kit (Cayman Chemical Company, Ann Arbor, MI, USA). Briefly, CAT
was estimated by adding (20 µl) samples or standards of different concentrations with
(100 µl) assay buffer and (30 µl) methanol in a 96-well plate. The reaction was initiated
by adding H2O2 (20 µl) to each well to produced formaldehyde, and the 96-well plate
was covered and incubated on a shaker for 20 min at RT. Potassium hydroxide (30 µl)
was used to terminate the reaction, and subsequently, (30 µl) CAT purpald was added
to react with formaldehyde and produce bicyclic heterocycle, and then the 96-well
plate was covered and incubated on a shaker for 10 min at RT. After that, (10 µl) CAT
potassium periodate was added to each well to oxidize the bicyclic heterocycle and
change the color to purple. The plate was covered and incubated for 5 min on a shaker
at RT. Finally, absorbance was read at 540 nm using a microplate reader. The assay
used a standard curve of CAT to calculate the amount of CAT in the samples. The
CAT activity was expressed as the amount of enzyme the cause the formation of 1
nmol of formaldehyde per min (nmol/min/mg).
3.2.5.4.1.4 SOD
The activity of the antioxidant enzyme SOD was estimated by using a commercially
available assay kit (Cayman Chemical Company, Ann Arbor, MI, USA). Briefly, SOD
was measured by adding (10 µl) diluted samples or standards of different
concentrations with (200 µl) radical detector in a 96-well plate. The reaction was
initiated by adding (20 µl) xanthine oxidase to each well; then, the 96-well plate was
covered and incubated on a shaker at RT for 30 min. Finally, absorbance was read at
450 nm using a microplate reader. The assay used a standard curve of SOD to calculate
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the amount of SOD in the samples. The SOD activity was expressed as the amount of
the enzyme required to reveal a 50% dismutation of the superoxide radical (U/ml).
3.2.5.4.2 AChE activity
The activity of AChE was estimated using a colorimetric assay kit (Biovision
company, Milpitas, USA). All samples (5 µl) were diluted with (45 µl) AChE assay
buffer in 96-well plate; then the reaction was initiated by adding (50 µl) reaction mix
(AChE assay buffer, AChE probe, AChE substrate, and choline oxidase enzyme mix)
to each well, after that the 96-well plate was incubated in 37°C for 20-30 min. Finally,
absorbance was read at 570 nm in a kinetic model using a microplate reader. The assay
used a standard curve of AChE to calculate the amount of choline in the samples.
AChE activity was expressed as the amount of the enzyme that produces 1.0 nmol of
choline per min (nmol/min/mg).
3.2.5.4.3 Neurochemical estimation
3.2.5.4.3.1 Estimation of hippocampus GABA concentration in both PTZ- acute
and chronic models
The hippocampal concentration of GABA was estimated using a quantitative sandwich
enzyme linked-immunosorbent assay (Elisa) kit (My BioSource company, Milpitas,
USA). The protocol of the assay was followed, as described in the kit datasheet. All
the samples and standards (50 μL) were incubated with HPR-conjugated reagent (100
μL) for 60 minutes at 37°C. After that, all the wells were automatically washed for 4
times using a wash solution. Later, chromogen A (50 μL) and chromogen B (50 μL)
were added to each well, and the plate was incubated for 15 minutes at 37°C.
Afterword, the reaction was stopped by adding (50 μL) of stop solution, and the
absorbance was recorded at 570 nm 15 minutes later. The assay used a standard curve
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of GABA to calculate the amount of GABA in the samples. GABA concentration was
expressed as µmol/mg.
3.2.5.4.3.2 Estimation of hippocampus (GLU) concentration in both PTZ- acute
and chronic models
The hippocampal concentration of GLU was estimated using a colorimetric assay kit
(Biovision company, Milpitas, USA). The protocol of the assay was followed, as
described in the kit datasheet. All samples and standards with different concentrations
were added to the wells in 96-well plate (10 μL), and each well was brought to (50 μL)
by assay buffer. The reaction started by adding (100 μL) of the working reagent (GLU
assay buffer, GLU developer, and GLU enzyme mix), and the plate was incubated for
30 minutes at 37°C. After that, the absorbance was recorded at 450 nm. The assay used
a standard curve of GLU to calculate the amount of GLU in the samples. GLU
concentration was expressed as nmol/mg.
3.2.5.4.3.3 Estimation of hippocampus histamine (HA) concentration in both
PTZ- acute and chronic models
The hippocampal HA concentration was estimated using a colorimetric assay kit
(Abecam company, Cambridge, United Kingdom). The protocol of the assay was
followed, as described in the kit datasheet. All samples and standards with different
concentrations were added to the wells in 96-well plate (10 μL), and each well was
brought to (50 μL) by HA assay buffer. The reaction started by adding (50 μL) of the
working reagent (HA assay buffer, HA probe, and HA enzyme mix), and the plate was
incubated for 30 minutes at 37°C. After that, the absorbance was recorded at 450 nm.
The assay used a standard curve of HA to calculate the amount of HA in the samples.
HA concentration was expressed as nmol/mg.
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3.2.5.4.3.4 Estimation of hippocampus (ACh) concentration in both PTZ- acute
and chronic models
The hippocampal ACh concentration was estimated using a colorimetric assay kit
(Abecam company, Cambridge, United Kingdom). The protocol of the assay was
followed, as described in the kit datasheet. All samples in duplicate and standards with
different concentrations were added to the wells in 96-well plate (10 μL), and each
well was brought to (50 μL) by choline assay buffer. The reaction started by adding
(50 μL) of the working reagent (choline assay buffer, choline probe, and choline
enzyme mix) in the first group of the samples to measure the free choline, while in the
other group same working reagent was added with addition of acetylcholinesterase to
measure the total choline, afterword the plate was incubated for 30 minutes at RT.
Finally, the absorbance was recorded at 570 nm. The assay used a standard curve of
choline to calculate the amount of choline in the samples. ACh concentration was
calculated using the equation: total choline- free choline. ACh concentration was
expressed as nmol/mg.
3.2.5.4.4 c-fos immunohistochemistry and quantification of c-fos positive cells
Tissue samples embedded in paraffin blocks were sectioned using a microtome
(Thermo Scientific™, England) to 5-10 μm sections. Then the sections were collected
on gelatin-coated slides and left for 2 hours to dry up at 45oC. The paraffin-embedded
sections were deparaffinized and hydrated momentarily in a series of xylene and
alcohol of different concentrations then treated with sodium citrate buffer after that
washed three times in phosphate buffered saline (PBS). The sections were treated with
a blocking agent [% of bovien serum albumin (BSA) in phosphate buffer (PB) and
Tween 20] for 45- 60 min, before adding the c-fos mouse monoclonal primary
antibody (1:100, Santa Cruz Biotechnology) for overnight incubation at 4°C in a
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humid chamber. The primary antibodies against c-fos were labeled with FITC donkey
anti-mouse IgG (Jackson ImmunoResearch Inc.). The sections were washed three
times in PBS before and after applying the secondary antibody. Then, the sections were
covered with fluoromount aqueous mounting medium (Sigma-Aldrich, St Louis, MI,
USA) and cover slipped. Two control groups (n=6); sections were processed according
to the same protocol explained earlier, but PBS was used to replace the primary or
secondary antibodies. The sections were examined using a Nikon fluorescent
microscope (Nikon, Japan) equipped with appropriate filters to reveal Alexa 488
(green fluorescent) to visualize the expression of the c-fos protein. The images were
taken using a 40× objective lens with a digital DS-Ri2 high-definition color camera
connected to the microscope (Nikon, Japan).
3.2.5.4.5 Morphometric analysis
All the images were examined using ImageJ software (NIH, USA), which facilities
several imaging system data comparisons, with density (densitometry) taken into
consideration, and the left overexpressed nuclei green particles were considered to
represent c-fos expression395. The number of the hippocampal c-fos positive cells were
obtained from 4 sections for each rat (n=6 rats per group). Location in the brain was
confirmed using the delineations in the Paxinos Atlas396. The number of c-fos
immunoreactive nuclei were counted in each field (at 40x) across the hippocampus
area over the layer extending from subregions CA1-CA3, then the values were
presented as means ± S.E.M of the positive c-fos cells per filed in each rat.
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3.2.6 Pilocarpine (PLC)-Induced Status Epilepticus (SE) model
3.2.6.1 Experimental Procedure of PLC-Induced SE
The PLC- induced SE model was applied as previously described397-399 (Figure 14).
PLC (400 mg/kg, i.p.) was systemically administered to all rats and immediately
observed for 30 min in separate plastic cages. Latency to first seizure (any epileptic
behavioral observed after PLC administration, e.g., wild running, clonus, tonus, and
tonic-clonic seizures), number of rats experienced SE, and the survival rates for all the
animals at 1 hour after PLC injection were recorded. Earlier findings indicated that
seizures and deaths detected within 1 and 24 hours following PLC administration
continually pursued in a comparable manner398,400. The PLC group consists of the rats,
which experienced SE and survived within 1 h. Inset of experiments the animals were
divided to seven experimental groups (n=10-12) rats matched for age and weight (180220 g) in each group as follows; group (1): naïve group injected with (SAL 0.9% i.p.),
group (2): PLC group injected with PLC (400 mg/kg, i.p.), group (3): positive control
group injected with DZP (10 mg/kg, i.p.) + PLC (400 mg/kg, i.p.) and groups (4-7):
treatment groups injected with test compound 4 (2.5, 5, 10, and 15 mg/kg, i.p.) + PLC
(400 mg/kg, i.p.).
All groups were treated with scopolamine methyl nitrate (1 mg/kg, i.p.) 30 min before
PLC injection to reduce the peripheral cholinergic effects of PLC. Moreover, the
protective effect of compound 4 was further investigated with abrogation tests by coadministration of the most effective dose of compound 4 + (PYR, ZOL, or RAM (10
mg/kg, i.p.) 30-45 minutes before the PLC injection, only for RAM 20 minutes before
the PLC injection to ensure its presence in the CNS, as RAM was described to show
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fast metabolism. PYR, ZOL, and RAM were co-injected alone with PLC or SAL to
eliminate any possible effects of PYR, ZOL, or RAM on SE incidence.

Figure 14: Schematic illustration of PLC- induced SE, experimental protocol, drug
treatments, and biochemical assessments.
Male Wistar rats were injected with PLC (400 mg/kg) for PLC- induced SE model. Compound 4 (5
and 10 mg/kg, i.p.) was injected 30-45 minutes before PLC injection. All animals were sacrificed in 1
hour after PLC injection for biochemical assessments.

3.2.6.2 Brain collection and tissue preparation for biochemical assessment
All animals that survived within 1 hour after PLC injection were anesthetized with
pentobarbital (40 mg/kg body weight). Cardiac perfusion was carried out using 0.01
M phosphate-buffered saline (PBS) at pH 7.4 for all the animals. Brains were quickly
removed and placed on an ice-plate where each brain was cut, and the hippocampus
was removed from the brain and immediately snap-frozen in liquid nitrogen for further
use. For tissue preparation, the hippocampus was weighed and divided into two equal
sections. The first part was homogenized in KCL buffer (Tris–HCl, 10 mM NaCl, 140
mM KCl, 300 mM EDTA, 1 mM Triton-X-100 0.5 %) at pH 8.0 supplemented with
protease and phosphatase inhibitor. The homogenate was centrifuged at 10,000×g for

81
30 min at 4°C. The clear supernatant was collected for estimation of oxidative stress
markers; MDA, GSH, CAT, and SOD. The second part was homogenized in ice-cold
(0.05 M, pH 8.0) phosphate buffer PB. The homogenate was then centrifuged at
10,000×g for 30 min at 4°C. The clear supernatant was collected for the estimation of
AChE activity.
3.2.6.2.1 oxidative stress marker
3.2.6.2.1.1 MDA
Same protocol was explained in 3.2.5.4.1.1.
3.2.6.2.1.2 GSH
Same protocol was explained in 3.2.5.4.1.2.
3.2.6.2.1.3 CAT
Same protocol was explained in 3.2.5.4.1.3.
3.2.6.2.1.4 SOD
Same protocol was explained in 3.2.5.4.1.4.
3.2.6.2.2 AChE
Same protocol as explained in section 3.2.5.4.2. was applied.
3.2.7 Statistical Analysis
For statistical comparisons, the software package Statistical Package for the Social
Sciences (SPSS) 25.0 (IBM Middle East, Dubai, UAE) was used. All data are
expressed as the means ± standard error of mean (SEM). Ki values at the H3R are
provided as means with the 95% confidence interval. All protective effects observed
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for H3R antagonists in acute- and chronic- induced seizure models were analyzed
using one -way analysis of variance, followed by the Bonferroni or Tukey post hoc
tests for multiple comparisons. The results observed for percentage seizures and
survival rates in PTZ- kindling model and PLC- induced seizure model is expressed as
percentages of the number of animals from each experimental group and were
analyzed using a nonparametric test (X2). The criterion for statistical significance was
set at P < 0.05.
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Chapter 4: Results

4.1 In vivo screening of anticonvulsant effect of H3R antagonists namely 1-16
4.1.1 Anticonvulsant effect screening of H3R antagonists 1-16 applying MESinduced seizure model
The initial screening for the anticonvulsant effect of acute systemic pretreatment with
H3R ligands 1-16 on MES-induced seizure model in male Wistar rats, was completed,
and the obtained results were compared with the protective effect of the reference
antiepileptic drug PHT in MES-induced seizure in rats (Figure 15). The observed
results revealed that acute systemic administration of PHT (10 mg/kg, i.p.) and H3R
ligands 1-16 (10 mg/kg, i.p.) demonstrated a significant protection against MESinduced seizures as confirmed by one-way analysis of variance (F(17,108) = 8.352; P <
0.001).
Following post hoc analysis, the obtained results indicated that acute systemic
administration of PHT (10 mg/kg, i.p.) and H3R ligands 3, 4, 5, 6, 7, and 14 (10 mg/kg,
i.p.) exhibited a significant protection against MES-induced seizures (significantly
decreased THLE time) (F(1,12) = 31.86; P < 0.001), (F(1,12) = 23.85; P < 0.001), (F(1,12)
= 34.6; P < 0.0001), (F(1,12) = 21.48; P < 0.05), (F(1,12) = 7.34; P < 0.05), (F(1,12) = 13.5;
P < 0.05), and (F(1,12) = 10.08; P < 0.05), respectively when compared to SAL-treated
group. Moreover, amongst the H3R antagonists tested and following post hoc analyses,
compound 4 at a dose of 10 mg/kg significantly displayed the most promising
protective effect in MES-induced seizure model when compared with the SAL-treated
group (F(1,12) = 34.6; P < 0.0001), and provided comparable protection to that of PHT
(F(1,12) = 1.14; p = 0.31) (Figure 15, Tables 3 & 4). Furthermore, the protective effect
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stated with H3R antagonist 4 at a dose of 10 mg/kg, i.p. was significantly higher than
that noticed for H3R antagonists 3, 5, 6, 7, and 14 (F(1,12) = 5.88; P < 0.05), (F(1,12) =
9.72; P < 0.05), (F(1,12) = 8.20; P < 0.05), (F(1,12) = 6.03; P < 0.05), and (F(1,12) = 7.11 ;
P < 0.05), respectively (Figure 15). However, acute pretreatment with the remaining
H3R antagonists 1, 2, 8, 9, 10, 11, 12, 13, 15, and 16 failed to exhibit a protective
effect in MES- induced seizure model (F(1,12) = 0.94; p = 0.35), (F(1,12) = 0.03; p =
0.85), (F(1,12) = 1.52; p = 0.24), (F(1,12) = 0.004; p = 0.94), (F(1,12) = 0.38; p = 0.55),
(F(1,12) = 0; p = 1), (F(1,12) = 0.04; p = 0.83), (F(1,12) = 0.94; p = 0.35), (F(1,12) = 0.44; p
= 0.5), and (F(1,12) = 0.73; p = 0.51), respectively when compared with SAL-treated
group.

Figure 15: Protective effect of acute systemic administration of H3R antagonists 1-16
(E171-E241) on MES-induced seizure model in male Wistar rats.
The figure shows the protective effect of (PHT, 10 mg/kg, i.p.) and test compounds1-16 (E171-E241)
(10 mg/kg, i.p.) on the duration of tonic hind limb extension (THLE) induced in the maximal
electroshock (MES) model in male Wistar rats. PHT and H3R antagonists 1-16 were injected 30-45
minutes before applying the MES. Values are represented as mean ± SEM (n=7). *P < 0.05 vs. the
SAL-treated group. **P < 0.001 vs. SAL-treated group. #P < 0.05 vs. the (3, 5, 6, 7, or 14)-treated
group.
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Furthermore, the results demonstrated that rats pretreated with H3R antagonist 4 (2.5
mg/kg, i.p.) 30-45 minutes before MES test failed to significantly decreased THLE
time (F(1,12) = 3.77; p = 0.07) when compared to SAL-treated group. While,
pretreatment with H3R antagonist 4 (5 and 15 mg/kg, i.p.) 30-45 minutes before MES
test exhibited a significant protective effect against MES-induced seizures (F(1,12) =
42.13; P < 0.001) and (F(1,12) = 15.93; P < 0.05), respectively when compared with
SAL- treated group (Figure 16, Tables 3 & 4). However, post hoc analysis revealed
that acute pretreatment with H3R antagonist 4 (5 and 15 mg/kg, i.p.) were protected to
a significantly lesser extent when compared with the H3R antagonist 4 (10 mg)-treated
group (F(1,12) = 6.09; P < 0.05) and (F(1,12) = 8.61; P < 0.05), respectively (Figure 16,
Tables 3 & 4).

Figure 16: Dose-dependent protective effect of H3R antagonist 4 against MESinduced seizure model.
Dose-dependent effect of H3R ligand 4 (2.5, 5, 10, and 15 mg/kg, i.p., respectively) on duration of
tonic hind limb extension (THLE) induced in MES model in male Wistar rats. Each value represents
mean ± SEM (n=7). *P < 0.05 vs. SAL-treated group. **P < 0.001 vs. SAL-treated group. $P < 0.05 vs.
(5, or 15 mg)-treated groups.
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Additionally, the abrogation of H3R antagonist 4-provided protection was evaluated
by acute systemic co-injection with the CNS penetrant histamine H3R agonist RAM
(10 mg/kg, i.p.), the H1R antagonist PYR, and the H2R antagonist ZOL (Figure 17).
As confirmed with post hoc analysis, the results indicated that acute co-administration
with RAM and PYR (10 mg/kg, i.p.) significantly abrogated the H3R antagonist 4 (10
mg)-provided protection (F(1,10) = 24.5; P < 0.001) and (F(1,10) = 8.91; P < 0.05) when
compared with the H3R antagonist 4 (10 mg)-treated group, respectively (Figure 17).
However, acute co-injection with ZOL (10 mg/kg, i.p.) failed to provide any
significant abrogative effect (F(1,10) = 1.25; p = 0.33) when compared with the H3R
antagonist 4 (10 mg)-treated group (Figure 17). Notably, RAM and PYR acute
administration alone with SAL did not affect MES-induced seizures (F(1,10) = 0.06; p
= 0.8) and (F(1,10) = 2.16; p = 0.16) for SAL– vs. SAL-RAM and for SAL vs. SALPYR, respectively (Figure 17).

Figure 17: Effect of RAM, PYR, and ZOL pretreatment on the H3R antagonist 4provided protection against MES-induced convulsions.
Effect of RAM (10 mg/kg, i.p.), PYR (10 mg/kg, i.p.), and ZOL (10 mg/kg) co-injection on the
protection provided by H3R antagonist 4 (10 mg/kg, i.p.) against MES-induced convulsions. Each
value represents mean ± SEM (n=6). **P < 0.001 vs. SAL-treated group. $P < 0.05 vs. H3R antagonist
4 (10 mg)-provided protection against MES-induced convulsions. $$P < 0.001 vs. H3R antagonist 4
(10 mg)-provided protection against MES-induced convulsions.
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4.1.2 Anticonvulsant effect screening of H3R antagonists 1-16 applying PTZinduced seizure model
The initial screening for anticonvulsant effect of acute systemic pretreatment with H3R
ligands 1-16 on PTZ- induced seizure model in male Wistar rats was completed and
the obtained results were compared with the protective effect of the reference
antiepileptic drug VPA in PTZ- induced seizure in rats (Figure 18). The observed
results indicated that acute systemic pretreatment with VPA (300 mg/kg, i.p.) and H3R
ligands 1-16 delivered a significant protective action against PTZ-induced seizures as
confirmed by applying one-way analysis of variance (F(17,108) = 23.92; P < 0.001).
Following post hoc analysis, the obtained results indicated that acute systemic
administration of VPA (300 mg/kg, i.p.) and H3R ligands 4, 7 and 11 (10 mg/kg, i.p.)
exhibited full protective actions when compared with the SAL-treated group (F(1,12) =
653.4; P < 0.001) for all (Figure 18). Moreover, H3R antagonists 12 and 13 provided
a significant protective effect against PTZ-induced seizures when compared with SALtreated group (F(1,12) = 7.14; P < 0.05) and (F(1,12) = 22.60; P < 0.001), respectively.
Nevertheless, compounds 12 and 13 were less significantly protective when compared
with H3R antagonist 4 (10 mg)-treated group (F(1,12) = 18.18; P < 0.05) and (F(1,12) =
17.76; P < 0.05), respectively (Figure 18). However, the remaining H3R antagonists
1, 2, 3, 5, 6, 8, 9, 10, 14, 15, and 16 failed to deliver any significant protective effect
against PTZ-induced seizures (F(1,12) = 2.88; p = 0.11), (F(1,12) = 0.67; p = 0.43), (F(1,12)
= 2.7; p = 0.12), (F(1,12) = 0.48; p = 0.50), (F(1,12) = 3.2; p = 0.09), (F(1,12) = 1.125; p =
0.30), (F(1,12) = 0.61; p = 0.69), (F(1,12) = 1.09; p = 0.31), (F(1,12) = 2.49; p = 0.14), (F(1,12)
= 2.16; p = 0.16), and (F(1,12) = 1.38; p = 0.26) when compared to SAL-treated group,
respectively (Figure 18).
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Figure 18: Protective effect of H3R ligands 1-16 pretreatment on PTZ-induced
seizure in rats.
The figure shows the protective effects of VPA (10 mg/kg, i.p.) and test compounds1-16 (E171-E241)
(10 mg/kg, i.p.) on the average seizure score in the PTZ- induced seizure model in male Wistar rats.
VPA and H3R antagonists 1-16 were injected 30-45 minutes before systemic injection of PTZ. Values
are represented as mean ± SEM (n=7). *P < 0.05 vs. the SAL-treated group. **P < 0.001 vs. SALtreated group. #Full protection.

Furthermore, further statistical analysis indicated that full protection was provided
following acute systemic administration with 10 or 15 mg/kg of H3R antagonist 4
(F(1,12) = 653.4; P<0.001) when compared with SAL-treated group (Figure 19).
Nevertheless, acute pretreatment with H3R antagonist 4 (2.5 or 5 mg/kg, i.p.) exhibited
significantly lesser protection effect when compared with that provided protection of
(10 or 15 mg)-treated group of the same compound (F(1,12) = 23.27; P < 0.001) and
(F(1,12) = 15; P < 0.001), respectively and (F(1,12) = 22.81; P < 0.001) and (F(1,12) =
235.2; P < 0.001), respectively when compared with SAL-treated group (Figure 19).
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Figure 19: Dose-dependent protective effect of H3R antagonist 4 against PTZinduced seizure model.
(VPA, 300 mg/kg, i.p.) and test compound 4 (2.5, 5, 10, and 15 mg/kg, i.p.) were injected 30-45 min
before PTZ (60 mg/kg, i.p.) treatments. Values are represented as the mean ± SEM (n = 7). **P<0.001
vs. SAL-treated group. &P < 0.001 vs. (2.5 and 5 mg)-treated group. #Full protection.

Additionally, the abrogation of H3R antagonist 4-provided protection was evaluated
by acute systemic co-injection with the CNS penetrant histamine H3R agonist RAM,
the H1R antagonist PYR, and the H2R antagonist ZOL (10 mg/kg, i.p.) (Figure 20).
As confirmed with further statistical analysis, the results indicated that RAM, PYR,
and ZOL acute co-administration failed to reverse the H3R antagonist 4-provided
protection in PTZ-induced seizure model (F(1,10) = 2.40; p = 0.15), (F(1,10) = 4.20; p =
0.06), and (F(1,10) = 4.5; p = 0.05) when compared with H3R antagonist 4 (10 mg)treated group (Figure 20). Notably, RAM, PYR, and ZOL acute administration alone
with PTZ did not affect PTZ-induced seizures (F(1,10) = 1.58; p = 0.23), (F(1,10) = 0.16;
p = 0.69) and (F(1,10) = 0.375; p = 0.55), respectively when compared with PTZ- treated
group (Figure 20).
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Figure 20: Effect of RAM, PYR, and ZOL pretreatment on the H3R antagonist 4provided protection against PTZ-induced convulsions.
(VPA, 300 mg/kg, i.p.) and test compound 4 (10 mg/kg, i.p.) were injected 30-45 min before PTZ (60
mg/kg, i.p.) treatments. RAM (10 mg/kg, i.p.), PYR (10 mg/kg, i.p.), and ZOL (10 mg/kg, i.p.) were
co-administered 30-45 for PYR and ZOL or 20 minutes for RAM before PTZ injection. Values are
represented as the mean ± SEM (n = 6). #Full protection.

4.1.3 Anticonvulsant effect screening of H3R antagonists 1-16 applying STRinduced seizure model
The initial screening for anticonvulsant effect of acute systemic pretreatment with H3R
ligands 1-16 on STR- induced seizure model in male Wistar rats was completed and
the obtained results were compared with the protective effect of the reference
antiepileptic drug VPA in PTZ- induced seizure in rats (Figure 21). The observed
results indicated that acute systemic administration of VPA (300 mg/kg, i.p.) and H3R
ligand 13 with no appreciable protection in MES- and with a low protection in PTZinduced seizure, provided reasonable protective effect in STR-induced seizure when
compared to the SAL-treated group (F(1,12) = 63.00; P < 0.001) for compound 13 and
(F(1,12) = 236.31; P < 0.001) for VPA (Figure 21). However, H3R antagonist 4 with the
most promising effect in MES-and PTZ-induced seizure models failed to provide any
appreciable protection in STR-induced seizure when compared to the SAL-treated
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group after 30 min of observation time (F(1,12) = 4.50; p = 0.06) (Figure 21, Tables 3
& 4). On the other hand, all the remaining H3R ligands failed to provide any significant
protective effect against STR-induced seizure (F(1,12)= 4.5; p = 0.06) for compounds 2,
5, 9, and 14, (F(1,12) = 3.69; p = 0.07) for compounds 1, 6, 8, 12, and 16, (F(1,12) = 2.88;
p = 0.11) for compounds 3 and 11, (F(1,12) =1; p = 0.33) for compound 7, (F(1,12) = 2.4;
p = 0.14) for compound 10, and (F(1,12) = 5.25; p = 0.052) for compound 15, when
compared to the SAL- treated group (Figure 21, Tables 3 & 4).

Figure 21:Anticonvulsant effect of H3R antagonists 1-16 pretreatment on strychnine
(STR)-induced seizure in rats.
(VPA, 300 mg/kg, i.p.) and test compounds 1-16 (10 mg/kg, i.p.) were injected 30-45 min before STR
(3.5 mg/kg, i.p.) treatments. Values are represented as the mean ± SEM (n = 7). **P < 0.001 vs. SALtreated group.

Furthermore, the outcomes indicated that acute systemic pretreatment with H3R
antagonist 13 at lower dose (2.5 mg/kg, i.p.) failed to exhibit any protective effect
against STR-induced seizures when compared with the SAL-treated group (F(1,12) =
1.00; p = 0.34) (Figure 22, Tables 3 & 4). Moreover, acute pretreatment with
compound 13 (5 or 15 mg/kg, i.p.) provided a significant protective effect against STR-
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induced seizures when compared with SAL-treated group (F(1,12) = 39.70; P < 0.001)
and (F(1,12) = 70.59; P < 0.001), respectively (Figure 22).
Additionally, no significant differences in the anticonvulsant effect provided by H3R
antagonist 13 (10 mg/kg, i.p.) were obtained when different doses of the same
compound were administered (5 or 15 mg/kg, i.p.) (F(1,12) = 2.84; p = 0.12) and (F(1,12)
= 0.08; p = 0.78), respectively (Figure 22, Tables 3 & 4). Also, the abrogation of H3R
antagonist 13-provided protection was evaluated by acute systemic co-injection with
the CNS penetrant histamine H3R agonist RAM, the H1R antagonist PYR, and the
H2R antagonist ZOL (10 mg/kg, i.p.) (Figure 22). As confirmed with statistical
analysis, the results indicated that RAM, PYR, and ZOL acute co-administration failed
to reverse the H3R antagonist 13-provided protection in STR-induced seizure model
(F(1,10) = 0.07; p = 0.80), (F(1,10) = 0.22; p = 0.64), and (F(1,10) = 0; p = 1) when compared
to 13 (10 mg)-treated group, respectively (Figure 22). Notably, RAM, PYR, and ZOL
when administrated alone did not affect STR-induced seizure when compared to STRtreated group (F(1,10) = 2.4; p = 0.15), (F(1,10) = 3.69; p = 0.08), and (F(1,10) = 2.08; p =
0.17), respectively (Figure 22).
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Figure 22: Dose-dependent protective effect of H3R antagonist 13 and effect of
RAM, PYR, and ZOL pretreatment on the protection provided by H3R ligand 13
against PTZ-induced convulsions.
(VPA, 300 mg/kg, i.p.) and test compound 13 (2.5, 5, 10, and 15 mg/kg, i.p.) were injected 30-45 min
before STR (3.5 mg/kg, i.p.) treatment. RAM (10 mg/kg, i.p.), PYR (10 mg/kg, i.p.), and ZOL (10
mg/kg, i.p.) were co-administered with compound 13 (10 mg/kg, i.p.) 30-45 before STR injection.
Values are represented as the mean ± SEM (n = 6-7). **P < 0.001 vs. SAL-treated group.
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Table 3: Anticonvulsant effect of H3R antagonists 1-16 in MES-, PTZ-, and STRinduced convulsion models.
MESinduced
seizure
Average
THLE (s)

Group

SAL
PHTc/
VPAh
1d
2d
3d
4d
5d
6d
7d
8d
9d
10d
11d
12d
13d
14d
15d
16d
4e
4f
4g
4d+RAMd
4d+PYRd
4d+ZOLd
SAL+RAMd
SAL+PYRd
SAL+ZOL

d

PTZa-induced seizure

STRb-induced seizure
Group

Average
seizure score

8.14±1.17
0.90±0.19**

4.71±0.16
0.00±0.00**

%
Protection
against
GTCS
28.57
100

6.43±1.14
7.86±0.84
1.29±0.17**
0.57±0.21**
1.71±0.26**
3.00±0.75*
2.00±0.49*
5.71±1.39
8.29±1.57
6.43±0.75
8.14±0.62
7.86±0.51
6.43±1.14
3.14±0.59*
7.14±0.74
6.57±1.22
5.83±1.01#
2.50±1.21**#
3.67±0.94*#
6.17±0.59$$
5.17±0.83$
1.83±0.55
7.92±0.6
6.83±0.7
7.33±0.52

4.00±0.35
4.43±0.27
4.29±0.17
0.00±0.00**
4.43±0.34
4.14±0.24
0.00±0.00**
4.29±0.33
4.57±0.27
4.43±0.19
0.00±0.00**
2.86±0.62*
2.14±0.47**
3.71±0.56
3.86±0.51
4.00±0.53
2.29±0.44**#
0.71±0.31**#
0.00±0.00**
0.29±0.16
1.00±0.42
0.86±0.35
4.29±0.25
4.57±0.26
4.86±0.12

57.14
42.86
71.43
100
28.57
71.43
100
57.14
28.57
57.14
100
71.43
85.71
42.86
57.14
42.86
100
100
100
100
100
100
14.29
14.29
14.29

Average
seizure
score
SAL
VPAh

5.00±0.00
0.43±0.27**

%
Protection
against
GTCS
NP
100

1d
2d
3d
4d
5d
6d
7d
8d
9d
10d
11d
12d
13d
14d
15d
16d
13e
13f
13g
13d+RAMd
13d+PYRd
13d+ZOLd

4.43±0.27
4.57±0.19
4.29±0.39
4.57±0.19
4.57±0.19
4.43±0.27
4.86±0.13
4.43±0.19
4.57±0.19
4.71±0.17
4.29±0.33
4.43±0.27
2.00±0.35**
4.57±0.19
4.00±0.40
4.43±0.27
4.86±0.13
3.00±0.31**
2.17±0.31**
2.14±0.35
2.29±0.44
2.00±0.40
4.71±0.16
4.43±0.27
4.57±0.27

42.86
28.57
42.86
28.57
42.86
42.86
14.29
42.86
42.86
28.57
42.86
42.86
100
28.57
57.14
42.86
14.29
85.71
100
100
100
100
28.57
42.86
28.57

SAL+RAMd
SAL+PYRd
SAL+ZOLd

a
60 mg/kg, b3.5 mg/kg, cPHT (10 mg/kg, i.p.), d10 mg/kg, e2.5 mg/kg, f5 mg/kg, g15 mg/kg, hVPA (300
mg/kg, i.p.). H3R antagonists 1-16 (10 mg/kg, i.p.) were injected 30-45 min before MES, PTZ (60
mg/kg, i.p), or STR (3.5 mg/kg, i.p.) challenge. The table shows the protective effects of phenytoin
(PHT, 10 mg/kg, i.p.), VPA (300 mg/kg, i.p.), and H3R antagonists 1-16 (10 mg/kg, i.p.) on the duration
of tonic hind limb extension (THLE) induced in the maximal electroshock (MES) model in rats and
average seizure score in PTZ- and STR- induced seizure models. Protective effects in PTZ- and STRinduced convulsion model are expressed as score of seizures for 30 min observation time after PTZ or
STR injection. Dose-dependent effect of H3R antagonist 4 and 13 (2.5, 5, 10, and 15 mg/kg, i.p.) on
duration of THLE induced in MES-, and average seizure score in PTZ- and STR- model in rats. Effect
of RAM, PYR, and ZOL (10 mg/kg, i.p.) pretreatment on the protection provided by H3R antagonist 4
(10 mg/kg, i.p.) against MES- and PTZ-, and H3R antagonist 13 against STR-induced convulsions.
Each value represents mean ± SEM (n=6-7). *P < 0.05 vs. (saline)-treated group. **P < 0.001 vs. (saline)treated group. #P < 0.05 vs. 4(10 mg/kg)-treated group. $ P < 0.05 vs. 4(10 mg/kg)-treated group. $$P <
0.001 vs. 4(10 mg/kg)-treated group.
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Table 4: Screening of in vivo anticonvulsant effect for H3R antagonists 1-16.
MESa-induced
seizure

PTZb-induced
seizure

STRc-induced
seizure

1

-

-

-

2

-

-

-

3

++

-

-

4

++

++

-

5

++

-

-

6

+

-

-

7

+

++

-

8

-

-

-

9

-

-

-

10

-

-

-

11

-

++

-

12

-

+

-

13

-

+

+

14

+

-

-

15

-

-

-

16

-

-

-

Ligand

a

Structure

50-Hz alternating current of 120 mA intensity applied through ear electrodes for a duration of 1 s. b60
mg/kg, c3.5 mg/kg. –, No protection; +, moderate protective effect; ++, high protective effect.
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4.2 In vivo screening of the procognitive effect of H3R antagonists 4 applying
different behavioral test
4.2.1 Effect of H3R antagonist 4 in both DIZ- and SCO- induced memory
impairment in IAP
The procognitive effect of compound 4 (10 mg/kg, i.p.) on DIZ- and SCO-induced
memory deficits in IAP in adults male Wistar rats were completed and compared with
the standard drug DOZ (1 mg/kg) (Figure 23). Statistical analysis on the average of
the STL times indicated, that H3R antagonist 4 (10 mg/kg) and DOZ (1 mg/kg) acute
pretreatment 30–45 minutes before the test conferred a significant memory-enhancing
effects in both DIZ- and SCO- induced memory deficits in rats (F(6,42) = 31.74; P <
0.001). Further statistical analysis revealed that DIZ and SCO systemic administration
30-45 min before the test caused memory impairment when compared with SALtreated group (F(1,12) = 991.64; P < 0.001) and (F(1,12) = 486.84.57; P < 0.001),
respectively. Moreover, the results revealed that DIZ-treated group significantly
reduced STL time when compared to SCO-treated group (F(1,12) = 99.1; P < 0.001)
(Figure 23). Furthermore, it was observed that acute systemic administration of H3R
antagonist 4 (10 mg/kg, i.p.) 30-45 min before the test exhibited a stronger significant
memory-enhancing effect in DIZ- when compared to SCO- induced memory deficits
(F(1,12) = 325.10; P < 0.001) and (F(1,12) = 12.48; P < 0.05), for DIZ-treated group vs
DIZ+4 (10 mg/kg) group and (SCO)-treated group vs SCO+4 (10 mg/kg) group,
respectively and (F(1,12) = 8.53; P < 0.05)when compared 4+DIZ group vs 4+SCO
group. Furthermore, DOZ (1 mg/kg) resulted in a significant enhancement effect of
STL times when compared with DIZ- and SCO-induced amnesia groups(F(1,12) =
424.55; P < 0.001) and (F(1,12) = 145.62; P < 0.001), respectively (Figure 23).
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Figure 23: H3R antagonist 4 attenuated SCO- and DIZ-induced memory deficits in
the IAP.
Average STL time measured on the first training day before the delivery of foot shock (black
columns), and average STL time measured on the test day (gray columns). Acute systemic
administration of H3R antagonist 4 (10 mg/kg, i.p.) or DOZ (1 mg/kg, i.p.) 30-45 minutes before the
test session. #P < 0.001 for average STL time compared with that in the SAL-treated group. $P <
0.001 for average STLs compared with the SCO-induced amnesic group. *P < 0.05 compared with the
SCO-or DIZ-treated group. **P < 0.001 compared with the SCO-or DIZ-treated group. &P < 0.05 for
average STLs compared with the effect of H3R antagonist 4 on SCO-induced amnesic group. The data
are expressed as the mean ± SEM (n=7).

Moreover, the procognitive effect of different doses of H3R antagonist 4 (1.25, 2.5,
and 5 mg/kg) on DIZ-induced memory deficits in IAP in adult male rats are shown in
(Figure 24). Furthermore, statistical analysis of STL times, indicated that acute
systemic administration of H3R antagonist 4 in different doses 30–45 minutes before
the test conferred a significant memory-enhancing effects (F(4,49) = 66.81; P < 0.001).
Further statistical analysis demonstrated that all other doses of H3R antagonist 4 (1.25,
2.5, and 5 mg/kg) resulted in a significant enhancement of STL times compared with
the DIZ-induced amnesia group (F(1,12) = 104.75; P < 0.001), (F(1,12) = 269.73; P <
0.001), and (F(1,12) = 1272.53; P < 0.001), respectively (Figure 26). Besides, more
significant memory-enhancing effect was observed when compared 5 (mg/kg) to 2.5
and 1.25 (mg/kg) doses (F(1,12) = 11.9; P < 0.05)and (F(1,12) = 47.6; P < 0.001),
respectively. However, no significant increase was observed between compound 4 (5
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and 10 mg/kg) doses (F(1,12) = 1.21; p = 0.94) (Figure 24). Moreover, the procognitive
effect of H3R antagonist 4 (5 and 10 mg/kg, i.p.) was comparable to the effect provided
with the reference drug DOZ (1 mg/kg) (F(1,12) = 2.62; p = 0.13) and (F(1,12) = 0.02; p
= 0.88), respectively.

Figure 24: H3R antagonist 4 attenuated DIZ-induced memory deficits in a dosedependent manner in the IAP.
Average STL time measured on the first training day before the delivery of foot shock (black
columns), and average STL time measured on the test day (gray columns). Acute systemic
administration of H3R antagonist 4 at different doses (1.25, 2.5, 5, and 10 mg/kg, i.p.) or DOZ (1
mg/kg, i.p.) 30-45 minutes before the test session. #P < 0.001 for average STL time compared with
that in the SAL-treated group. **P < 0.001 for average STLs compared with the (DIZ)-treated group.
&
P < 0.05 compared with the 1.25 and 2.5 (mg/kg)-treated group. The data are expressed as the mean
± SEM (n=7).

Furthermore, the abrogation of H3R antagonist 4 procognitive provided protection was
evaluated by acute systemic co-injection of H3R antagonist 4 most promising dose (5
mg/kg) with the CNS penetrant histamine H3R agonist RAM, the H1R antagonist
PYR, and the H2R antagonist ZOL (10 mg/kg, i.p.) (Figure 25). As confirmed with
statistical analysis, compound 4 (5 mg/kg) procognitive effect was reversed following
acute systemic co-administration with RAM 20 min before the test and ZOL 30-45
min before the test (F(1,12) = 659.00; P < 0.001) and (F(1,12) = 5.60; P < 0.05),
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respectively when compared to compound 4 (5 mg/kg)-treated group. Notably, acute
systemic administration of DIZ (0.1 mg)- treated animals with RAM (10 mg/kg) or
ZOL (10 mg/kg) failed to significantly alter the STL times observed in the group
(F(1,12)= 1.31; p = 0.27) and (F(1,12) = 2.01; p = 0.13), respectively when compared with
DIZ-treated group (Figure 25). Remarkably, PYR co-injection with compound 4 (5
mg/kg) 30-45 min before the test, failed to reverse the procognitive effect provided by
compound 4 (5 mg/kg) (F(1,12) = 0.52; p = 0.48) when compared with compound 4 (5
mg/kg) group (Figure 25). Notably, acute systemic administration of DIZ (0.1 mg)treated animals with PYR (10 mg/kg) failed to significantly alter the STL times
observed in the group (F(1,12)= 0.86; p=0.31) (Figure 25).

Figure 25: Effect of H3R antagonist 4, RAM, PYR, and ZOL on DIZ-induced
memory deficit in IAP.
Gray columns represent the mean STLs measured during the retention test (test latencies) and black
columns the mean STLs measured during the training trial before the delivery of the foot-shock (preshock latencies). Rats were injected with H3R antagonist 4 (5 mg/kg, i.p.), RAM (10 mg/kg, i.p.),
PYR (10 mg/kg, i.p.) or ZOL (10 mg/kg, i.p.) 30-45 min before the test session. #P < 0.001 for mean
STLs vs. the value of the SAL-treated group. **P < 0.001 for mean STLs vs. the value of (DIZ +SAL)treated group. $P < 0.05 for mean STLs vs. the value of (DIZ + H3R antagonist 4 (5 mg/kg)-treated
group. $$P < 0.001 for mean STLs vs. the value of (DIZ + H3R antagonist 4 (5 mg/kg)-treated group.
Data are expressed as mean ± SEM (n = 7).
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4.2.2 Effect of H3R antagonist 4 in DIZ-induced STM deficits in NOR
The procognitive effect of H3R antagonist 4 on DIZ-induced STM memory deficits in
NOR in adult male Wistar rats were completed and discussed in (Figure 26). Statistical
analysis on the average of the DIs times indicated that post-T1, acute systemic
administration of H3R antagonist 4, and DOZ significantly counteracted the time spent
exploring the objects in the T2 session (F(8,54) = 17.58; P < 0.001). Further statistical
analysis on the average of the DIs times showed that DIZ (0.1 mg/kg, i.p.) systemic
administration post-T1 significantly impaired the novel object memory in T2 (120
minutes later) when compared with the SAL-treated group (F(1,10) = 52.54; P < 0.001)
(Figure 26). Moreover, further analysis of the DI results showed that acute systemic
administration of H3R antagonist 4 (5 mg/kg) and DOZ (1 mg/kg) post T1,
significantly counteracted the time spent exploring the objects in the T2 session (F(1,10)
= 6.13; P < 0.05) and (F(1,10) = 22.13; P < 0.001), respectively when compared with
DIZ-treated group (Figure 26). Furthermore, acute systemic administration of H3R
antagonist 4 (10 mg/kg) post T1, also significantly counteracted the STM impairment
induced by DIZ (F(1,10) = 6.19; P < 0.05). In contrast, lower dose of E177 (2.5 mg/kg)
post T1, failed to reverse the DIZ-induced memory impairment (F(1,10) = 0.31; p = 0.59)
(Figure 26). Notably, no significant difference in the protective effects was observed
for either dose of H3R antagonist 4, namely, 5 and 10 mg/kg (F(1,10) = 0.02; p = 0.88)
(Figure 26). Additionally, the abrogation of H3R antagonist 4 procognitive provided
protection was evaluated by acute systemic co-injection of H3R antagonist 4 most
promising dose (5 mg/kg) with the CNS penetrant histamine H3R agonist RAM, the
H1R antagonist PYR, and the H2R antagonist ZOL (10 mg/kg, i.p.) (Figure 26). As
confirmed with post hoc analysis, that the compound 4 (5 mg/kg) procognitive effect
was abrogated with H3R agonist RAM (10 mg/kg, i.p.) co-injection post T1 (F(1,10) =
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10.11; P < 0.05) when compared with compound 4 (5 mg/kg)-treated group (Figure
26). In addition, further statistical analysis of DI revealed that RAM (10 mg/kg, i.p.)
alone did not modulate STM in T2 compared with the saline- and DIZ-treated groups
(F(1,10) = 0.92; p = 0.35) and (F(1,10) = 0.54; p = 0.47), respectively (Figure 26).
Nevertheless, acute co-injection of both PYR and ZOL (10 mg/kg) with H3R
antagonist 4 (5 mg/kg, i.p.) failed to abrogate the procognitive effect of H3R antagonist
4 (5 mg) with (P > 0.05) for both. Importantly, the time spent exploring both objects
through T1 and T2 was not significantly different in the DIZ-treated group and the
saline-treated group (Table 5). This is essential to confirm the elimination of any
confounding factors, such as the failure of DIZ post-training treatment in T1 to alter
the spontaneous locomotion and/or motivations of tested animals.

Figure 26: H3R antagonist 4 mitigated DIZ-induced short-term memory deficits in
NOR paradigm
H3R antagonist 4 (2.5, 5, or 10 mg/kg, i.p.) or DOZ (1 mg/kg, i.p.) were injected after T1 (training
session) with DIZ (0.1 mg/kg, i.p.). The T2 (test session) was conducted 120 minutes (for short-term
memory) after T1 (training session). The results are expressed as Discrimination indices for the time
spent exploring both objects (familiar and novel). #P < 0.001 compared with the SAL-treated group.
*
P < 0.05 compared with the (DIZ)-treated group. **P < 0.001 compared with the (DIZ)-treated
group. $P < 0.05 compared with the 4 (5 mg)-treated group. The data are expressed as the mean ±
SEM (n=6).

102
4.2.3 Effect of H3R antagonist 4 in DIZ-induced LTM deficits in NOR
The procognitive effects for H3R antagonist 4 (2.5, 5, and 10 mg/kg) and DOZ (1
mg/kg, i.p.) on time spent exploring both objects in T2 when the compounds were
injected in the post-training session T1 and 30-45 minutes before T2 on the following
day in DIZ-induced LTM impairment in the NOR task are discussed in (Figure 27).
Statistical analysis on the average of the DIs times indicated significant modulatory
effects of compound 4 and DOZ on time spent exploring both objects in T2 (F(8,54) =
5.071; P < 0.001). Further statistical analysis demonstrated that DIZ (0.1 mg/kg, i.p.)
systemic administration post-T1, significantly impaired the novel object memory in
T2 (24 hours later) when compared with the SAL-treated group (F(1,10) = 9.77; P <
0.05) (Figure 27). Moreover, further analysis of the DI results indicated that acute
systemic administration of DOZ (1 mg/kg) when injected post T1 and 30-45 min
before T2 (24 h later), significantly improved the DI between the two objects (F(1,10) =
16.34; P < 0.05) when compared with the DIZ-treated group (Figure 29). Nevertheless,
H3R antagonist 4 (2.5, 5, and 10 mg/kg) acute administration post T1 and 30-45 min
before T2, failed to mitigate the DI between the two objects with (F(1,10) = 1.21; p =
0.29), (F(1,10) = 5.67; p = 0.06), and (F(1,10) = 4.25; p = 0.07), respectively when
compared with DIZ-treated group (Figure 27). Importantly, the time spent exploring
both objects through T1 and T2 was not significantly different in the DIZ-treated group
and the saline-treated group (Table 5). This is essential to confirm the elimination of
any confounding factors, such as the failure of DIZ post-training treatment in T1 to
alter the spontaneous locomotion and/or motivations of tested animals.
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Figure 27: H3R antagonist 4 failed to mitigate DIZ-induced long-term memory
deficits in NOR paradigm.
H3R antagonist 4 (2.5, 5, or 10 mg/kg, i.p.) or DOZ (1 mg/kg, i.p.) were injected after T1 (training
session) with DIZ (0.1 mg/kg, i.p.) and 30-45 minutes before T2. The T2 (test session) was conducted
24h (for long-term memory) after T1 (training session). The results are expressed as Discrimination
indices for the time spent exploring both objects (familiar and novel). #P < 0.05 compared with the
SAL-treated group. *P < 0.05 compared with the DIZ-treated group. The data are expressed as the
mean ± SEM (n=6).

Table 5: Effect of H3R antagonist 4 on DIZ-induced total exploratory time spent
with both objects during training and test session in NOR paradigm.

Group

N

Training session
STM

Saline

6

36.50 ± 2.69

DIZ + Saline

6

37.00 ± 2.49

DIZ + 4 (2.5 mg/kg)

6

38.50 ± 2.37

DIZ + 4 (5 mg/kg)

6

38.67 ± 2.52

DIZ + 4 (10 mg/kg)

6

38.17 ± 2.17

DIZ + DOZ(1 mg/kg)

6

37.33 ± 4.41

DIZ + 4 (5 mg/kg) +
RAM(10 mg/kg)
DIZ + RAM(10 mg/kg)

6

39.17 ± 1.34

6

38.00 ± 4.22

Saline + RAM(10 mg/kg)

6

38.25 ± 2.88

Time exploring objects (s)
Test
Training session
session
LTM
STM
40.33 ±
2.75
33.75
±3.09
40.08
±1.57
38.63 ±
2.48
36.08 ±
0.72
37.75 ±
2.17
39.25 ±
2.39
37.42 ±
1.86
37.42 ±
2.20

Test session
LTM

36.67 ± 2.93

38.17 ± 3.86

37.63 ±2.30

38.14 ± 6.47

36.83 ±1.99

36.17 ± 1.66

37.67 ± 2.55

33.17 ± 2.19

37.50 ± 2.63

37.83 ± 3.16

38.50 ± 1.16

38.29 ± 2.29

39.88 ± 2.57

37.96 ± 1.56

39.33 ± 1.56

37.46 ± 1.30

38.75 ± 2.14

37.83 ± 4.29

No significant changes in total exploratory times between treated groups was observed. Data are
expressed as mean ±SEM (n=6).
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4.2.4 Effect of H3R antagonist 4 on animal performance in the EPM paradigm
The modulating effects for H3R antagonist 4 (5 and 10 mg/kg) and DZP (10 mg/kg,
i.p.) acute treatment 30-45 minutes before the test, on the anxiety-like behaviors and
locomotion activity applying EMP are discussed in (Figure 28). Statistical analysis
indicated that, no change was observed in the time spent in the open arms for the H3R
antagonist 4 (5 and 10 mg)-treated groups (F(1,10) = 0.05; p = 0.83) and (F(1,10) = 0.11;
p = 0.75), respectively when compared with SAL-treated group (Figure 28A).
Moreover, no significant alternation in the total numbers of entries into the open arms
for compound 4 (5 and 10 mg/kg) (F(1,10) = 0.03; p = 0.88) and (F(1,10) = 0.008; p=0.93),
respectively when compared with the SAL-treated group (Figure 28B). However,
Statistical analysis shown that acute pretreatment with DZP (10 mg/kg) significantly
altered both the time spent in the open arms and the total number of entries into the
open arms (F(1,10) = 8.60; P < 0.05) and (F(1,10) = 6.13; P < 0.05), respectively when
compared with SAL-treated group (Figure 28A and B). Remarkably, no significant
change was observed in the total number of entries into the closed arms after acute
systemic administration of H3R antagonist 4 (5 and 10 mg/kg) or DZP (10 mg/kg),
(F(1,10) = 0.005; p = 0.94), (F(1,10) = 0.59; p = 0.46), and (F(1,10) = 0.004; p = 0.95),
respectively when compared with SAL-treated group (Figure 28C).

Figure 28: H3R antagonist 4 failed to alter anxiety-like behavior or locomotion in the EPM test.
Effect of H3R antagonist 4 (5 or 10 mg/kg, i.p.) and DZP (10 mg/kg, i.p.) injections on the percentage of time spent in open arms (A), total number of open arm entries (B),
and total number of closed arms entries (C). *P < 0.05 for the value of the DZP-treated group compared with the SAL-treated groups. The data are expressed as the mean ±
SEM (n=6).
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4.2.5 Effect of H3R antagonist 4 on animal performance in the OFT paradigm
The modulating effects for H3R antagonist 4 (5 and 10 mg/kg) and DZP (10 mg/kg,
i.p.) acute treatment 30-45 minutes before the test, on the anxiety-like behaviors and
locomotion activity applying OFT are discussed in (Table 6). Statistical analysis
indicated that, no change was observed on the time spent in the center and periphery
and on the total time spent for locomotion after acute treatment with H3R antagonist
4 (5 and 10 mg/kg) and DOZ (1 mg/kg) (F(1,10) = 0.38; p = 0.55), (F(1,10) = 0.06; p =
0.81), and (F(1,10) = 0.02; p = 0.88), respectively, for 4 (5 mg/kg), (F(1,10) = 0.02;
p=0.88), (F(1,10) = 0.02; p = 0.89), and (F(1,10) = 0.01; p = 0.92), respectively, for 4 (10
mg/kg) and (F(1,10) = 0.29; p = 0.6), (F(1,10 )= 0.53; p = 0.48) and (F(1,10) = 1.23; p =
0.29), respectively, for DOZ (1 mg), as shown in (Table 6). Statistical analysis of the
results of the total distance traveled, the number of rearing events, and the number of
grooming events for H3R antagonist 4 (5 and 10 mg/kg) and DOZ (1 mg/kg) provided
essentially the same result, no significant alternation (all P < 0.05) Table 6.
Table 6: Effect of acute systemic administration of H3R antagonist 4 on anxiety
levels and locomotor activity in open field test.

Saline
4 (5 mg/kg)
4 (10 mg/kg)
DOZ
(1
mg/kg)

Time for
locomotion
(s)
99.67±6.47
98.33±4.78
100.86±8.16
109.83±5.31

Distance
Travelled (cm)

Time in
Center (s)

1003.33±51.34
1085.67±33.95
999.86±52.44
1022.67±44.65

1.67±0.19
1.83±0.15
1.71±0.26
1.50±0.20

Time in
periphery
(s)
78.67±6.40
76.67±3.93
77.14±7.87
71.33±6.63

No. of
Rearing

No. of
Grooming

18.17±2.41
16.17±1.79
15.14±2.54
16.67±2.55

2.00±0.58
1.50±0.39
1.86±0.31
0.67±0.45

H3R antagonist 4 (5 and 10 mg/kg, i.p.) failed to alter time spent in center arena, time spent in periphery,
total time spent for locomotion, total distance travelled, number of rearing, and number of grooming.
Data are expressed as mean ± SEM (n=6).

107
4.3 PTZ- acute model results, behavioral assessment, biochemical measurements
and IHC
The anticonvulsant effect of acute pretreatment of H3R antagonist 4 (5 and 10 mg/kg,
i.p.) and VPA (300 mg/kg, i.p.) 30-45 minutes before PTZ (60 mg/kg, i.p.) are
discussed in section 4.1.2 and described in (Figure 19).
4.3.1 Effect of acute treatment of H3R antagonist 4 on memory impairment
induced by PTZ systemic administration applying IAP
The procognitive effect of compound 4 (5 and 10 mg/kg, i.p.) after PTZ-induced
memory deficits in IAP in adult male Wistar rats were completed and discussed in
(Figure 29). Statistical analysis on the average of the STL times revealed that acute
pretreatment with H3R antagonist 4 and VPA 30-45 minutes before PTZ injection
conferred a significant memory-enhancing effect in IAP (F(4,25) = 21.6; P < 0.001).
Further statistical analysis showed that PTZ systemic administration post-training
session in day 1 caused memory impairment when compared with SAL-treated group
(F(1,10) = 23.97; P < 0.05). Moreover, results of acute pretreatment with VPA (300
mg/kg, i.p.) 30-45 minutes before PTZ injection, indicated a significant improvement
in STL time (F(1,10) = 184.93; P < 0.001) when compared with PTZ- treated group.
Further statistical analysis results exhibited, that acute pretreatment with H3R
antagonist 4 (5 and 10 mg/kg, i.p.) significantly counteracted the memory impairment
induced by PTZ- acute injection (F(1,10) = 73.93; P < 0.05)and (F(1,10) = 46.3; P < 0.05)
when compared with PTZ-treated group (Figure 29). Remarkably, no significant
difference was observed in the procognitive effect provided by H3R antagonist 4 (5
and 10 mg/kg) (F(1,10) = 0.48; p = 0.52). Notably, no significant difference was
indicated between all the groups in the training day, indicating that no modulating
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factors, e.g., locomotion or anxiety, have confounded that modulatory effect in the test
day.

Figure 29: H3R antagonist 4 attenuated PTZ-induced memory deficits in the IAP.
Average of STL time measured on the test day (gray columns). Acute systemic administration of H3R
antagonist 4 (5 and 10 mg/kg, i.p.) or VPA (300 mg/kg, i.p.) 30-45 minutes before PTZ- acute
administration. #P < 0.05 for average STL time compared with that in the SAL-treated group. *P < 0.05
for average STL time compared with the PTZ-treated group. **P < 0.001 for average STL time compared
with the PTZ-treated group. The data are expressed as the mean ± SEM (n=6).

4.3.2 Effect of H3R antagonist 4 on memory impairment induced by PTZ- acute
systemic administration applying EPM
The procognitive effect of compound 4 (5 and 10 mg/kg, i.p.) after PTZ-induced
memory deficits in EPM in adult male Wistar rats were completed and discussed in
(Figure 30). Statistical analysis on the average of the TLT revealed that acute
pretreatment with H3R antagonist 4 and VPA 30-45 minutes before PTZ injection
conferred significant memory-enhancing effect in EPM (F(4,25) = 44.3; P < 0.05).
Further statistical analysis showed that PTZ systemic administration post training
session in day 1 caused memory impairment when compared with SAL-treated group
(F(1,10) = 18.64; P < 0.05). Moreover, results of acute pretreatment with VPA (300
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mg/kg, i.p.) 30-45 minutes before PTZ injection, indicated a significant improvement
in TLT time (F(1,10) = 12.34; P < 0.05) when compared with PTZ- exposed group.
Further statistical analysis on the observed results exhibited, that acute pretreatment
with H3R antagonist 4 (5 and 10 mg/kg, i.p.) significantly counteracted the memory
impairment induced by PTZ- acute injection (F(1,10) = 18.6; P < 0.05) and (F(1,10) =
12.91; P < 0.05) when compared with PTZ-treated group (Figure 30). Remarkably, no
significant difference was observed in the procognitive effect provided by H3R
antagonist 4 (5 and 10 mg/kg) (F(1,10) = 0.48; p = 0.52). Notably, no significant
difference was indicated between all the groups in the training day, indicating that no
modulating factors e.g., locomotion or anxiety have confounded that modulatory effect
in the test day.

Figure 30: H3R antagonist 4 attenuated PTZ-induced memory deficits in the EPM.
Average of TLT measured on the test day (gray columns). Acute systemic administration of H3R
antagonist 4 (5 and 10 mg/kg, i.p.) or VPA (300 mg/kg, i.p.) 30-45 minutes before PTZ- acute
administration. #P < 0.05 for average TLT compared with that in the SAL-treated group. *P < 0.05 for
average TLT compared with the PTZ-treated group. The data are expressed as the mean ± SEM (n=6).
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4.3.3 Effect of H3R antagonist 4 on oxidative stress levels in hippocampal brain
tissue of PTZ- acute treated rats
The capability of H3R antagonist 4 to attenuate oxidative stress was evaluated in
hippocampus tissue of PTZ- treated male Wistar rats and discussed in (Figure 31).
Statistical analysis of the observed results demonstrated that acute pretreatment with
H3R antagonist 4 and VPA 30-45 minutes before PTZ injection modulated the statues
of oxidative stress markers (MDA and GSH) (F(4,25) = 3.32; P < 0.05) and (F(4,25) =
6.19; P < 0.05), respectively. Further statistical analysis revealed that MDA levels
were markedly increased in PTZ-treated group (F(1,10) = 16.03; P < 0.05) when
compared with SAL-treated group, while GSH levels were significantly decreased in
PTZ-treated group (F(1,10) = 21.56; P < 0.05) when compared with SAL-treated group
(Figure 31A and B). Moreover, the results exhibited no significance difference in CAT
and SOD levels between PTZ-treated group and SAL-treated group (F(1,10) = 0.004; p
= 0.95) and (F(1,10) = 1.23; p = 0.3), respectively (Figure 31C and D). Further statistical
analysis indicated that acute pretreatment with H3R antagonist 4 (5 and 10 mg/kg)
significantly decreased MDA levels (F(1,10) = 13.82; P < 0.05) and (F(1,10) = 25.02; P <
0.05), respectively when compared with PTZ-treated group. Also, pretreatment with
H3R antagonist 4 (5 and 10 mg/kg) significantly increased GSH levels (F(1,10) = 32.38;
P < 0.05) and (F(1,10) = 79.81; P < 0.001), respectively when compared with PTZtreated group. Notably, no significance difference was detected in the antioxidant
effect provided by H3R antagonist 4 (5 and 10 mg/kg) (F(1,10) = 2.43; p = 0.18) and
(F(1,10) = 0.93; p = 0.39) for both MDA and GSH, respectively (Figures 31A & B).
Moreover, acute pretreatment with VPA (300 mg/kg) significantly attenuated the
oxidative stress by decreasing the MDA levels and increasing GSH levels (F(1,10) =
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8.75; P < 0.05) and (F(1,10) = 79.72; P < 0.001) when compared with PTZ-treated group
(Figures 31A & B).

Figure 31: H3R antagonist 4 attenuated oxidative stress levels in hippocampal brain
tissue of PTZ- acute treated rats.
Modulated levels of malondialdehyde (MDA), glutathione (GSH), catalase (CAT), and superoxide
dismutase (SOD) were assessed. PTZ-(60 mg/kg)-treated mice showed a significant increase in MDA
(A) and significant decrease in GSH levels (B) but failed to alter CAT (C) or and SOD (D) levels
compared with SAL-treated rats. H3R antagonist 4 (5 and 10 mg/kg, i.p.) or VPA (300 mg/kg, i.p.)
were administered 30-45 min prior to PTZ-injection. H3R antagonist 4 (5 and 10 mg/kg, i.p.) and
VPA (300 mg/kg, i.p.) significantly mitigated hippocampal MDA levels (A) and GSH levels (B). Data
are expressed as the mean ± SEM (n=6). #P < 0.05 vs. SAL-treated rats. *P < 0.05 vs. PTZ-treated rats.
**
P < 0.001 vs. PTZ-treated rats.
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4.3.4 Effect of H3R antagonist 4 on AChE activity in hippocampal brain tissue
of PTZ- acute treated rats
The effect of H3R antagonist 4 on AChE activity was evaluated in hippocampal tissue
of PTZ- treated male Wistar rats and discussed in (Figure 32). Statistical analysis of
the observed results indicated that PTZ- acute systemic administration failed to exhibit
any significant difference in hippocampal AChE activity when compared with SALtreated group (F(1,10) = 0.41; p=0.54) (Figure 32).

Figure 32: Effect of H3R antagonist 4 on AChE activity on hippocampal brain tissue
of PTZ- acute treated rats.
Activity of (AChE) were assessed post PTZ-(60 mg/kg) acute systemic administration. PTZ (60
mg/kg), VPA (300 mg/kg), and H3R antagonist 4 (5 and 10 mg/kg) treatment failed to exhibit any
significant change. Data are expressed as the mean ± SEM (n=6).

4.3.5 Effect of acute treatment of H3R antagonist 4 on neurotransmitters’ levels
in hippocampal brain tissue of PTZ treated rats
The levels of hippocampal neurotransmitters levels in brain tissue of PTZ- acute
treated rats were assessed and discussed in (Figure 33). Statistical analysis of the
results indicated, that PTZ (60 mg/kg, i.p.) systemic administration failed to exhibit
any significant change in brain neurotransmitters (GABA, GLU, HA, and ACh) levels
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(F(1,10) = 0.19; p = 0.67), (F(1,10) = 0.54; p = 0.82), (F(1,10) = 1.76; p = 0.23), and (F(1,10)
= 1.7; p = 0.24) when compared with SAL-treated group.

Figure 33: Effect of H3R antagonist 4 on neurotransmitters levels in hippocampal
brain tissue of PTZ treated rats.
The levels of hippocampus neurotransmitters levels were assessed post PTZ-(60 mg/kg) acute
systemic administration. PTZ (60 mg/kg), VPA (300 mg/kg) and H3R antagonist 4 (5 and 10 mg/kg)
treatment failed to exhibit any significant change. Data are expressed as the mean ± SEM (n=6).
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4.3.6 Effect of H3R antagonist 4 on c-fos expression in rat’s hippocampus after
PTZ- acute model
The expression of c-fos in the rat hippocampus after acute systemic administration of
PTZ (60 mg/kg, i.p.) is shown in (Figures 34 & 35). Statistical analysis on hippocampal
average c-fos positive cells per field, showed that acute pretreatment with H3R
antagonist 4 and VPA 30-45 minutes before PTZ injection presented a significant
decreasing effect (F(4,25) = 23.56; P < 0.001). Further statistical analysis revealed that
PTZ (60 mg/kg, i.p.) systemic administration significantly raised the average of c-fos
positive cells in rat’s hippocampus (F(1,10) = 57.33; P < 0.001) when compared with
SAL-tretaed rats. Moreover, acute pretreatment with H3R antagonist 4 (5 and 10
mg/kg) and VPA (300 mg/kg) 30-45 minutes before PTZ injection significantly
reduced c-fos positive cells (F(1,10) = 16.81; P < 0.05), (F(1,10) = 24.45; P < 0.05), and
(F(1,10) = 53.24; P < 0.001), respectively when compared with PTZ- exposed rats.
Notably so significant difference was observed in protective effect provided by H3R
antagonist 4 (5 and 10) mg/kg (F(1,10) = 0.78; p = 0.4) (Figures 34 & 35).
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Figure 34: Effect of H3R antagonist 4 on hippocampal c-fos expression in PTZacute treated rats.
Quantitative analysis of hippocampal c-fos expression was assessed post PTZ-(60 mg/kg) acute
systemic administration. PTZ (60 mg/kg), VPA (300 mg/kg), and H3R antagonist 4 (5 and 10 mg/kg)
treatment exhibited a significant modulatory change. ##P < 0.001 for average c-fos positive cells
compared with that in the SAL-treated group. *P < 0.05 for average c-fos positive cells compared with
the PTZ-treated group. **P < 0.001 for average c-fos positive cells compared with the PTZ-treated
group. Data are expressed as the mean ± SEM (n=6).

116

Figure 35: H3R antagonsit 4 reduced c-fos expression in hippocampal tissues of
PTZ-exposed rats.
A Profound expression of c-fos positive cells was observed in the acute PTZ-exposed rats compared
to SAL-treated rats. In contrast, acute treatment with H3R antagonist 4 (5 and 10 mg/kg, i.p.) showed
significantly reduced activation of c-fos compared to the PTZ-treated rats. A SAL, B PTZ, C VPA, D
4 (5 mg/kg), E 4 (10 mg/kg).

4.4. PTZ- chronic model results, behavioral assessment, biochemical
estimations, and IHC
4.4.1 Effect of chronic administration of H3R antagonist 4 on the average
seizure score in PTZ-kindling model
The average seizure score upon each PTZ (40 mg/kg, i.p.) injection was scored and
discussed in (Figure 36). The results indicated that repeated administration of a subconvulsant dose of PTZ (40 mg/kg, i.p.) three times a week led to a significant increase
of the average seizure score to seizure 4 or 5 on three consecutive injections starting
from the 8th injection. The statistical analysis of the obtained results revealed that
average seizure score of PTZ- treated rats increased remarkably from 1st injection to
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12th injection (F(1,18) = 47.27; P < 0.001). Furthermore, further statistical analysis
indicated that the average seizure score for each PTZ injection was significantly higher
(F(1,22) = 19.28; P < 0.05), (F(1,22) = 30; P < 0.001), (F(1,22) = 160; P < 0.001) for 1st to
3th injections, respectively, (F(1,22) = 65535; P < 0.001) for 4th to 7th injections, (F(1,22)
= 361; P < 0.001), (F(1,22) = 302.5; P < 0.001), (F(1,21) = 235.2; P < 0.001) for 8th to 10th
injections, respectively and (F(1,18) = 65535; P < 0.001) for 11th and 12th injections
when compared with SAL- treated rats (Figure 36). However, the results showed that
chronic pretreatment with H3R antagonist 4 (5 mg/kg, i.p.) 30-45 minutes before each
PTZ injection, caused a significant reduction of the average seizure score starting from
the 3rd to 12th injections (F(1,22) = 20; P < 0.05), (F(1,22) = 169; P < 0.001), (F(1,22) =
5; P < 0.05), (F(1,22) = 7.5; P < 0.05), (F(1,22) = 7.5; P < 0.05), (F(1,22) = 6; P < 0.05),
(F(1,22) = 14.41; P < 0.05), (F(1,21) = 7.68; P < 0.05), (F(1,18) = 12; P < 0.05), and (F(1,18)
= 12; P < 0.05), respectively. While, chronic pretreatment of H3R antagonist 4 (10
mg/kg, i.p.) caused only a significant decrease in the average seizure score in the 2nd,
3rd, 6th, 11th, and 12th injection (F(1,22) = 15.62; P < 0.05), (F(1,22) = 15.62; P < 0.05),
(F(1,22) = 5; P < 0.05), (F(1,18) = 12; P < 0.05), and (F(1,22) = 14.7; P < 0.05), respectively
when compared with PTZ- treated rats (Figure 38). Moreover, chronic pretreatment
with the positive drug VPA (300 mg/kg, i.p.) 30-45 minutes before each PTZ injection
led to a significant decrease of the average seizure score among all the injections
(F(1,22) = 19.28; P < 0.05), (F(1,22) = 20.86; P < 0.05), (F(1,22) = 289; P < 0.001), (F(1,22)
= 49; P < 0.001), (F(1,22) = 15.94; P < 0.05), (F(1,22) = 30.62; P < 0.001), (F(1,22) =
53.57; P < 0.001), (F(1,22) = 20.6; P < 0.05), (F(1,22) = 14.41; P < 0.001), (F(1,21) =
35.56; P < 0.001), (F(1,18) = 14.94; P < 0.05), and (F(1,18) = 7.5; P < 0.05) when
compared with PTZ- treated group. Notably, no significant difference was observed
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between the average seizure score of H3R antagonist 4 (5 and 10 mg/kg)- treated rats
among all the 12th injections (all P > 0.05).
Additionally, the abrogation of H3R antagonist 4-provided protection was evaluated
by chronic co-injection with the CNS penetrant histamine H3R agonist RAM, the H1R
antagonist PYR, and the H2R antagonist ZOL (10 mg/kg, i.p.) before each PTZ
injection (Figure 36). As confirmed with statistical analysis, the results indicated that
RAM chronic co-injection led to a significant increase of the average seizure score in
the 3rd, 4th, 8th, 9th, 10th and 12th when compared with H3R antagonist 4 (5 mg)-treated
PTZ-exposed rats (F(1,22) = 7.1; P < 0.05), (F(1,22) = 9.41; P < 0.05), (F(1,22) = 7.27; P <
0.05), (F(1,22) = 5; P < 0.05), (F(1,21) = 5.71; P < 0.05), and (F(1,18) = 5; P < 0.05),
respectively (Figure 38). However, chronic co-injection with PYR and ZOL failed to
change the average seizure score among all the injections (all P > 0.05) when
compared with H3R antagonist 4 (5 mg)-treated PTZ-exposed rats. Notably, chronic
administration of RAM, PYR, and ZOL with PTZ alone, failed to exhibit any
significant change on the average seizure score when compared with PTZ- treated rats
(all P > 0.05).
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Figure 36: Chronic administration of H3R antagonist 4 attenuated the average seizure
score in PTZ-kindling model.
Effects shown are expressed as average of seizure score for 30 min observation time for each PTZ
injection. Effect of PTZ-(40 mg/kg), H3R antagonist 4 (5 and 10 mg/kg; i.p.), and VPA (300 mg/kg,
i.p.) on average seizure score was assessed. H3R antagonist 4 (5 and 10 mg/kg; i.p.) and VPA (300
mg/kg, i.p.) were administered 30-45 min prior each PTZ-injection. Effects of systemic co-injection
with RAM (10 mg/kg, i.p.) on H3R antagonist 4 (5 mg/kg)-provided anticonvulsant effect was
evaluated. Values are expressed as the average + SEM (n=12). *P < 0.05 vs PTZ-treated group. **P <
0.001 vs PTZ-treated group. #P < 0.05 vs saline-treated group. ##P<0.001 vs saline-treated group. $P <
0.05 vs H3R antagonist 4 (5 mg)-treated PTZ-exposed rats. Black lines represent SAL-treated group
and the RAM-treated control group. Green line represents VPA (300 mg/kg)-treated group. Blue line
represents H3R antagonist 4 (5 mg/kg)-treated group. Pink line represents H3R antagonist 4 (10
mg/kg)-treated group. Dark-yellow line represents RAM (10 mg/kg) + 4 (5 mg/kg)-treated group. Red
represents PTZ (40 mg/kg)-treated group. Violet line represents RAM-treated PTZ-kindled group.

4.4.2 Effect of chronic administration of H3R antagonist 4 on kindling and
mortality rate
The kindling and mortality rate were calculated as percentages of the number of
animals from each experimental group and were discussed in (Table 7). The observed
results revealed that 83.33 % of the PTZ- treated rats (40 mg/kg, i.p.) 3 times a week
for 12 injections showed GTCS convulsions (seizure score 4 or 5) in two consecutive
injections and 16.67% of the animals died during PTZ- kindling model. Following
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statistical analysis, the obtained results indicated that PTZ chronic treatment
significantly raised the kindling rate with (P < 0.001) when compared with SALtreated rats, but no significant change was observed in mortality rate (p = 14) when
compared with SAL-treated rats (Table 7). However, the kindling rate had
significantly decreased to 0.00 %, when rats were chronically pre-treated with H3R
antagonist 4 (5 and 10 mg/kg) and VPA (300 mg/kg) 30-45 minutes before each PTZ
injection with (P < 0.001) when compared with PTZ-exposed rats (Table 7). Also, the
mortality rate had reduced to 0.00% with chronic pre-treatment with H3R antagonist
4 (5 and 10 mg/kg) and VPA (p = 0.14) (Table 7).
Additionally, the abrogation of H3R antagonist 4-provided protection was evaluated
by chronic co-injection with the CNS penetrant histamine H3R agonist RAM, the H1R
antagonist PYR, and the H2R antagonist ZOL (10 mg/kg, i.p.) before each PTZ
injection (Table 7). As confirmed with statistical analysis, chronic co-injection with
RAM (10 mg/kg) 20 minutes before each PTZ injection significantly raised the
kindling rate to 75.00% (P < 0.001) when compared with H3R antagonist 4 (5 mg)treated PTZ-exposed rats. In contrast, chronic co-injection with ZOL (10 mg/kg) 3045 minutes before each PTZ injection markedly elevated the kindling rate to 50.00%
(P < 0.05) when compared with H3R antagonist 4 (5 mg)-treated PTZ-exposed rats
(Table 7). However, chronic co-injection with PYR (10 mg/kg) 30-45 minutes before
each PTZ injection failed to significantly alter the kindling rate (p = 1) when compared
with H3R antagonist 4 (5 mg)-treated PTZ-exposed rats. Furthermore, chronic coinjection with RAM, PYR, and ZOL failed to significantly modify the mortality rate
(p = 307, p = 1 and p = 0.307), respectively. when compared with H3R antagonist 4 (5
mg)-treated PTZ-exposed rats (Table 7). Notably, chronic co-injection with RAM,
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PYR, and ZOL with PTZ alone failed to alter both kindling and mortality rate (P >
0.05) when compared with PTZ-treated rats.

Table 7: Effect of chronic administration of H3R antagonist 4 on kindling and
mortality rates.
Group
SAL
PTZ
4 (5 mg)
4 (10 mg)
VPA
4 (5 mg) + RAM
4 (5 mg) + PYR
4 (5 mg) + ZOL
PTZ + RAM
PTZ + PYR
PTZ + ZOL

Kindling rate
0.00%
83.33%##
0.00%**
0.00%**
0.00%**
75.00%$$
0.00%
50.00%$
75.00%
83.33%
83.33%

Mortality Rate
0.00%
16.67%
0.00%
0.00%
0.00%
8.33%
0.00%
8.33%
16.67%
16.67%
8.33%

H3R antagonist 4 (5 and 10 mg/kg) and VPA (300 mg/kg) were injected 30-45 min before each PTZ
injection. Effects shown are expressed as average of seizure score for 30 min observation time for each
PTZ injection. Values are expressed as percentages of the number of animals from each experimental
group(n=12-16). ##P < 0.001vs SAL-treated group. **P < 0.001vs PTZ-treated group. $P < 0.05 vs H3R
antagonist 4 (5 mg)-treated PTZ-exposed rats. $$P < 0.001vs H3R antagonist 4 (5 mg)-treated PTZexposed rats.

4.4.3 Effect of chronic administration of H3R antagonist 4 on PTZ-induced
memory deficits in IAP
The procognitive effect of compound 4 (5 and 10 mg/kg, i.p.) after chronic PTZinduced memory deficits in IAP in male Wistar rats were completed and discussed in
(Figure 37). Statistical analysis on the average of the STL times revealed that chronic
pretreatment with H3R antagonist 4 and VPA 30-45 minutes before each PTZ injection
conferred a significant memory-enhancing effect in IAP with (F(4,25) = 11.3; P < 0.001).
Further statistical analysis indicated, that PTZ chronic administration significantly
decreased STL time when compared with SAL-treated rats (F(1,10) = 22.06; P < 0.001).
Moreover, results of chronic pretreatment with VPA (300 mg/kg, i.p.) 30-45 minutes
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before each PTZ injection, indicated a significant improvement in STL time (F(1,10) =
22.06; P < 0.001) when compared with PTZ-treated rats. Moreover, further statistical
analysis exhibited, that chronic pretreatment with H3R antagonist 4 (5 and 10 mg/kg,
i.p.) significantly counteracted the memory impairment induced by PTZ- chronic
injections (F(1,10) = 14.24; P < 0.05) and (F(1,10) = 6.87; P < 0.05) when compared with
PTZ-treated rats (Figure 37). Remarkably, no significant difference was observed in
the procognitive effect provided by H3R antagonist 4 (5 and 10 mg/kg) (F(1,10) = 1.4;
p = 0.26). Notably, no significant difference was indicated between all the groups in
the training day, indicating that no modulating factors, e.g., locomotion or anxiety,
have confounded that modulatory effect in the test day.

Figure 37: H3R antagonist 4 (5 and 10 mg/kg) chronic treatment counteracted PTZinduced memory deficits in IAP.
Average of STL time measured on the first training day before the delivery of foot shock (black
columns), and average of STL time measured on the test day (gray columns). Effect of chronic
systemic administration of PTZ (40 mg/kg, i.p.) for 12 injections, H3R antagonist 4 (5 and 10 mg/kg,
i.p.), or VPA (300 mg/kg, i.p.) 30-45 minutes before each PTZ injection on the average of STL time.
##
P < 0.001 for average STL time compared with that in the SAL-treated group. *P < 0.05 for average
STL time compared with the PTZ-treated group. **P < 0.001 for average STL time compared with the
PTZ-treated group. The data are expressed as the mean ± SEM (n=6).
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Additionally, the abrogation of H3R antagonist 4-provided procognitive effect was
evaluated by chronic co-injection with the CNS penetrant histamine H3R agonist
RAM, the H1R antagonist PYR, and the H2R antagonist ZOL (10 mg/kg, i.p.) before
each PTZ injection (Figure 40). As confirmed with statistical analysis, chronic coinjection with RAM (10 mg/kg, i.p.) 20 minutes before each PTZ injection
significantly decreased STL time (F(1,10) = 5.42; P < 0.05) when compared with H3R
antagonist 4 (5 mg)- treated rats. However, chronic co-injection of PYR and ZOL (10
mg/kg, i.p.) 30-45 minutes before each PTZ injection failed to exhibit any change on
STL time (F(1,10) = 0.21; p = 0.65) and (F(1,10) = 0.34; p = 0.56), respectively when
compared with H3R antagonist 4 (5 mg)- treated rats. Notably, RAM chronic
administration with PTZ or SAL alone did not significantly alter STL time when
compared with PTZ- treated rats (F(1,10) = 0.02; p = 0.87) and (F(1,10) = 3.6; p = 0.08),
respectively (Figure 38).
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Figure 38: Effect of RAM, PYR, and ZOL on PTZ-induced memory deficit in IAP.
Average of STL time measured on the first training day before the delivery of foot shock (black
columns) and the average of STL time measured on the test day (gray columns). Effect of chronic coinjection of RAM, PYR, and ZOL before each PTZ injection on the average of STL time. ##P < 0.001
for average STL time compared with that in the SAL-treated group. *P < 0.05 for average STL time
compared with the PTZ-treated group. $P < 0.05 for average STL time compared with the H3R
antagonist 4 (5 mg)-treated rats. The data are expressed as the mean ± SEM (n=6).

4.4.4 Effect of chronic administration of H3R antagonist 4 on PTZ-induced
memory deficits in EPM
The procognitive effect of compound 4 (5 and 10 mg/kg, i.p.) after chronic PTZinduced memory deficits in EPM in male Wistar rats were completed and discussed in
(Figure 39). Statistical analysis on the average of the TLT revealed that chronic
pretreatment with H3R antagonist 4 and VPA 30-45 minutes before each PTZ injection
conferred a significant memory-enhancing effect in EPM (F(4,25) = 11.91; P < 0.001).
Further statistical analysis indicated, that PTZ chronic administration significantly
increased TLT time when compared with SAL-treated rats with (F(1,10) = 5.16; P <
0.05). Moreover, results of chronic pretreatment with VPA (300 mg/kg, i.p.) 30-45
minutes before each PTZ injection, indicated a significant decrease in TLT time (F(1,10)
= 7; P < 0.05) when compared with PTZ-treated rats. Further statistical analysis
exhibited, that chronic pretreatment with H3R antagonist 4 (5 and 10 mg/kg, i.p.)
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significantly counteracted the memory impairment induced by PTZ- chronic injections
by decreasing TLT (F(1,10) = 14.20; P < 0.05) and (F(1,10) = 10.82; P < 0.05) when
compared with PTZ-treated rats (Figure 39). Remarkably, no significant difference
was observed in the procognitive effect provided by H3R antagonist 4 (5 and 10
mg/kg) (F(1,10) = 1.47; p = 0.25). Notably, no significant difference was indicated
between all the groups in the training day, indicating that no modulating factors, e.g.,
locomotion or anxiety, have confounded that modulatory effect in the test day.

Figure 39: H3R antagonist 4 (5 and 10 mg/kg) chronic treatment counteracted PTZinduced memory deficits in EPM.
Average of TLT time measured on the first training day before the delivery of foot shock (black
columns) and the average of TLT time measured on the test day (gray columns). Effect of chronic
systemic administration of PTZ (40 mg/kg, i.p.) for 12 injections, H3R antagonist 4 (5 and 10 mg/kg,
i.p.), or VPA (300 mg/kg, i.p.) 30-45 minutes before each PTZ injection on the average of TLT time.
#
P < 0.05 for average TLT compared with that in the SAL-treated group. *P < 0.05 for average TLT
compared with the PTZ-treated group. The data are expressed as the mean ± SEM (n=6).

Additionally, the abrogation of H3R antagonist 4-provided procognitive effect was
evaluated by chronic co-injection with the CNS penetrant histamine H3R agonist
RAM, the H1R antagonist PYR, and the H2R antagonist ZOL (10 mg/kg, i.p.) before
each PTZ injection (Figure 40). As confirmed with statistical analysis, chronic co-
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injection with RAM (10 mg/kg, i.p.) 20 minutes before each PTZ injection
significantly increased TLT (F(1,10) = 23.93; P < 0.001) when compared with H3R
antagonist 4 (5 mg)- treated rats. However, chronic co-injection of PYR and ZOL (10
mg/kg, i.p.) 30-45 minutes before each PTZ injection failed to exhibit any change on
TLT (F(1,10) = 3.26; p = 0.1) and (F(1,10) = 4.68; p = 0.06), respectively when compared
with H3R antagonist 4 (5 mg)- treated rats. Notably, RAM chronic administration with
PTZ or SAL alone did not significantly alter TLT time when compared with PTZ- or
SAL- treated rats (F(1,10) = 0.27; p = 0.61) and (F(1,10) = 0.79; p = 0.39), respectively
(Figure 40).

Figure 40: Effect of RAM, PYR, and ZOL on PTZ-induced memory deficit in EPM.
Average of TLT time measured on the first training day before the delivery of foot shock (black
columns) and the average of TLT measured on the test day (gray columns). Effect of chronic coinjection of RAM, PYR, and ZOL before each PTZ injection on the average of TLT. #P<0.05 for the
average of TLT compared with that in the SAL-treated group. *P<0.05 for the average of TLT
compared with PTZ-treated group. $$P<0.001 for the average of TLT compared with the H3R
antagonist 4 (5 mg)-treated rats. The data are expressed as the mean ± SEM (n=6).
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4.4.5 Effect of chronic administration of H3R antagonist 4 on statues of
oxidative stress levels in rat’s hippocampus after PTZ-kindling model
The capability of H3R antagonist 4 to attenuate oxidative stress was evaluated in
hippocampus tissue of PTZ- treated male Wistar rats and discussed in (Figure 41).
Statistical analysis on the average of the MDA, GSH, CAT, and SOD revealed that
chronic pretreatment with H3R antagonist 4 and VPA 30-45 minutes before each PTZ
injection presented significant antioxidant effect (F(5,30) = 10.26; P < 0.001), (F(5,30) =
28.48; P < 0.001), (F(5,30) = 10.63; P < 0.001), and (F(5,30) = 13.86; P < 0.001),
respectively. Further statistical analysis of the observed results indicated that MDA
levels were markedly increased in PTZ-treated rats (F(1,10) = 63.96; P < 0.001) when
compared with SAL-treated group, while GSH levels were significantly decreased in
PTZ-treated rats (F(1,10) = 16.7; P < 0.001) when compared with SAL-treated rats
(Figure 41A and B). Moreover, the statistical analysis of the obtained results exhibited
a significance decrease in CAT and SOD levels in PTZ-treated rats when compared
with SAL-treated group (F(1,10) = 25.6; P < 0.05) and (F(1,10) = 23.71; P < 0.05),
respectively (Figure 41C and D). Further statistical analysis indicated that chronic
pretreatment with H3R antagonist 4 (5 and 10 mg/kg) significantly decreased MDA
levels (F(1,10) = 60.47; P < 0.001) and (F(1,10) = 18.35; P < 0.05), respectively when
compared with PTZ-treated rats. Also, chronic pretreatment with H3R antagonist 4 (5
and 10 mg/kg) significantly increased GSH levels (F(1,10) = 96.74; P < 0.001) and
(F(1,10) = 356.1; P < 0.001), respectively when compared with PTZ- treated rats. In
addition, chronic pretreatment with H3R antagonist 4 (5 and 10 mg/kg) significantly
increased CAT levels (F(1,10) = 45.06; P < 0.001) and (F(1,10) = 32.91; P < 0.05),
respectively and SOD levels (F(1,10) = 40.43; P < 0.001) and (F(1,10) = 37.03; P < 0.001),
respectively when compared with PTZ- exposed rats. (Figures 41C & D). Notably, no
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significance difference was detected in the antioxidant effect provided by H3R
antagonist (5 and 10 mg/kg) (F(1,10) = 0.69; p = 0.42), (F(1,10) = 1.93; p = 0.19), (F(1,10)
= 0.01; p = 0.9), and (F(1,10) = 1.6; p = 0.25) for MDA, GSH, CAT, and SOD,
respectively (Figure 42). Moreover, chronic pretreatment with VPA (300 mg/kg)
significantly attenuated the oxidative stress by decreasing the MDA levels and
increasing GSH levels (F(1,10) = 16.18; P < 0.05) and (F(1,10) = 8.74; P < 0.05)and
decreasing both CAT and SOD levels (F(1,10) = 16.06; P < 0.05) and (F(1,10) = 7.34; P
< 0.05) when compared with PTZ- exposed rats (Figures 41C & D).
Additionally, the abrogation of H3R antagonist 4-provided antioxidant effect was
evaluated by chronic co-injection with the CNS penetrant histamine H3R agonist
RAM (10 mg/kg, i.p.) 20 min before each PTZ injection (Figure 41). Statistical
analysis of the observed results indicated that chronic co-injection of RAM (10 mg/kg)
20 minutes before each PTZ injection, significantly abrogated the H3R antagonist 4 (5
mg)- antioxidant protective effect (Figure 41). As chronic co-injection of RAM
significantly increased MDA levels and decrease GSH levels (F(1,10) = 7; P < 0.05) and
(F(1,10) = 16.06; P < 0.05), respectively when compared with H3R antagonist 4 (5 mg)treated rats (Figures 41A & B). In addition, chronic co-injection of RAM significantly
decreased both CAT and SOD levels (F(1,10) = 6.45; P < 0.05) and (F(1,10) = 24.92; P
< 0.05), respectively when compared with H3R antagonist 4 (5 mg)-treated rats
(Figures 41C & D). Notably, chronic pretreatment of RAM with PTZ alone did not
significantly alter oxidative stress statues (F(1,10) = 1.28; p = 0.28), (F(1,10) = 0.26; p =
0.62), (F(1,10) = 0.53; p=0.49), and (F(1,10) = 0.42; p=0.54), respectively for MDA, GSH,
CAT, and SOD when compared with PTZ-treated rats (Figures 41A & B). Also,
chronic pretreatment of RAM with SAL alone did not significantly alter oxidative
stress statues (F(1,10) = 1.13; p = 0.31), (F(1,10) = 0.18; p = 0.68), (F(1,10) = 0.02; p =
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0.89), and (F(1,10) = 0.42; p = 0.54), respectively for MDA, GSH, CAT, and SOD when
compared with SAL-treated rats (Figures 41C & D).

Figure 41: H3R antagonist 4 (5 and 10 mg/kg) mitigated oxidative stress associated
with PTZ kindling model.
Levels of malondialdehyde (MDA), glutathione (GSH), catalase (CAT), and superoxide dismutase
(SOD) were assessed in rat hippocampus. Effect of PTZ-(40 mg/kg), H3R antagonist 4 (5 and 10
mg/kg; i.p.) and VPA (300 mg/kg, i.p.) on MDA levels (A), GSH levels (B), CAT levels (C), and
SOD levels (D) were assessed. H3R antagonist 4 (5 and 10 mg/kg; i.p.) and VPA (300 mg/kg, i.p.)
were administered 30-45 min prior each PTZ-injection. Effects of systemic co-injection with RAM
(10 mg/kg, i.p.) on H3R antagonist 4 (5 mg/kg)-provided modulation of oxidative stress levels were
assessed. Data are expressed as the mean ± SEM (n=6). #P < 0.05 vs. SAL-treated rats. ##P < 0.001 vs.
SAL-treated rats. *P < 0.05 vs. PTZ-treated rats. **P < 0.001 vs. PTZ-treated rats. $P < 0.05 vs. H3R
antagonist 4 (5 mg)-treated rats.
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4.4.6 Effect of chronic administration of H3R antagonist 4 on AChE activity in
rat’s hippocampus after PTZ-kindling model
The effect of H3R antagonist 4 on AChE levels was evaluated in the hippocampal
tissue of PTZ- treated male Wistar rats and discussed in (Figure 42). Statistical analysis
on the average of the AChE activity revealed that chronic pretreatment with H3R
antagonist 4 and VPA 30-45 minutes before each PTZ injection presented a significant
modulating effect (F(5,30) = 15,05; P < 0.001). Further statistical analysis of the
observed results indicated that PTZ- chronic systemic administration for 12 injections
led to a significant increase of hippocampal AChE activity (F(1,10) = 12.82; P < 0.05)
when compared to SAL-treated rats (Figure 42). Moreover, chronic pretreatment with
H3R antagonist 4 (5 and 10 mg/kg, i.p.) 30-45 minutes before each PTZ injection,
significantly decreased the elevated hippocampal AChE activity (F(1,10) = 22.67; P <
0.05) and (F(1,10) = 15.39; P < 0.05), respectively when compared with PTZ- exposed
rats (Figure 44). Notably, no significance difference was detected in the protective
effect provided by H3R antagonist (5 and 10 mg/kg) (F(1,10) = 1.83; p = 0.21).
Furthermore, chronic pretreatment with the positive drug VPA (300 mg/kg, i.p.) 3045 minutes before each PTZ injection, resulted in a significant decrease of
hippocampal AChE activity (F(1,10) = 14.0; P < 0.05) (Figure 42). Additionally, the
abrogation of H3R antagonist 4-provided effect was evaluated by chronic co-injection
with the CNS penetrant histamine H3R agonist RAM (10 mg/kg, i.p.) 20 min before
each PTZ injection (Figure 44). Statistical analysis of the observed results indicated
that chronic co-injection of RAM (10 mg/kg) 20 minutes before each PTZ injection,
significantly abrogated the H3R antagonist 4 (5 mg)- protective effect (Figure 42). As
chronic co-injection of RAM significantly increased AChE activity (F(1,10) = 47.73; P
< 0.001) when compared with H3R antagonist 4 (5 mg)-treated rats (Figure 42).
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Notably, chronic pretreatment of RAM with PTZ or SAL alone did not significantly
alter AChE activity (F(1,10) = 1.8; p = 0.20) and (F(1,10) = 0.3; p = 0.6), respectively
when compared with PTZ- or SAL- treated rats (Figure 42).

Figure 42: H3R antagonist 4 (5 and 10 mg/kg) chronic treatment modulated AChE
activity in rat’s hippocampus after PTZ-kindling model.
Levels of AChE activity were assessed in rat’s hippocampus. H3R antagonist 4 (5 and 10 mg/kg; i.p.)
and VPA (300 mg/kg, i.p.) were administered 30-45 min prior each PTZ-injection. Effect of systemic
co-injection with RAM (10 mg/kg, i.p.) on H3R antagonist 4 (5 mg/kg)-provided modulation on
AChE activity were assessed. Data are expressed as mean ± SEM (n=6). #P < 0.05 vs. SAL-treated
rats. *P < 0.05 vs. PTZ-treated rats. $$P < 0.001 vs. H3R antagonist 4 (5 mg)-treated rats.

4.4.7 Effect of chronic administration of H3R antagonist 4 on neurotransmitters
levels in rat’s hippocampus after PTZ-kindling model
The capability of H3R antagonist 4 to modulate neurotransmitters concentration was
evaluated in hippocampal tissue of PTZ- treated male Wistar rats and discussed in
(Figure 43). Statistical analysis on the average of the hippocampal HA, ACh, GABA,
and GLU levels revealed that chronic pretreatment with H3R antagonist 4 and VPA
30-45 minutes before each PTZ injection presented a significant modulating effect
(F(5,30) = 7.56; P < 0.001), (F(5,30) = 12.62; P < 0.001), (F(5,30) = 218.2; P < 0.001), and
(F(5,30) = 15.76; P < 0.001), respectively. Further statistical analysis of the observed
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results indicated that PTZ- chronic systemic administration for 12 injections led to a
significant decrease in both HA and ACh hippocampal levels (F(1,10) = 6.69; P < 0.05)
and (F(1,10) = 60.87; P < 0.001), respectively when compared with SAL-treated rats.
Furthermore, the obtained results indicated that PTZ chronic administration resulted
in a significant increase in GLU hippocampal concentration (F(1,10) = 53.16; P < 0.001)
when compared with SAL-treated rats. However, hippocampal GABA concentration
in PTZ-treated rats was not altered (F(1,10) = 0.09; p =0.76) when compared with SALtreated rats (Figure 43). However, further statistical analysis of the observed results
revealed, that chronic treatment with H3R antagonist 4 (5 and 10 mg/kg) 30-45
minutes before each PTZ injection significantly increased hippocampal HA
concentration (F(1,10) = 6.67; P < 0.05) and (F(1,10) = 6.68; P < 0.05), respectively when
compared with PTZ exposed rats (Figure 45A). Also, chronic treatment with H3R
antagonist 4 (5 and 10 mg/kg) significantly improved ACh levels in the hippocampus
(F(1,10) = 53.51; P < 0.001) and (F(1,10) = 10.2; P < 0.05), respectively when compared
with PTZ-treated rats (Figure 43B). Moreover, chronic treatment of H3R antagonist 4
(5 and 10 mg/kg) markedly decreased GLU hippocampal levels (F(1,10) = 11.6; P <
0.001) and (F(1,10) = 5.98; P < 0.05), respectively, but it failed to modify hippocampal
GABA concentration (F(1,10) = 0.49; p = 0.5) and (F(1,10) = 0.34; p = 0.57), respectively
when compared with PTZ-treated rats (Figures 43C & D). Notably, no significance
difference was observed between H3R antagonist 4 (5 and 10 mg/kg) in the modulating
effect of HA, ACh, and GLU levels (F(1,10) = 0.12; p = 0.74), (F(1,10) = 0.66; p = 0.44),
and (F(1,10) = 0.31; p = 0.59), respectively. In addition, chronic treatment with VPA
(300 mg/kg) 30-45 minutes before each PTZ injection, failed to change hippocampus
HA and GABA levels (F(1,10) = 0.66; p = 0.44) and (F(1,10) = 0.66; p = 0.44), respectively
when compared with PTZ exposed rats. However, VPA chronic treatment enhanced
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ACh brain levels and decreased GLU brain levels (F(1,10) = 10.15; P < 0.05) and (F(1,10)
= 6.07; P < 0.05), respectively when compared with PTZ-treated rats (Figure 43).
Additionally, the abrogation of H3R antagonist 4-provided effect was evaluated by
chronic co-injection with the CNS penetrant histamine H3R agonist RAM (10 mg/kg,
i.p.) 20 min before each PTZ injection (Figure 43). Statistical analysis of the observed
results indicated that chronic co-injection of RAM (10 mg/kg) 20 minutes before each
PTZ injection, abrogated the enhancement effect provided with H3R antagonist 4 (5
mg/kg) on hippocampal brain HA and ACh levels (F(1,10) = 21.18; P < 0.05) and (F(1,10)
= 35.53; P < 0.001), respectively; however, it failed to abrogate brain GLU levels
(F(1,10) = 2.46; p = 0.14) when compared with H3R antagonist 4 (5 mg)-treated rats
(Figure 45). Notably, chronic pretreatment of RAM with PTZ or SAL alone did not
significantly alter HA levels (F(1,10) = 0.06; p = 0.80) and (F(1,10) = 0.6; p = 0.47),
respectively when compared with PTZ- or SAL- treated rats, not either ACh levels
(F(1,10) = 1.04; p = 0.34) and (F(1,10) = 0.84; p = 0.39), respectively when compared with
PTZ- or SAL- treated rats, respectively (Figures 43A & B).
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Figure 43: H3R antagonist 4 (5 and 10 mg/kg) chronic treatment modulated HA,
ACh, and GLU levels in rat's hippocampus after PTZ-kindling model.
Levels of histamine (HA), acetylcholine (ACh), (GABA), and glutamate (GLU) were assessed in rat's
hippocampus. Effect of PTZ-(40 mg/kg), H3R antagonist 4 (5 and 10 mg/kg; i.p.), and VPA (300
mg/kg, i.p.) on HA levels (A), ACh levels (B), GABA levels (C), and GLU levels (D) were assessed.
H3R antagonist 4 (5 and 10 mg/kg; i.p.) and VPA (300 mg/kg, i.p.) were administered 30-45 min prior
each PTZ-injection. Effects of systemic co-injection with RAM (10 mg/kg, i.p.) on H3R antagonist 4
(5 mg/kg)-provided modulation of brain neurotransmitters levels were assessed. Data are expressed as
the mean ± SEM (n=6). #P < 0.05 vs. SAL-treated rats. ##P < 0.001 vs. SAL-treated rats. *P < 0.05 vs.
PTZ-treated rats. **P < 0.001 vs. PTZ-treated rats. $P < 0.05 vs. H3R antagonist 4 (5 mg)-treated rats.

4.4.8 Effect of chronic administration of H3R antagonist 4 on c-fos positive cell
in rat’s hippocampus after PTZ- kindling model
The expression of c-fos in rat’s hippocampus after chronic systemic administration of
PTZ (40 mg/kg, i.p.) three times a week for a total of 12 injections is shown in (Figures
44 & 45). Statistical analysis of hippocampal c-fos positive cells per field, showed that
chronic pretreatment with H3R antagonist 4 and VPA 30-45 minutes before each PTZ
injection presented a significant decreased effect (F(5,30) = 11.95; P < 0.001). Further
statistical analysis revealed that PTZ (40 mg/kg, i.p.) chronic systemic administration
significantly increased the number of c-fos positive cells in rat’s hippocampus (F(1,10)
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= 17.58; P < 0.05) when compared with SAL-treated rats. Moreover, chronic
pretreatment with H3R antagonist 4 (5 and 10 mg/kg) and VPA (300 mg/kg) 30-45
minutes before PTZ injection significantly reduced the number of c-fos positive cells
(F(1,10) = 7.97; P < 0.05), (F(1,10) = 9.95; P < 0.05) and (F(1,10) = 11.52; P < 0.05),
respectively when compared with PTZ- exposed rats. Notably no significant difference
was observed in protective effect provided by H3R antagonist 4 (5 and 10 mg/kg) with
(F(1,10) = 2.55; p = 0.15) (Figures 44 & 45).
Additionally, the abrogation of the H3R antagonist 4-provided effect was evaluated by
chronic co-injection with the CNS penetrant histamine H3R agonist RAM (10 mg/kg,
i.p.) 20 min before each PTZ injection (Figures 44 & 45). Statistical analysis of the
observed results indicated that chronic co-injection of RAM (10 mg/kg) 20 minutes
before each PTZ injection, abrogated the protective effect provided with H3R
antagonist 4 (5 mg/kg) on hippocampal c-fos expression (F(1,10) = 19.92; P < 0.05)
(Figures 44 & 45).
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Figure 44: Effect of H3R antagonist 4 on hippocampal c-fos expression in PTZkindled rats.
The hippocampal c-fos expression was assessed post PTZ-(40 mg/kg) chronic systemic
administration. VPA (300 mg/kg) and H3R antagonist 4 (5 and 10 mg/kg) treatment exhibited
significant modulatory change. #P < 0.05 for average c-fos positive cells compared with that in the
SAL-treated group. *P < 0.05 for average c-fos positive cells compared with the PTZ-treated group. $P
< 0.05 for average c-fos positive cells vs. H3R antagonist 4 (5 mg)-treated PTZ-exposed rats. Data are
expressed as mean ± SEM (n=6).
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Figure 45: H3R antagonsit 4 decreased c-fos expression in hippocampal tissues of
PTZ-exposed rats.
A Profound expression of c-fos positive cells was observed in chronic PTZ-exposed rats compared to
SAL-treated rats. In contrast, chronic treatment with H3R antagonist 4 (5 and 10 mg/kg, i.p.) showed
significantly reduced activation of c-fos compared to the PTZ-treated rats. A SAL, B PTZ, C VPA, D
4 (5 mg/kg), E 4 (10 mg/kg), F RAM + 4 (5 mg/kg).
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4.5 Pilocarpine (PLC)-Induced Status Epilepticus (SE)
4.5.1 Effect of H3R antagonist 4 on latency time to first seizure in PLC-induced
SE model
The average of the latency time to first seizure for 1 hour following PLC acute systemic
administration (400 mg/kg, i.p.) was scored and discussed in (Figure 46). All observed
seizures were GTCS with SE. Statistical analysis on the average of the latency time to
first seizure in PLC-induced SE model revealed that acute pretreatment with H3R
antagonist 4 and VPA 30-45 minutes before PLC injection presented a significant
protective effect (F(5,42) = 7.56; P < 0.001). Further statistical analysis of the obtained
results of systemic administration of PLC (400 mg/kg, i.p.) showed that the average of
the latency time to the first seizure was significantly higher when compared with SALtreated rats, as no seizures were observed (F(1,14) = 49.46; P < 0.001). Moreover, no
seizures were observed with acute pretreatment with the reference drug DZP (10
mg/kg, i.p.) and the average of the latency time to the first seizure was significantly
altered (F(1,14) = 49.46; P < 0.001) when compared with PLC-treated rats. Furthermore,
further statistical analysis of the obtained results showed that pretreatment with H3R
antagonist 4 (2.5 and 15 mg/kg, i.p.) 30-45 minutes before PLC injection failed to
prolong the average of the latency time to first seizure (F(1,14) = 7.2; p = 0.06), and
(F(1,14) = 6.82; p = 0.06), respectively as compared to the PLC-exposed rats (Figure
46). However, acute pretreatment with H3R antagonist 4 (5 and 10 mg/kg, i.p.) 30-45
minutes before PLC injection significantly extended the average of the latency time to
the first seizure (F(1,14) = 13.84; P < 0.05) and (F(1,14) = 25.44; P < 0.001), respectively
when compared to the PLC-exposed rats.
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Figure 46: H3R antagonist 4 prolonged the average of the latency time to first seizure
in PLC- induced SE model.
Effects of acute systemic injection with H3R antagonist 4 (2.5, 5, 10, and 15 mg/kg, i.p.) or DZP (10
mg/kg, i.p.) on latency time (min) to the first PLC-induced seizure. $$ P <0.001 vs. SAL treated rats.
*
P < 0.05 vs. PLC-treated rats. **P < 0.001 vs. PLC-treated rats. # Full protection as compared to PLCtreated rats. Values are expressed as the mean ± SEM (n=8).

In addition, the abrogation of H3R antagonist 4-provided protection was evaluated by
acute co-injection with the CNS penetrant histamine H3R agonist RAM, the H1R
antagonist PYR, and the H2R antagonist ZOL (10 mg/kg, i.p.) before PLC injection
(Figure 47). As confirmed with statistical analysis, the results showed that PYR (10
mg/kg, i.p.) co-administration failed to significantly abrogate the average of the
latency time to first seizure (F(1,14) = 1.61; p = 0.23) when compared to H3R antagonist
4 (10 mg)- protective effect. However, co-injection with ZOL (10 mg/kg, i.p.)
significantly reversed the protective effects of H3R antagonist 4 (10 mg/kg) on the
average of latency time to first seizure (F(1,14) = 30.71; P < 0.001) when compared to
H3R antagonist 4 (10 mg)- protective effect (Figure 47). Moreover, co-injection with
RAM (10 mg/kg, i.p.) significantly decreased the average of the latency time to first
seizure (F(1,14) = 4.72; P < 0.05)when compared to H3R antagonist 4 (10 mg)protective effect (Figure 47).
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Notably, systemic administration of RAM, PYR, and ZOL alone did not alter the
average of the latency to first seizure (F(1,14) = 1.76; p = 0.22), (F(1,14) = 1.73; p = 0.21),
and (F(1,14) = 3.21; p = 0.10), respectively when compared with PLC-treated group.

Figure 47: Effect of RAM, PYR, and ZOL on average of latency time to first seizure
in PLC- induced SE model.
Effects of acute systemic injection with RAM, PYR and ZOL (10 mg/kg, i.p.) on latency time (min) to
the first PLC-induced seizure. **P < 0.001 vs. PLC-treated rats. $P < 0.05 vs. H3R antagonist 4 (10
mg)- protective effect. $$P < 0.001 vs. H3R antagonist 4 (10 mg)- protective effect. Values are
expressed as the mean ± SEM (n=8).

4.5.2 Effect of H3R antagonist 4 on SE incidence and survival rate
The SE incidence and survival rate were calculated as percentages of the number of
animals from each experimental group and were discussed in (Table 8). Following
statistical analysis, the obtained results indicated that all tested animals injected with
PLC (400 mg/kg, i.p.) showed convulsions with SE and 66.66% of the animals
survived from SE after 1 h from injection with (P < 0.001 and P < 0.05), respectively
when compared to SAL-treated rats (Table 8). However, acute pre-treatment with DZP
(10 mg/kg, i.p.) 30–45 min before PLC treatment showed that SE incidence was
significantly decreased (P < 0.001) and survival rate was markedly increased (P <
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0.05) when compared with the PLC-treated rats. In addition, the obtained results
revealed that acute pre-treatment with H3R antagonist 4 (2.5, 5, 10, and 15 mg/kg, i.p.)
30-45 minutes before PLC injection significantly reduced SE incidence when
compared with the PLC-treated group (all P < 0.05) except for H3R antagonist 4 (10
mg/kg) (P < 0.001). Furthermore, H3R antagonist 4 (2.5, 5, and 10 mg/kg, i.p.) acute
pre-treatment significantly improved survival rate when compared with the PLCtreated group (all P < 0.05). However, H3R antagonist 4 (15 mg/kg, i.p.) failed to
significantly raise the survival rate when compared with the PLC-treated group (Table
8).
Besides, the abrogation of H3R antagonist 4-provided protection was evaluated by
acute co-injection with the CNS penetrant histamine H3R agonist RAM, the H1R
antagonist PYR, and the H2R antagonist ZOL (10 mg/kg, i.p.) before PLC injection
(Table 8). As confirmed with statistical analysis, the results showed that PYR (10
mg/kg, i.p.) co-administration failed to significantly alter SE incidence and survival
rate with (P > 0.05) when compared to H3R antagonist 4 (10 mg)- protective provided
effect. However, co-injection with ZOL partially reversed the SE incidence average
(P < 0.05) and reduced the survival rate to (P < 0.05) (Table 8). Furthermore, coinjection with RAM raised the SE incidence (P > 0.05) and no change was observed
on the survival rate. Notably, systemic administration of RAM, PYR, and ZOL alone
did not alter SE incidence with (all P > 0.05) when compared with H3R antagonist 4
(10 mg)- protective provided effect (Table 8).
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Table 8: Effect of H3R antagonist 4 on SE incidence and survival rate in PLCinduced SE model.
Group
SAL
PLC (400 mg/kg)
DZP (10 mg/kg)
4 (2.5 mg/kg)
4 (5 mg/kg)
4 (10 mg/kg) a
4 (15 mg/kg)
4a + RAMb
4 a + PYRc
4 a + ZOLd
RAM + PLC
PYR + PLC
ZOL + PLC

Percentage of SE Incidence
(%)
0.00
100.00#
0.00**
50.00*
50.00*
33.33**
50.00*
66.67
50.00
100.00$
83.33
83.33
66.67

Percentage of Survival (%)
100.00
66.67
100.00
100.00
100.00
100.00
83.33
100.00
100.00
83.33
100.00
83.33
100.00

a

(10 mg/kg, i.p.), b(10 mg/kg, i.p.), cPYR (10 mg/kg, i.p.), dZOL (10 mg/kg, i.p.). #P<0.001 as compared
to SAL-treated rats, *P < 0.05, **P < 0.001 as compared to PLC-treated rats. $P < 0.05 as compared to
H3R antagonist 4 (10 mg/kg)-treated group. Values are expressed as percentages of the number of
animals from each experimental group (n = 12).

4.5.3 Effect of H3R antagonist 4 on statues of oxidative stress in rat’s
hippocampus after PLC- induced SE model
The ability of H3R antagonist 4 to attenuate oxidative stress was evaluated in
hippocampal tissue of PLC- treated male Wistar rats and discussed in (Figure 48).
Statistical analysis on the average of the hippocampal MDA and GSH levels revealed
that acute pretreatment with H3R antagonist 4 and DZP 30-45 minutes before PLC
injection presented a significant antioxidant effect (F(6,35) = 6.48; P < 0.001) and (F(6,35)
= 5.34; P < 0.001). Statistical analysis of the observed results indicated that MDA
levels were markedly increased in PLC-treated rats (F(1,10) = 28.05; P < 0.001) when
compared with SAL-treated group, while GSH levels were significantly decreased in
PLC-treated rats (F(1,10) = 69; P < 0.001) when compared with SAL-treated rats
(Figures 48A & C). However, no significant difference was observed of both CAT and
SOD levels after PLC injection (F(1,10) = 0.24; p = 0.64) and (F(1,10) = 1.74; p = 0.22),
respectively when compared with SAL-treated group (Figure 48E and F). Moreover,
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the obtained results revealed that (GSH) levels were noticeably elevated in the DZP
group (F(1,10) = 32.84; P < 0.001) as compared to the PLC group, also MDA levels
were significantly reduced in the DZP group (F(1,10) = 11.08; P < 0.05), respectively
when compared with PLC-treated group (Figure 48A and C). Furthermore, the results
showed that pre-treatment with H3R antagonist (2.5, 5, 10, and 15 mg/kg, i.p.) 30-45
minutes before PLC injection significantly reduced hippocampal MDA levels (F(1,10)
= 9.21; P < 0.05), (F(1,10) = 11.74; P < 0.05), (F(1,10) = 36.47; P < 0.001), and (F(1,10) =
11.76; P < 0.05) when compared to PLC-treated group (Figure 48C ). In addition, the
results demonstrated that pretreatment with H3R antagonist 4 (5, 10 and 15 mg/kg,
i.p.) markedly increased GSH levels (F(1,10) = 11.31; P < 0.05), (F(1,10) = 12.18; P <
0.05), and (F(1,10) = 11.86; P < 0.05) when compared with PLC-treated group, while
unnoticeable change was observed in animals treated with the lower dose H3R
antagonist 4 (2.5 mg/kg, i.p.) (F(1,10) = 1.02; p = 0.34) when compared with PLCtreated group (Figure 48A). In addition, the abrogation of H3R antagonist 4-provided
protection was evaluated by acute co-injection with the CNS penetrant histamine H3R
agonist RAM (10 mg/kg, i.p.) 20 minutes before PLC injection (Figure 48B and D).
As confirmed with statistical analysis, that pretreatment with RAM (10 mg/kg, i.p.)
significantly abrogated the protective effect observed by H3R antagonist 4 (10 mg/kg,
i.p.) on the levels of MDA and GSH (F(1,10) = 5.89; P < 0.05) and (F(1,10) = 9.51; P <
0.05), respectively when compared with H3R antagonist 4 (10 mg)-treated PLCexposed rats (Figure 48B and D). Notably, RAM administered alone with PLC did not
modulate the levels of MDA and GSH when compared to PLC-treated group (F(1,10) =
0.98; p = 0.41) and (F(1,10) = 1.91; p = 0.56), respectively, also RAM did not modulate
the levels of MDA and GSH when administrated with SAL (F(1,10) = 0.88; p = 0.51)
and (F(1,10) = 1.25; p = 0.39), respectively when compared with SAL-treated group.

Figure 48: H3R antagonist 4 (5 and 10 mg/kg) mitigated hippocampal oxidative stress associated with PLC-induced SE model.
Levels of malondialdehyde (MDA), glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD) were assessed in rat hippocampus. Effect of PLC-(400 mg/kg),
H3R antagonist 4 (2,5, 5, 10 and 15 mg/kg; i.p.) and DZP (10 mg/kg, i.p.) on GSH levels (A), MDA levels (C), CAT levels (E), SOD levels (F) were assessed. H3R antagonist
4 and DZP were administered 30-45 min prior PLC injection. Effects of systemic co-injection with RAM (10 mg/kg, i.p.) on H3R antagonist 4 (10 mg/kg)-provided
modulation of oxidative stress levels were assessed. Data are expressed as the mean ± SEM (n=6). #P < 0.05 vs. SAL-treated rats. ##P < 0.001 vs. SAL-treated rats. *P < 0.05
vs. PLC-treated rats. **P < 0.001 vs. PLC-treated rats. $P < 0.05 vs. H3R antagonist 4 (10 mg)-treated PLC-exposed rats.
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4.5.4 Effect of H3R antagonist 4 on AChE activity in rat’s hippocampus after
PLC-induced SE model
The effect of H3R antagonist 4 on AChE activity was evaluated in hippocampal tissue
of PLC-treated male Wistar rats and discussed in (Figure 49). Statistical analysis on
the average of the hippocampal AChE activity revealed that acute pretreatment with
H3R antagonist 4 and DZP 30-45 minutes before PLC injection presented a significant
modulating effect (F(6,35) = 6.31; P < 0.001). Further statistical analysis of the observed
results indicated that PLC- acute systemic administration significantly decreased
AChE activity (F(1,10) = 20.94; P < 0.05) when compared with SAL-treated rats.
However, acute pretreatment with H3R antagonist 4 and DZP 30-45 minutes before
PLC injection, failed to significantly exhibit any change on hippocampus on AChE
activity (F(1,10) = 0.43; p = 0.53), (F(1,10) = 0.98; p = 0.41), and (F(1,10) = 0.97; p = 0.10),
respectively (Figure 49).
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Figure 49: Effect of H3R antagonist 4 on (AChE) activity in rat’s hippocampus after
PLC-induced SE model.
Effects of acute systemic injection of rats with test compound 4 (2.5, 5, 10, and 15 mg/kg, i.p.) or
DZP (10 mg/kg, i.p.) on acetylcholine esterase enzyme activity in the hippocampus of PLC-seizure
rats. Quantitative analysis revealed a significant decrease ( #P < 0.001) in the AChE activity in the
hippocampus of PLC-seizure rats compared to the control rats. Acute systemic treatment with test
compound 4 (2.5, 5, 10, and 15 mg/kg, i.p.) or DZP (10 mg/kg, i.p.) to the PLC-rats failed to restore
this activity compared to the PLC-treated rats. Values are expressed as the percent mean ± SEM (n =
6).
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Chapter 5: Discussion
All novel H3R antagonists in the form of hydrogen oxalate salts were evaluated in
radioligand displacement binding assays for affinity at human recombinant histamine
H3 receptor (hH3R) stably expressed in human embryonic kidney (HEK-239) cells.
Moreover, all examined H3R antagonists, namely 1-16, exhibited affinities at the
hH3R in a nanomolar concentration range (Ki: 36-137 nM, Table 2). All the
compounds, except for 9, 11, and 13, were comparable with the standard H3R PIT (Ki:
37- 83 nM), while 9,11, and 13 were less potent (Ki: 110-137 nM). Furthermore, as
H1R also plays a crucial role in the anticonvulsant activity of the central histamine,
selected potential H3R antagonists (4, 7, and 13) were examined in a binding assay at
the human histamine H1R and revealed weak affinities (915 ≤ Ki ≤ 1338 nM), being
10-fold lower than at the H3R. In addition, because of the high degree of homology
between H3R and H4R, selected potential H3R antagonists (4, 7, and 13) were
examined in a binding assay at the human histamine H4R and showed no affinity for
hH4R (Ki > 10,000 nM). The potential H3R antagonist 4 displayed high affinity to
hH3R (Ki = 69.3 nM), weak affinity to hH1R (Ki = 1273.0 nM) and no affinity to hH4R
(Ki > 10,000 nM).
In the present study, the anticonvulsant effect of all the H3R antagonists was screened
applying different electrically- (MES) and chemically- (PTZ and STR) acute induced
seizure models. All the previous models are preclinical models against GTCS with
different mechanisms of action. The H3R antagonists, namely 1-16, varied in their
protection level in the three acute seizure models utilized in this present study. In the
MES-acute induced seizure model, the results demonstrated that H3R antagonist 4 (10
mg/kg, i.p.) showed the most promising protective effect against GTCS when
compared with SAL-treated rats (Figure 15, Table 3). However, H3R antagonist 4
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lower doses (2.5 and 5 mg/kg) and the higher dose (15 mg/kg) failed to enhance the
(10 mg) H3R antagonist 4-provided protection (Figure 16, Table 3). Consequently, the
obtained findings showed a dose-dependence relationship of the protection provided,
beside the existence of a maximum effect for H3R antagonist 4 in the MES-induced
seizure model reached with a dose of 10 mg/kg, i.p. The previous results are in line
with earlier observations that indicated a dose-dependent effect of numerous H3R
antagonists examined for their anticonvulsant potential in MES-induced seizure
model303,304,361,371,374. Markedly, the anticonvulsant effect of H3R antagonist 4 (10
mg/kg, i.p.) was comparable to that noted in rats treated with the reference antiepileptic
drug PHT (10 mg/kg, i.p.), and was significantly higher than that noticed for H3R
antagonists 3, 5, 6, 7, and 14 (Figure 15, Table 3). PHT is a traditional antiepileptic
drug that provided a high protective effect against GTCS induced by MES401-404.
Additionally, another test in this study revealed that the protective effect of H3R
antagonist 4 was abrogated when rats were co-injected with the CNS penetrated H3R
agonist RAM and H1R antagonist PYR (10 mg/kg, i.p.) (Figure 17). Notably, RAM
and PYR co-injection alone with SAL failed to modify THLE time in the MES test.
Suggesting that the protection provided effect by H3R antagonist 4 in the MESinduced seizure model involves, to some extent, to blockade of H3R and interaction
with postsynaptically H1R by the released histamine. H3Rs are auto-receptors placed
on histaminergic neurons presynaptically, with an inhibitory influence on the
biosynthesis and release of histamine405. Thus, inhibition of H3Rs by selective H3R
antagonists, the same as test compound H3R antagonist 4, would increase the neuronal
release of brain histamine, supplying the anticonvulsant protective effect in the MESinduced seizure model. The previous implied mechanism underlying the
anticonvulsant effect of H3R antagonist 4 is also in agreement with former preclinical
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observations in animal seizure models in which high doses of several centrally acting
H1R antagonists used as anti-allergic drugs promoted the development of convulsions
of tested animals, indicating the involvement of H1R antagonism, and, consequently,
brain histaminergic neurotransmission in the seizure promotion. Moreover, H1
receptor and HDC deficient animals were more susceptible to have convulsions162,369.
Remarkably, comparable protective effects of imidazole-based (e.g., clobenpropit) and
non-imidazole-based H3R antagonists (e.g., DL77 and E159) were previously shown
to be abrogated either by H3R agonists or by centrally acting H1R antagonists,
signifying an interaction of the H3R antagonism-released histamine with
postsynaptically located H1Rs on neurons289,296,305,361.
In PTZ-induced seizure model, acute pretreatment with H3R antagonists 4, 7, and 11
(10 mg/kg) and VPA (300 mg/kg) 30-45 minutes before PTZ injection exhibited full
protection (Figure 18). Moreover, H3R antagonist 4 (15 mg/kg) also showed full
protection, whereas lower doses showed a lower protective effect when compared with
(10 mg)-protective effect (Figure 19), indicating a dose-dependent effect in PTZinduced seizure model, which is in line with previous preclinical studies2,7,13,16,58,65.
Notably, the protective effect provided by H3R antagonist 4 in the PTZ-induced
seizure model was comparable to the standard antiepileptic drug VPA (Figure 18).
VPA is a traditional antiepileptic drug that provided a high protective effect against
GTCS induced by PTZ and STR289,305,404,406,407, and the dose of VPA (300 mg/kg) used
in this study is the minimal dose of VPA that protected animals against PTZ- and STRinduced seizures without mortality. However, the protective effect provided by H3R
antagonist 4 was not abrogated with co-injection with RAM, PYR, or ZOL (10 mg/kg)
before PTZ injection (Figure 20), suggesting that the protective effect provided by
H3R antagonist 4 in the PTZ- induced seizure model is not facilitated through
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modulation of histaminergic neurotransmission. The previously obtained outcome can
be explained by the difference in the mechanism of seizure induction, triggers, and
type of seizures each model represents (MES is considered as a model of GTCS, while
PTZ [60 mg/kg) is believed to provoke generalized myoclonic and /or clonic-tonic
seizures)292,408-410. The failure of RAM to abrogate the protective effect provided by
H3R antagonist 4 in the PTZ-induced seizure model, can be explained with H3R
antagonist 4 ability to diminish the excitation of glutaminergic or increase the
inhibition of GABAergic synaptic transmission via blockade of H3 hetero-receptors
function in CNS, thereby demanding further analysis if H3R antagonist 4 modulates
the release of GABA or GLU brain concentration.
In the STR- induced seizure model, H3R antagonist 4 failed to exhibit any protective
effect against GTCS induced by STR (3.5 mg/kg, i.p.) acute administration (Figure
21), which suggested a lack of effect of the test compound H3R antagonist 4 on the
glycine receptors. However, with high antagonist affinity and high in vitro selectivity
and without any appreciable protective effect against MES- and PTZ-induced seizure
models, H3R antagonist 13 exhibited a high protective effect against STR-induced
seizure models, indicating that H3R antagonist 13 is protective against convulsion
induced through glycine receptors. The failure of H3R antagonist 4 to provide a
protective effect in the STR-induced seizure model, despite its anticonvulsant effect in
both MES- and PTZ-induced seizure models, can be explained by the variation in
mechanisms of action and type of seizures in each model. MES and PTZ are believed
to be of the most widely used acute seizure models because seizure initiation is simple,
and the predictive value for discovering clinically active anticonvulsant compounds is
high. MES is a model for inducing GTCS, and it has frequently been stated that
antiepileptic drugs that block MES-induced tonic-clonic extension act via inhibiting
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seizure spread411. MES- induced seizures are elicited by stimulation of all neuronal
pathways in the brain stream, and the abuse only lasts for a short time. Additionally,
it was previously indicated that AEDs that prevent MES-induced tonic extension could
elicit its action either by compounds that block voltage-dependent Na+ channels, such
as PHT and lamotrigine, or by compounds that block glutamatergic excitation
mediated by the (NMDA) receptor, such as felbamate375. Moreover, the PTZ-induced
seizure model represents a model for inhibiting human generalized myoclonic seizures
and /or absence seizures410. Furthermore, the systemic administration of PTZ is
commonly used to induce different types of seizures, depending on the dose applied412.
Accordingly, low doses of PTZ (20-30 mg/kg) were found to be capable of inducing
absence like seizures, medium doses (40-50 mg/kg) resulted in clonic seizures, while
clonic-tonic seizures appeared only with the administration of high doses of PTZ (5060 mg/kg)413.Electrophysiological studies indicated that PTZ-induced seizures were
elicited by decreasing the GABAergic neurotransmission through inhibition of
benzodiazepine binding site in GABAA receptor complex206,207. MacDonald and
Barker reported that the acute effect of PTZ on cultured mammalian neurons was
mediated through blocking GABA-mediated transmission414. It was also revealed that
AEDs that prevented PTZ-induced generalized seizures could elicit its action either by
the modulation of GABAergic neurotransmission or by the reduction of T-type Ca2+
currents, such as ETX. Moreover, STR-induced seizures are provoked by the inhibition
of glycine-operated chloride ion channels in the brain stem and spinal cord, and STRinduced seizure test is a model of GTCS415.
Remarkably, a high number of marketed AEDs were not protective in all acuteinduced seizure models. For example, PHT and CBZ are protective against THLE in
the MES-induced seizure model, but they exhibit no protective effect against GTCS
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induced by PTZ or STR. Oppositely, ETX, and tiagabine, which exhibit high
protection in chemically-induced seizure models, lack the effectiveness in the MESinduced seizure model. Interestingly, VPA provided a protective effect in both MESand PTZ-induced seizure models416,417. These preclinical indications justify the
provided effectiveness of PHT and CBZ, but not ETX and tiagabine, in patients with
GTCS, and the opposite in patients with absence seizures, and the protective effect of
VPA in patients with both GTCS and absence seizures.
From the previous observations, it was suggested that the compound H3R antagonist
4, namely 1-(6-(naphthalen-2-yloxy)hexyl)azepane hydrogen oxalate, with high
antagonist affinity (Ki=69.40 nM) and high in vitro selectivity, is promising to be
effective against GTCS and absence seizures through the modulation of the
histaminergic neurotransmission and consequently of the glutaminergic and/or
GABAergic neurotransmissions, since different neurotransmitters, including GABA
or GLU, may be implicated in the anticonvulsant provided effect. It can also be
postulated that H3R antagonist 4 possibly also blocks histamine H3 hetero-receptors
that control the release of other neurotransmitters, including GABA and GLU224,418; as
previously noted, thioperamide increased the release of HA and GABA from rat
hypothalamus419.
All earlier observations revealed that acute systemic pretreatment with H3R antagonist
4 in electrically- and chemically-induced seizure models exhibited its anticonvulsant
effect through modulation of the histaminergic neurotransmission and, at least
partially, the post-synaptic H1Rs activation. Besides, mechanisms dependent on
GABAenergic and glutaminergic neurotransmission might be involved.
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Cognitive impairment accompanied some types of epilepsy at the onset and got worse,
particularly with chronic uncontrolled seziures63. Memory deficit was also listed as
one of the main adverse effects of AEDs420, as around 70% of epilepsy patients
respond well to the mono-therapy treatment. However, the rest require polytherapy,
which will further augment the adverse effects421. Therefore, more pharmacological
effective compounds that control seizures and attenuate memory deficits are required.
Remarkably, H3R antagonists/inverse agonists have shown a prospective procognitive
effect when compared to other AEDs, as indicated in earlier studies305,420. Also, shortterm and long-term memory defects associated with DIZ or SCO were attenuated by
the use of various H3R antagonists belonging to different chemical classes305,379,422,423.
PIT has been approved in clinics for increasing wakefulness and fast rhythms, which
are features of cognition282,424. Furthermore, PIT and numerous H3R antagonists are
presently under clinical investigations for their effectiveness in cognitive disorders
treatment425,426. Besides, the anticonvulsant provided effect of H3R antagonist 4 in
both acute MES- and PTZ-induced seizure models was exhibited through modulation
of histaminergic neurotransmission and probable involvement of GABAenergic and
glutaminergic neurotransmission. The question here is whether this impact on
histaminergic neurotransmission can influence DIZ- or SCO-induced memory deficits
in male Wistar rats.
The procognitive effect of H3R antagonist 4 was investigated in this study applying
IAP in DIZ and SCO-induced amnesic effects in adult male Wistar rats. IAP test is a
fear-motivated test mainly used to evaluate the effect of chemical compounds on
different types of learning and memory. The obtained results indicated that DIZ (0.1
mg/kg) and SCO (1 mg/kg) acute treatment, 30 minutes before the test, induced
memory deficits in IAP with DIZ inducing higher memory impairment effect (Figure
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23). The observations are in line with previous studies, which indicate the amnesic
effect of both DIZ and SCO in several behavioral tests123,377,427,428.
DIZ is a noncompetitive NMDA receptor antagonist, and the considerable contribution
of NMDA receptors have been proved in the retrieval memory process; also, NMDA
receptors were previously indicated to regulate long-term potentiation LTP and
memory process including long-term memory379,429,430. Similarly, the vital role of
GLU has been documented in learning, memory, and neurodegenerative diseases431.
Numerous studies have also documented the involvement of SCO, a nonselective
muscarine antagonist, in retrieval memory process380,432,433. Additionally, previous
publications had confirmed the essential role of cholinergic neurotransmission in
different types of cognitive functions. Likewise, the rise in ACh brain concentration is
positively related to high performance during learning434,435. Pretreatment with H3R
antagonist 4 (10 mg/kg, i.p.), 30-45 minutes before DIZ or SCO injections, mitigated
both DIZ- and SCO-induced memory impairment with the higher procognitive effect
observed in DIZ-induced amnesic effect (Figure 23). The latter outcome is in line with
an earlier study in which clobenpropit attenuated SCO-induced memory impairment
applying IAP, and the ameliorative effect was reversed when rodents were co-injected
with RAM and PYR436. Based on the previous results, it is feasible that H3R
antagonist 4 mitigated the memory impairment induced by DIZ or SCO, as a result of
antagonizing the H3 auto-receptors resulting in brain histamine release, which is
believed to react with and stimulate NMDA and muscarine receptors, respectively.
The last assumptions were reinforced by recent publications, which showed that
histamine improved the neurotransmission facilitated by NMDA receptors in cultured
hippocampal cells and indicated that brain histamine and NMDA receptor
collaboration could aid in attenuating the memory impairment induced by DIZ in
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IAP437. Moreover, i.c.v. injection of histamine and acetylcholine attenuated SCOinduced memory impairment in male Wistar rats438. Taken together, it was proposed
that other neurotransmitters (e.g., ACh and GLU) released by H3 hetero-receptors
might be involved in the provided procognitive effect of H3R antagonist 4. Since H3R
antagonist 4 provided a higher procognitive effect in DIZ- rather than SCO induced
memory deficits model, the DIZ- induced amnesic model was selected to apply in both
IAP and NOR tests.
Furthermore, H3R antagonist 4 (1.25, 2.5, and 5 mg/kg) significantly and dosedependently attenuated DIZ-induced memory impairment in male Wistar rats. It was
observed that H3R antagonist 4 (5 and 10 mg/kg) significantly prolonged STL time
when compared with the lower doses (1.25 and 2.5 mg/kg), and there was no
significant observed difference in STL time with increasing the dose from 5 to 10
(mg/kg) (Figure 24). H3R antagonist 4 (5 mg/kg, i.p.) was considered the most optimal
dose to exhibit a memory-enhancing effect in DIZ-induced amnesic effect applying
IAP. The procognitive and dose-dependent effect of various H3R antagonists (e.g.,
DL77, UW-MD-71, E159, UW-MD-72, GSK189254, and thioperamide) in DIZinduced memory impairment was previously observed applying IAP305,307,322,379-381,439.
Remarkably, the memory-enhancing effects of H3R antagonist 4 (5 and 10 mg/kg)
were similar to the procognitive effect accomplished with the standard drug DOZ
(Figure 24).
Interestingly, H3R antagonist 4 (5 mg/kg) provided procognitive effect in IAP was
abolished when rats were co-injected with RAM and ZOL but not with PYR (Figure
25), implying that the procognitive provided effect was facilitated through an
alternation of the central histaminergic neurotransmission to some degree with the
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interaction between the released histamine and the postsynaptically located H2Rs but
not H1Rs. The latter observations for abrogation effects also concurred with those
stated for numerous H3R antagonists in previous preclinical studies, as RAM and ZOL
co-injection reversed the procognitive effect of DL77 and UW-MD-72, while only coinjection with RAM abolished the protective effect of thioperamide and clobenpropit
in IAP305,315,380. Notably, acute systemic co-injection of RAM or ZOL with DIZ (0.1
mg) or SAL in IAP failed to significantly alter the STL times observed in each group,
indicating that RAM and ZOL have no memory modulating effect when administered
alone.
Previously obtained memory-enhancing effects for H3R antagonist 4 in DIZ-induced
memory impairment further support that histaminergic pathway through activation of
H2Rs is profoundly involved in neuronal pathways essential for modification of
retrieval processes.
NOR test is a standard test in rodent to evaluate both STM and LTM recognition
memory440. Interestingly, NOR test depends on the natural behavioral of the rodent, as
there is no incentive or penalty for the animals in NOR test441,442. The test evaluates
the animal’s natural tendency to explore their atmosphere as it is reliant on the animal’s
natural behavior440. The observed results indicated that DIZ treatment following T1
significantly altered the rodent’s behavior toward the novel objects in T2, indicating
both STM and LTM recognition impairment (Figure 26). The indicated findings were
in line with previous studies demonstrating DIZ amnesic effect in NOR test443. In this
present study, H3R antagonist 4 (5 and 10 mg/kg) significantly attenuated DIZinduced STM memory deficits in NOR. However, H3R antagonist 4 (2.5 mg/kg) failed
to exhibit any protective effect (Figure 26). Notably, no remarkable difference was
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observed between the procognitive effects provided by H3R antagonist 4 (5 and 10
mg/kg); also, the observed procognitive effect was comparable to the standard drug
DOZ. Then H3R antagonist 4 (5 mg/kg, i.p.) was considered the most optimal dose to
exhibit a memory-enhancing effect in DIZ- induced amnesic effect applying NOR.
Additionally, the procognitive effect obtained with H3R antagonist 4 was previously
documented with several imidazole- based H3R antagonists, e.g., thioperamide and
clobenpropit315 and non-imidazole based H3R antagonists, e.g., E159, pitolisant, ABT239, GSK189254, and SAR110894 in NOR test. In addition, E159, pitolisant, and
ABT-239 exhibited a dose-dependency effect in ameliorating DIZ- induced memory
impairments307,312,320,444,445. Furthermore, the protective effect of H3R antagonist 4
was abrogated with systemic co-injection with RAM (10 mg/kg), indicating the
involvement of the histaminergic system in the procognitive effect provided by the test
compound H3R antagonist 4 (Figure 26). It was documented earlier, that RAM coinjection had reversed the protective effect provided by imidazole-based H3R
antagonists thioperamide, clobenpropit315, and ciproxifan446 as well as the nonimidazole-based H3R antagonist E159443 in the NOR test. Notably, acute systemic coinjection of RAM with DIZ (0.1 mg) or SAL in NOR failed to significantly alter the
time spent exploring the novel object observed in each group, indicating that RAM has
no memory modulating effect when administered alone.
In contrast, H3R antagonist 4 systemic administration post-training T1 and 30-45
minutes before T2 (2.5, 5, and 10 mg/kg) failed to exhibit any procognitive effect
against DIZ-induced LTM impairment (Figure 27). The earlier result agreed with a
former publication in which the non-imidazole based H3R antagonist E159 failed to
attenuate DIZ-induced LTM impairment applying the NOR task in rodents322. All
previously observed results in NOR noticeably designate that histaminergic H3Rs are
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deeply participating in neuronal circuits involved in the H3R antagonist 4-provided
STM-memory improving effects, but not in LTM-memory ameliorative effects. It is
essential to mention that cholinergic and glutaminergic neurotransmission is possibly
involved in both IAP and NOR response since both paradigms are impaired by a
choline receptor and NMDA receptor antagonists. DOZ, an acetylcholine esterase
inhibitor, was selected as a standard drug in both IAP and NOR since DOZ is clinically
utilized for memory-enhancing effects in Alzheimer’s and dementia patients447-449.
Numerous previous publications also documented the ameliorative effect of DOZ on
the memory impairment induced by DIZ in different behavioral tests443,445,450-452.
Furthermore, the inconsistencies detected for H3R antagonist 4 in PAP and NOR could
be justified with the variation of performs and evaluated elements of both models in
rodents. Since NOR measures the natural behavior of animals and benefits from their
unique interest in discovering their surroundings, and it does not involve a penalty or
compensation, whereas IAP is a fear motivated test which measures retrieval LTM in
rodents, and it includes punishment.
The EPM and OFT tests are a necessity for memory tests that require normal rodent
movement and regular anxiety levels. Any modulation of the tested compounds on
rodent’s anxiety levels or locomotion activity might alter or confound their activity in
the memory experiment. The EPM test relies on the innate propensity of rodents to
favor closed areas across open areas. Acute systemic administration of H3R antagonist
4 with the most procognitive provided effect doses (5 and 10 mg/kg) in IAP and NOR
30-45 minutes before EPM test failed to exhibit any alternation on anxiety parameters,
namely, the total time spent in open arms (Figure 28A) and the total number of entries
into open arms (Figure 28B). Also, H3R antagonist 4 (5 and 10 mg/kg) failed to display
any change in locomotion activity expressed as the total number of entries into closed
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arms (Figure 28C). The former results are in agreement with earlier studies, which
indicate the failure of several imidazole-based H3R antagonists (e.g., thioperamide and
clobenpropit) and non-imidazole-based H3R antagonist (e.g., DL77 and E159) to alter
locomotion or anxiety levels in rodents applying EPM322,453,454. However, DZP (10
mg/kg) exhibited anxiolytic effect when administered 30-45 minutes before EPM by
modifying both the total time spent in open arms and the total number of entries into
open arms, but it failed to alter the locomotor activity of the rats (Figure 28). DZP is a
benzodiazepine derivate, widely used for the management of human anxiety disorders,
and the earlier observation agreed with former publications, which indicated the
anxiolytic effect of DZP applying EPM in different rodent species305,455-457.
Moreover, H3R antagonist 4 at the dose (5 and 10 mg/kg) that showed the most
promising procognitive effect in PAP and NOR did not modulate the spontaneous
locomotion parameters in OFT; namely, the total distance traveled, the time spent in
the central arena as well as in the periphery, and the number of rearing and grooming
events during a 3-minute test in the OFT (Table 6). The former results are consistent
with previous studies in which imidazole-based H3R antagonists like thioperamide
and non-imidazole-based H3R antagonists, e.g., DL77, E159, and A-349821, failed to
modify the spontaneous locomotion activity of the tested rodent305,322,354,381,458.
Moreover, DOZ (1 mg/kg) failed to alter the spontaneous locomotion activity in OFT
in male Wistar rats, which was indicated in numerous previous studies as DOZ failed
to alter locomotion activity in C57BL/6J mice450,459 and Wistar rats305,322. The total
number of grooming is considered to signify the ability of tested animals in making
decisions correlated to anxiety-like behaviors460. The former observations indicated
that H3R antagonist 4 failed to modify anxiety levels or locomotion activity, implying
that the procognitive effect provided by H3R antagonist 4 was not correlated to
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influence emotional responses (anxiety) or modified spontaneous locomotion activity
which counted as confounding features when assessing memory-enhancing effects in
PAP and NOR.
Taken together, all the above-mentioned findings demonstrated that the non-imidazole
H3R antagonist 4 procognitive provided effects were mediated through histaminergic
neurotransmission and – at least partially – H2Rs activation.
Seizures happen due to irregular hypersynchronous uncontrollable brain emissions
from neurons, which ultimately result in permanent damage to the neurons and their
surroundings. There has been a massive development in epilepsy treatment in the last
decades. Though most of the antiepileptic compounds are focused on preventing
seizures, they are still unable to prevent the associated comorbidities (e.g., memory
impairment). That is why an ideal antiepileptic agent should be able to prevent both
the seizures and the associated memory impairments. Based on the previous observed
anticonvulsant effect in MES- and PTZ-acute induced seizure models and the
procognitive effect of the test compound H3R antagonist 4 applying IAP and NOR
behavioral tests, this part of the current study was designed to investigate the
ameliorative effect of H3R antagonist 4 on the simultaneous memory impairment
associated with PTZ-acute induced seizure and PTZ-kindling models in male Wistar
rats. In addition, to explore the probable mechanisms mediating the protective effect
of H3R antagonist 4, oxidative stress markers, AChE, neurotransmitters concentration,
and c-fos expression were examined.
Even though the temporary seizure lasts typically a minute or less in acute models, the
electrographic convulsive activity may stay beyond the behavioral seizures and will
consequently influence learning and memory. Here, in this part of the study the effect
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of brief seizures lasting 60–70 seconds was investigated by administering a single
convulsive dose of (PTZ, 60 mg/kg, i.p.).
The proconvulsant effect of PTZ (60 mg/kg) acute administration and the full
protective effect of H3R antagonist 4 (10 mg/kg) in PTZ-acute induced seizure model
were reported earlier.
Memory assessment was conducted applying IAP and EPM 24 h following PTZinduced seizures. IAP is one of the most widely used behavioral tests to investigate
memory impairments associated with PTZ acute as well as chronic seizures. On the
other hand, the EPM test is usually used to assess anxiety-related behaviors in
rodents461. However, based on the way of experimental conduct, EPM was shown to
provide convincing experimental face validity for the assessment of spatial memory
impairments associated with PTZ seizures in rodents462,463,133,464,131,49. The observed
results of the memory assessment in IAP indicated that PTZ (60 mg/kg) acute
administration led to a significant decrease of STL time, which indicates memory
impairment in tested;2 rats (Figure 29). The showed result is consistent with earlier
documented studies in which seizures associated with PTZ (60 mg/kg) administration
resulted in memory impairment applying IAP in male Wistar rats69,133,465. Moreover,
acute pretreatment with H3R antagonist 4 (5 and 10 mg/kg) mitigated the memory
impairment associated with PTZ-acute induced seizures, and no significant difference
was observed between the two doses (Figure 29). Furthermore, PTZ (60 mg/kg)
administration resulted in spatial memory impairment applying EPM in male Wistar
rats (Figure 30). Spatial memory impairment evoked by PTZ acute injection in EPM
was previously verified49,131,386,466. Furthermore, H3R antagonist 4 (5 and 10 mg/kg)
mitigated the memory impairment associated with PTZ-induced seizures, and no
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remarkable difference was detected between the two doses (Figure 30). The
procognitive effect of H3R antagonists was not documented before in PTZ-acute
seizure model. However, the ameliorative effect of thioperamide acute pretreatment
on memory impairment associated with SCO- induced learning deficits applying EPM
in mice was previously detected316. VPA was used as a positive control drug because
of its high antiepileptic effect and less harmful effect on memory impairment375. VPA
(300 mg/kg) acute pretreatment significantly attenuated the memory impairment
associated with PTZ-induced seizure model in both IAP and EPM (Figures 29 & 30).
The memory-enhancing effect of VPA was previously noted following PTZ-induced
seziures133,386; also, VPA attenuated memory impairment in a transgenic mouse model
of Alzheimer’s disease467. The procognitive effect of the promising compound H3R
antagonist 4 can be confounded in the test day by alternations in locomotion or anxiety
levels. However, similar STL and TLT times achieved by rats on the training day
between the different groups on IAP and EPM, respectively, demonstrate that these
nonspecific factors have been randomized between the groups.
Electrically and chemically acute seizure models allow only for rapid examination of
the potential anticonvulsant effect of the respective drugs, whereas PTZ-induced acute
model can only investigate the effect of brief seizures on the brain and the associated
comorbidities. However, chronic animal models were established to identify the
mechanisms underlying epileptogenesis and seizures production and to investigate the
emotional, cognitive, and memory impairments associated with epilepsy as well as
with the chronic use of several AEDs468. It is consensually agreed that the behavioral
deficits and memory impairment associated with repetitive seizures increase with the
severity and frequency of the convulsions469. PTZ-kindling model is an extensively
accepted animal model of TLE where repetitive sub-convulsive doses of PTZ reduced
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seizure threshold results in behavioral signs of convulsions imitating symptoms of
human TLE. In the next part of the study, the antiepileptic and procognitive
simultaneous effect of the potent non-imidazole based H3R antagonist 4 was
investigated applying PTZ chemical kindling model.
The results indicated that rats chronically treated with PTZ (40 mg/kg, i.p.) three times
a week for 12 injections showed decreased seizure threshold as indicated by increased
average seizure severity score when compared to naïve animals, and gradually
exhibited generalized tonic-clonic convulsions starting from 9th injection which
eventually resulted in kindled rats: 83.33% of the rats chronically treated with PTZ
were kindled, while 16.67% died (Figure 36). Moreover, the seizure score curve was
linear, signifying that PTZ easily penetrated the brain tissue. Therefore, it was
considered that repetitive sub-convulsive treatment of PTZ (40 mg/kg, i.p.) three times
a week for 12 injections effectively induced a chronic epilepsy-like condition. The
obtained results are in harmony with former studies in which PTZ was applied for
kindling in male Wistar rats470,471 and in different species of rodents388,468,470,472,473. At
the beginning of kindling, an antiepileptic and adaptive system is contrary to neuronal
hyperactivity by decreasing the inhibitory neuron activation threshold. Nevertheless,
a chronic and repeated administration of the chemical convulsant compound beats
these defense methods210. At the last stage of the kindling, an increase of the brain
sensitivity to PTZ results in significant damage to the antiepileptic mechanisms,
leading to chronic epileptization of the brain. Interruptions of balance between
inhibitory and excitatory systems cause the progression in the seizure score in PTZ
kindling model from 1st to 12th injections, which can begin from a partial numeral of
neurons till neuronal hyperactivity becomes satisfactory to the disruption of the
balance.
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Chronic pretreatment with H3R antagonist 4 (5 and 10 mg/kg, i.p.) 30-45 minutes
before each PTZ injection significantly prevented the kindling procedure and reduced
the average seizure score in most of the injections (Figure 36). No animals were
kindled or died when H3R antagonist 4 (5 and 10 mg/kg) was administered 30-45
minutes before each PTZ injection (Table 7). No significant difference was observed
in the average seizure score in each injection, kindling rate, and mortality rate between
H3R antagonist 5 and 10 mg/kg; so H3R antagonist 4 (5 mg/kg) was considered the
optimal dose in PTZ-chronic model. The protective effect of H3R antagonist 4 (5
mg/kg) was reversed when rats were co-injected with RAM, which indicated that the
H3R antagonist 4 provided protective effect was mediated through alternations of the
histaminergic neurotransmission (Figure 36). Notably, RAM co-injection alone with
PTZ or SAL failed to modify the kindling procedure or the average seizure score.
Previous studies had confirmed the earlier result as i.c.v injections of histidine,
clobenpropit, and carnosine (a precursor of histidine) before each PTZ injection had
significantly and dose-dependably extended the latency to myoclonic jerks and
generalized clonic seizures, and the protective effect provided was partially abrogated
with co-injection with RAM160,162,299,474. Also, thioperamide chronic i.c.v. treatment
significantly and dose-dependently delayed the onset of PTZ-kindling and reduced the
seizure score in PTZ-chronic model475. All the previous observations emphasize the
essential role of the histaminergic system in the antiepileptic provided protection
against PTZ- kindled model. VPA anticonvulsant effect observed in this study was
documented earlier in numerous publications in PTZ-kindling model103,133,464.
The PTZ kindling procedure was associated with memory impairment in both IAP and
EPM tests, as PTZ chronic treatment resulted in a significant decrease of STL time in
IAP and significantly prolonged TLT in EPM (Figures 37 & 39). The retrieval memory
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impairment accompanied by PTZ chronic treatment was formerly noted applying
IAP71,102,106,388,470,476-478. Besides, numerous former studies have documented the
spatial

memory

impairment

caused

by

PTZ

chronic

treatment

utilizing

EPM48,72,384,385,477,479. Moreover, memory impairment was noted in post chronic PTZ
treatment

applying

numerous

behavioral

tests

(e.g.,

mirror

water

maze

MWM)318,480,481. It was documented that memory impairment associated with the PTZ
kindling model mimicked human epilepsy482,483. The assessment of the procognitive
effect of the compound H3R antagonist 4 on the first day can be confounded by several
causes, like alternations in locomotion or anxiety levels. However, similar STL and
TLT times achieved by rats on the training day between the different groups on EPM
demonstrate that these nonspecific factors have been randomized between the groups.
These findings are in accordance with previous studies signifying behavioral
alternations and memory impairment accompanied by PTZ-induced kindling model,
which similarly mimics human epilepsy484.
Chronic treatment with H3R antagonist 4 (5 and 10 mg/kg) significantly mitigated the
memory impairment associated with PTZ- chronic administration (Figures 37 & 39).
The concomitant antiepileptic and procognitive effects were indicated in previous
studies in which thioperamide i.c.v injection resulted in simultaneous antiepileptic and
memory-enhancing effect475 in male Wistar rats applying MWM. Also, thioperamide
and JNJ-5207852 attenuated memory deficits associated with PTZ-kindling model
applying the IAP test in weanling mice485. No significant difference was observed in
the memory-enhancing effect between H3R antagonist 4 (5 and 10 mg/kg). The
procognitive effect of H3R antagonist 4 (5 mg/kg) was reversed when rats were coinjected with RAM in IAP and EPM tests, indicating that histaminergic
neurotransmission was involved in the provided procognitive effect by the test
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compound H3R antagonist 4 in PTZ- kindling model (Figures 38 & 40). Remarkably,
rats injected with RAM and PTZ or SAL alone failed to modulate the memory function
in each group. Based on the previous results, it is possible that H3R antagonist 4
prevented the kindling effect and mitigated the memory impairment induced by
repetitive injections of PTZ, as a result of antagonizing the H3 auto-receptors resulting
in brain histamine release, which is believed to react with and stimulate GABAA
receptors. The last assumptions were reinforced by earlier publications, which showed
that i.c.v. injection of histidine increased brain histamine concentration and exhibited
a memory-enhancing effect in PTZ-kindling model159,486. Moreover, histamine
administration was documented to potentiate GABA action on GABAA receptors487.
VPA (300 mg/kg) chronic treatment also attenuated the memory deficits associated
with PTZ-kindling model. The memory-enhancement effect associated with VPA was
recently documented in preclinical studies, in which VPA treatment attenuated
memory-impairment associated with PTZ-chronic model while PHT failed to provide
any effect48. Moreover, VPA mitigated SE-induced spatial memory; however, VPA
caused spatial memory impairment in normal rats108.
Oxidative stress is a foundation for several neurological and neurodegenerative
disorders, and it has been involved in the pathogenesis of epilepsy. Besides, it was
suggested that oxidative stress demonstrates as a result of the initial convulsion, which
can initiate the procedure of epileptogenesis and the consequent memory deficit due
to brain damage488. Oxidative stress has been accompanied by neuronal
hyperexcitation produced by different CNS diseases (e.g., epilepsy)489. Interestingly,
it was observed that antioxidant compounds had mitigated memory impairment in
different animal models490,491. Therefore, evaluating numerous oxidative stress
markers (e.g., MDA, GSH, CAT, and SOD) of tested animals in both PTZ -acute and
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-chronic models were required to assess the modifying effects of the prospective novel
and centrally acting H3R antagonist 4. Furthermore, and amongst all the brain regions,
the hippocampus has gained attention in the PTZ model as it contains several distinct
neuronal circuits related to seizure genesis. Moreover, previous publications indicated
that PTZ- induced acute seizures resulted in hippocampal morphological changes,
which returned to normal one week after492,493. Also, it was documented that the
hippocampus is involved in the epileptogenesis when tonic-clonic seizures appeared
post repetitive sub-convulsive administration of PTZ210.
In this study, PTZ acute injection led to elevated hippocampal levels of MDA and
reduced levels of GSH (Figures 31A & B). The decrease levels of GSH indicated that
during seizures, GSH levels were depleted fighting oxidative stress. Consequently, the
observed results revealed an elevated MDA level associated with a reduction in GSH
levels in the hippocampus 24 h post-PTZ-induced seizures, and these results were in
line with prior studies performed on numerous rodents, which indicated oxidative
stress in hippocampus and other brain regions69,131,133. On the other hand, natural
antioxidant enzymes in the brain, e.g., CAT and SOD, are typically used to scavenge
the elevated ROS and defend the hippocampus from convulsions. PTZ (60 mg/kg)
acute treatment had no significant changes in both hippocampal CAT and SOD levels
24 h following PTZ injection (Figures 31C & D). The aforementioned finding was
endorsed previously as SOD levels were noted to be not altered 24 h post-PTZ-induced
acute seizures494,495. However, another study indicated a decreased level of SOD 15
minutes after PTZ injection496, which can be explained by the time point difference of
brain collection in earlier studies from this study. The obtained observations revealed
no change in the hippocampal levels of CAT and SOD activities 24 h post seizures,
implying that an enhanced metabolic demand can be showed during the epileptic
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seizure, and CAT and SOD activities are not modified in this acute phase of PTZinduced seizure. Also, the unaffected CAT and SOD activity may be justified by the
simultaneous upregulation of CAT and SOD and the enzyme degradation caused by
oxidative stress. Elevated oxidative stress by convulsion activity raises the incidence
of oxidative brain damage, which might be the major reason of memory deterioration
associated with by PTZ seziures72. As, it was indicated previously that treatment with
antioxidant compounds had ameliorated the memory impairment by decreasing the
MDA levels, in traumatic brain injury rats model and Alzheimer's disease497,498,51.
Additionally, acute pretreatment with numerous antioxidant compounds had
attenuated the memory impairment associated with PTZ- induced seizure model131,133.
Pretreatment with H3R antagonist 4 (5 and 10 mg/kg) 30-45 minutes before PTZ
injection had mitigated the hippocampal oxidative stress associated with PTZ-induced
seizures (Figure 31). However, the observed antioxidant effect for H3R antagonist 4
was observed to be dose-independent as 5 and 10 mg/kg were statistically comparable
in the providing protective effect. The previous observation indicated the potential
antioxidant effect of H3R antagonist 4, which participates in the memory-enhancing
effect observed with acute treatment. The potential antioxidant dose-independent
effect of H3R antagonists was documented earlier as DL77 (10 or 15 mg/kg, i.p.)
provided similar antioxidant effects against the cerebellum altered oxidative stress
parameters in the VPA-induced autism-like behaviors in mice454. Also, it was
previously documented that ciproxifan and clobenpropit treatment attenuated
oxidative stress in experimental models of schizophrenia499.
The results indicated that the VPA acute treatment had mitigated the hippocampal
oxidative stress induced by PTZ seizures (Figure 31). Also, the antioxidant effect

169
provided by H3R antagonist 4 was comparable to VPA provided effect. The earlier
findings were previously noted as VPA acute pretreatment provided antioxidant and
memory-enhancing effect 24 h following PTZ-induced seizures133,386. Also, VPA
treatment showed an antioxidant effect in children with idiopathic epilepsy500.
The obtained results in PTZ-kindling model indicated that PTZ repetitive subconvulsive injections led to elevated hippocampal levels of MDA and reduced levels
of GSH, which was previously noted in former publications (Figures 41A &
B)72,384,392,477,501. Moreover, PTZ repetitive sub-convulsive injections led to decreased
hippocampal levels of both CAT and SOD enzymes (Figures 41C & D). The earlier
observation was noted previously following PTZ chronic treatment, which indicated
elevated hippocampal oxidative stress levels96,383,502. Elevated oxidative stress by
convulsion activity raises the incidence of oxidative brain damage, which might be the
major reason of memory deterioration associated with PTZ kindling72. As it was
indicated previously that treatment with antioxidant compounds ameliorates the
memory impairment by decreasing the oxidative stress levels, in traumatic brain injury
rats model and Alzheimer's disease497,498,51. The previous results indicated the H3R
antagonist 4 (5 and 10 mg/kg) chronic treatment significantly mitigated oxidative
stress evoked by PTZ chronic treatment, and the effect was dose-independent (Figure
41).
VPA chronic treatment 30-45 minutes before each PTZ injection had attenuated the
hippocampal oxidative stress levels associated with PTZ-repetitive injections (Figure
41). The latter outcome is in harmony with earlier studies in which the VPA
antioxidant effect was documented in rodents133,464,503. Furthermore, VPA exhibited
an antioxidant effect in epileptic children with high oxidative stress level504,505.
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According to all earlier observations, it was suggested that all consequences that occur
during oxidative stress are accompanied by the rise in the glutamatergic response that
promotes the neuronal hyperexcitability, which triggers epileptic seizures. Therefore,
VPA, by positively altering the antioxidant enzymes it regulates hyperexcitability
either directly or secondarily to the modulation of the glutamatergic response in
resulting epileptic seizures control.
The significant role of the central cholinergic system in memory and cognitive
functions is well established433. Learning and memory disabilities are associated with
changes in the cholinergic system function138, and it was observed that anticholinergic
compounds induced memory deficit in different behavioral tests506,507,508. Moreover,
various preclinical studies showed notably that H3R antagonists demonstrated an
exceptional element by their potential memory-enhancing effect225,425,509 and by
functioning also as hetero-receptors, which can adjust the release of numerous other
brain neurotransmitters, e.g., ACh, GABA, serotonin, and dopamine in diverse brain
regions510-512. AChE is considered an important therapeutic target, as reversible
inhibitors of AChE are being used as a memory enhancer in epileptic patients and other
neurodegenerative diseases148,513. Therefore, assessing the AChE activity of tested
animals in both PTZ acute and chronic models was needed to evaluate the modifying
effects of the prospective novel and centrally acting H3R antagonist 4 on the
cholinergic system.
The observed results indicated that acute PTZ-induced seizures failed to modify
hippocampal AChE activity (Figure 32). Nevertheless, previous studies indicated a
significant decrease of the brain AChE 24 h after PTZ seizures131,133, which can be
explained by the different brain regions tested. Hippocampus is tested in the current
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study while the cerebral hemisphere was tested in the previous studies, suggesting that
hippocampal AChE activity was not sensitive to acute PTZ-induced seizure model.
However, repetitive seizures induced by chronic PTZ administration resulted in
significantly increased of hippocampal AChE activity (Figure 42). Numerous previous
studies have endorsed the above finding in which PTZ kindling led to high levels of
AChE activity in different brain regions103,147,383,463. In accordance with former
indications, AChE is a well-recognized enzyme involved in memory impairment in
experimental animal models, as inhibition of AChE will cause a hippocampal ACh
release that mediates a memory improvement514. The AChE overexpression was noted
to be associated with memory deterioration515, and it was postulated that high AChE
activity could be explained as compensatory to cholinergic transmission modulation
induced by PTZ-chronic treatment516. The previous results indicated that H3R
antagonist 4 (5 and 10 mg/kg) restored hippocampal AChE activity to normal, and no
significant difference was noted in the modulating effect between the two doses
(Figure 42). It was also previously noted that AChE inhibitors could be used as
memory-enhancer compounds in epileptic patients517. Moreover, it was documented
that normalizing the abnormal brain of AChE activity in kindled rodents by numerous
compounds was associated with memory-enhancing effect in PTZ- kindling
model103,147,383,463. H3R antagonist 4 was not documented in its in vitro profile to have
AChE inhibitory effect368. However, the modulatory effect of H3R antagonist 4 on
AChE activity may be due to the anticonvulsant provided effect, which resulted in an
inhibition of the AChE overexpression or a prevention of the notable alternation of the
cholinergic transmission. Remarkably, the modulatory provided effect by H3R
antagonist 4 (5 mg/kg) was reversed with RAM co-injection, suggesting that the
modulatory effect of H3R antagonist 4 on hippocampal AChE activity is related to the
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anticonvulsant provided effect facilitated through the released histamine. Notably,
RAM injection with PTZ alone failed to modify the hippocampal AChE activity in the
PTZ group. But chronic treatment with VPA (300 mg/kg) 30-45 minutes before each
PTZ injection reduced the hippocampal elevated levels of AChE activity (Figure 42).
This result was previously noted, in which VPA treatment reduced the aberrant AChE
activity in different brain regions in PTZ-kindling model, and the modulated effect
was accompanied by mitigation of the associated memory impairment48,147,133. The
modulated effect of VPA on hippocampal AChE activity could be responsible for the
provided memory-enhancing effect. The previous finding is contrary to the elevated
hippocampal AChE activity observed with PHT treatment associated with memory
impairment in PTZ-kindling model48.
The above-mentioned results had proved that the anticonvulsant and memoryenhancing protective effects of H3R antagonist 4 were related to brain histamine
increased synthesis and release from histaminergic nerve terminals. On the other hand,
H3 receptors are also recognized as hetero-receptors plus auto-receptors in both the
central and peripheral nervous systems, controlling the release of numerous other
neurotransmitters. According to all previous observations on the postulated
mechanism of action of the test compound H3R antagonist 4 and the suggested
involvement of several neurotransmitters (e.g., HA, Ach, and GABA) in the provided
anticonvulsant and procognitive effect and for superior comprehension of the
connection between epilepsy psychophysiology and the associated memory deficits,
evaluating various hippocampal neurotransmitters concentration (e.g., HA, ACh,
GABA, and GLU) of tested animals in both PTZ-acute and -chronic models was
required to assess the modifying effects of the prospective novel and centrally acting
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H3R antagonist 4. Neurotransmitters perform an essential role in controlling neuronal
inhibition and excitation and providing natural behavior of memory function518.
The earlier results indicated that chronic repetitive systemic administration of PTZ (40
mg/kg) 3 times a week for 12 injections resulted in a significant decrease of
hippocampal HA concentration 48 h after the last PTZ injection (Figure 43A).
However, acute PTZ (60 mg/kg) injection failed to alter hippocampal HA
concentration 24 h after injection (Figure 33A). The observed results were consistent
with previous studies in which hippocampal HA levels were decreased in fully kindled
rats159,486. However, hippocampal HA concentration was not changed 10 days after the
last PTZ injection in PTZ-kindling model, which can be explained by the time
difference of brain collection519, suggesting that HA brain levels may be normalized
10 days after last PTZ injection. Furthermore, it was earlier noted that PTZ acute
treatment decreased hippocampal HA levels 30 minutes after PTZ injection474, while
in this study, HA levels were not changed 24 h after PTZ acute injection520. This
indicates that HA levels will go back to normal 24 h after PTZ injection, and this
implication was endorsed previously as HA levels were normal 8 h after PTZ acute
injection520. The anticonvulsant effect of the endogenous histamine was recently
confirmed, and the function of brain histamine in controlling seizure susceptibility had
been recognized157,158,291,520. Moreover, the vital role of the histaminergic neurons in
the convulsions pathogenesis was noted521,522. Likewise, the essential role of brain
histamine in learning and memory was recognized523, as i.c.v. injections of histidine
had improved the spatial memory impairment associated with PTZ-kindling model486.
Furthermore, the increase in HA release attenuated the memory impairment associated
with spontaneously hypertensive rat (SHR), an appropriate genetic model for ADHD.
Chronic treatment with H3R antagonist 4 (5 and 10 mg/kg) 30-45 minutes before each
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PTZ injection significantly restored the depleted hippocampal HA concentration, and
the effect was dose-independent (Figure 43A). The previous results are in agreement
with the proposed mechanism of action of the centrally acting H3R antagonist 4, which
antagonized H3 auto-receptors and enhanced brain HA synthesis and release298,405.
Previous in vitro studies indicated that thioperamide, ciproxifan, clobenpropit, A304121, and A-317920 application resulted in increased HA release in cortical brain
slices524. Besides, former in vivo experimental preclinical studies indicated the
influence of several H3R antagonists in increasing brain HA release (e.g., ciproxifan
increased cortical HA release in the SHR model525) and HA release in the anterior
hypothalamic in urethane-anesthetized rats526. Also, GT-2016 increased cortical HA
release in freely moving rats527, while thioperamide increased HA release in the
hypothalamus in rats528.. However, the provided enhancement effect of hippocampal
HA release by the H3R antagonist 4 (5 mg/kg) was partially abrogated when rats were
co-injected with RAM, confirming that the protective effect provided by H3R
antagonist 4 is facilitated through the histaminergic system (Figure 43A). As observed
earlier, RAM administration had blocked potassium-induced HA release in cortical
brain slices405. In addition, RAM administration abrogated both A-304121 and A317920 enhanced brain HA release effect in cortical brain slices524.
The results indicated that chronic repetitive systemic administration of PTZ (40
mg/kg) 3 times a week for 12 injections resulted in a significant decrease of
hippocampal ACh concentration 48 h after the last PTZ injection (Figure 43B).
However, acute PTZ (60 mg/kg) injection failed to alter ACh concentration in the
hippocampus 24 h after injection (Figure 33C). ACh plays a vital role in memory,
attention, and learning529, and it was implicated in kindling procedure, as repetitive
administration of muscarinic antagonists had decelerated the kindling development530.
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In addition, ACh has been involved in regulating brain GLU release throughout the
epileptic action531. The indicated results were in line with previous studies which
documented that PTZ-kindling model led to decreased concentration of hippocampal
ACh in male Wistar rats141,142,485,532 and zebrafish model128,533. In addition, it was noted
that hippocampal ACh levels would return to normal 30 days following the last PTZ
injection532. Nevertheless, other preclinical studies were contrary to the obtained
findings; in these studies, elevated ACh levels were noted 60 minutes after PTZ acute
administration130. However, ACh levels in the hippocampus went back to normal 90
minutes after PTZ acute injection, which can explain the results of unchanged
hippocampus ACh levels 24 h after PTZ acute injection. It was postulated that low
ACh brain concentration might facilitate the kindling progression532, and the reduction
of hippocampal ACh levels after PTZ chronic systemic administration can be related
to cholinergic neurons cell loss induced by chronic repetitive administration of PTZ.
This suggestion is further supported by a previous observation in which progressive
hippocampal neuronal cell loss was noted following PTZ-kindling model214,482. In
addition, low brain ACh concentration was associated with memory impairment in
PTZ-kindling model533, and it was documented that donepezil (AChE inhibitor)
treatment attenuated the memory impairment induced by PTZ-kindling model485. The
results indicated that PTZ-chronic model was associated with a reduction in
hippocampal cholinergic function, while no change was observed in PTZ-acute model.
All aforementioned findings endorsed the contribution of the cholinergic system to
both seizure induction and memory function.
Chronic treatment with H3R antagonist 4 (5 and 10 mg/kg) significantly restored the
depleted hippocampal ACh concentration. This indicated the modulating effect of H3R
antagonists 4 on cholinergic transmission function, and no remarkable difference was
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noted between the two doses (Figure 43B). The modulating effect of H3R antagonists
on brain ACh levels was previously noted523. Initial in vitro potassium-stimulated
tritium experiments proved the regulatory effect of H3 receptors, where thioperamide
increased ACh transmission from entorhinal cortex slices534. Then several in vivo tests
demonstrated the modulatory effect of numerous H3R antagonists on ACh
neurotransmission. JNJ-10181457 chronic administration significantly normalized
brain ACh levels in translational rat models of cognition535. Moreover, ABT-239,
GSK189254, and thioperamide increased hippocampal ACh release in Wistar rats307309

, while BF2.649 enhanced ACh release from prefrontal cortex in Wistar rats320, and

ciproxifan increased hippocampal ACh in freely moving rats536. The provided
modulating effect of the hippocampal ACh levels by H3R antagonist 4 (5 mg/kg) was
abrogated with RAM co-injection (figure 43B). This result is consistent with previous
documented observations in which RAM systemic administration prevented
potassium-induced cortical ACh release in rats317 and decreased electrically induced
hippocampal ACh release309. Likewise, RAM also reversed thioperamide enhanced
hippocampal ACh release in freely moving rats537. Notably, RAM injection with PTZ
alone failed to modify hippocampal ACh levels when compared with PTZ treated rats.
The previous results are in agreement with the proposed mechanism of action of the
centrally acting H3R antagonist 4, which is antagonizing H3 auto- and hetero-receptors
and enhanced brain HA and ACh release298,405.
The results indicated that chronic repetitive systemic administration of PTZ (40
mg/kg) 3 times a week for 12 injections resulted in a significant increase of
hippocampal GLU concentration 48 h after last PTZ injection (Figure 43D). In
contrast, acute PTZ (60 mg/kg) injection failed to alter GLU concentration 24 h after
injection in the hippocampus (Figure 33D). On the other hand, hippocampal GABA
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levels were not changed either 48 h after the last PTZ chronic injection nor 24 h after
PTZ acute injection (Figures 43C & 33B). It was indicated that kindling-induced
epileptogenesis is a consequence of an imbalance between inhibitory and excitatory
activities representing an enhanced glutaminergic or decline in GABAergic
transmission in both humans and animals. Also, most of the AEDs working through
GABAergic mechanisms effectively control seizures, they were unsuccessful in
attenuating the accompanied memory deficits in epileptic patients538. Consequently,
GABAergic transmission is not the most appropriate contributor to memory
deterioration associated with PTZ-kindling model. The finding on unaffected
hippocampal GABA levels 48 h after the last PTZ injection was documented earlier in
both hippocampus and cortex 10 and 17 days after the last PTZ injection in PTZkindling model519,539. Additionally, brain GABA levels were not changed 30 minutes
after the last PTZ injection540. It was also noted that GABA levels in several brain
regions, including the hippocampus, were not changed 4 weeks after kindling541, which
may explain the normal GABA levels 48 h after kindling. Hippocampal GABA levels
were also previously noted to be unchanged after PTZ acute injection542. Nevertheless,
the result from this study and the results of previous studies were inconsistent, as
GABA levels were decreased 4 h and 1.5 h following the last PTZ chronic injection in
the hippocampus and prefrontal cortex, respectively, which can be explained by the
time difference of brain collection and different brain region tested126,542. Furthermore,
it was previously noted that there is a persistent increase of hippocampal GABA
release through the kindling epileptogenesis543, which resulted in GABA decrease few
hours following the last PTZ injection, and the previous observations indicated that
reduction in GABA levels might go back to normal 48 h after kindling. GLU is the
main excitatory neurotransmitter and has been widely involved in synaptic plasticity

178
underlying memory function544. However, high abnormal levels of GLU associated
with epilepsy or Alzheimer’s diseases serve as a neurotoxic compound. Consequently,
high GLU brain levels may be a contributory cause of memory deficits accompanied
by uncontrolled seizures126. The earlier indication was supported by the observed high
GLU levels associated with schizophrenia patients545,546. Several former preclinical
experiments indicated high GLU levels in different brain regions after PTZ-kindling
model48,383,542,547,548, results which are harmonious with the results indicated in this
study. As documented earlier, GLU levels would go back to normal 4 weeks after
kindling541. However, low hippocampal GLU levels were noted 17 days following the
last PTZ injection, which was justified by the upregulation of GLU transporters519,549.
Also, hippocampal GLU levels were lower 1 h after PTZ acute injection, which can be
explained by different brain collecting time, indicating the GLU levels will be
normalized 24 h after PTZ acute injection542. The previous results indicated a swing in
the equilibrium among excitatory and inhibitory actions toward excitation in PTZkindling model, suggesting a high neuronal activity, which resulted in decreasing the
seizure threshold and inducing memory deficit. The neurotransmitters alternation
noted in this study on PTZ-treated rats, which includes the decline in hippocampal HA
and ACh levels and increased GLU levels when compared with SAL-treated rats,
might be responsible for the observed reduction in seizure threshold of the kindled rats
and the observed behavioral changes including memory impairment. Nevertheless,
neurotransmitters levels (HA, Ach, GABA, and GLU) were not changed 24 h
following PTZ acute injection, indicating that changes will occur during the epileptic
seizure, and the alternations will not be noticeable after 24 h. A different technique
that detects instant hippocampal neurotransmitters changes, e.g., microdialysis, will be
useful in PTZ-acute model.
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Chronic pretreatment of H3R antagonist 4 (5 and 10 mg/kg) 30-45 min before each
PTZ injection led to a significant dose-independent decrease of the abnormal
hippocampal GLU levels associated with PTZ kindling to be comparable to SAL group
(Figure 43D). The previous result is contrary to the proposed mechanism of action of
H3R antagonists, which usually are supposed to enhance neurotransmitter release, as
it was noted that thioperamide increased in vitro GLU release after necrosis mediated
by NMDA receptors in rat cultured cortical neurons550. However, the earlier
observation is in harmony with previous experiments in which ciproxifan decreased
the hippocampal 4-AP-evoked glutamate release in Sprague Dawley rats551. Moreover,
it was noted previously that thioperamide administration decreased the potassiuminduced GABA release in the prefrontal cortex552. Furthermore, it was postulated that
H3R antagonists could increase some neurotransmitters release through blockade of
H3Rs, a neurotransmitter which could prevent GLU release through its pre- or postsynaptic receptor552. The aforementioned result was endorsed with previous in vitro
experiments, in which HA use inhibited intracellular excitatory post-synaptic potential
in rat amygdala and dentate gyrus265,553. HA also decreased GLU release in rat dentate
gyrus554, suggesting that the released HA by H3R antagonist 4 can attenuate the
abnormal induced hippocampal GLU levels by chronic PTZ administration. However,
co-injection with RAM failed to reverse the modulating effect of H3R antagonist 4 (5
mg/kg) at hippocampal high GLU levels (Figure 43D), suggesting that the
hippocampal GLU modulating effect provided by H3R antagonist 4 is not only
mediated through histaminergic transmission and that another possible mechanism
may be contributed. It can be suggested form earlier findings that H3R antagonists
may modify neurotransmitters release differently under normal and stimulated
conditions552. This explains the inhibitory effect of H3R antagonist 4 on the high PTZ-
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evoked GLU release, and this modulate effect may be mediated through H3 heteroreceptors. Another point to add is that RAM injection with PTZ alone failed to modify
GLU levels in PTZ group. According to the aforementioned observations, it was
suggested that reducing the abnormal hippocampal GLU levels is at least partially
involved in the antiepileptic and memory-enhancing effect of H3R antagonist 4 in the
PTZ kindling model. The results indicated that VPA chronic treatment (300 mg/kg)
30-45 minutes before each PTZ injection significantly restored hippocampal ACh
levels and decreased high abnormal hippocampal GLU levels (Figure 43). An earlier
study indicated unchanged GABA levels with VPA chronic treatment when compared
with PTZ and SAL treated rats in PTZ-chronic model555, which is consistent with the
observed result. Moreover, decreased hippocampal GLU levels were noted with VPA
chronic treatment in PTZ-kindled rats556. It was also noted that VPA treatment alone
caused lower brain GLU levels557. The modulation effect of VPA treatment on brain
ACh levels was documented previously, wherein VPA administration restored the
depleted ACh levels in streptozotocin-induced mice, and the alternation on ACh levels
was associated with memory improving effect558. The amendment effect of VPA on
the primary amino acid neurotransmitters undoubtedly plays an essential part in the
antiepileptic and memory-enhancing provided effect. The indicated findings were in
agreement with numerous comparable results of chronic VPA treatment with regard
to neurotransmitters levels, indicating its contribution to the provided antiepileptic and
memory-enhancing effect557,95,558. Several other well-recognized AEDs, e.g., as PHT
and PB, prevented the progression of kindling but failed to attenuate the accompanied
memory impairment in contrast to VPA48,559. Nevertheless, VPA prevented kindling
associated with an alleviation of memory impairment in PTZ-kindling model.
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It was noted that comorbidities accompanied by epilepsy were not only related to a
single complication. There is a collective matrix of oxidative stress, neurochemical
changes, and histological alterations in the brain that cooperatively provoke
comorbidities59,560,561. The transcription factor c-fos belongs to the IEG (immediate
early gene) family that is rapidly activated after numerous cellular inducements. IEGs
are able to detect stimulated neurons of seizure activity and other excitatory
provocations. Besides, IEGs is believed to be implicated in the neuronal excitation and
to perform an essential role in the kindling process development562,563. The basal
expression of brain c-fos is low; however, c-fos was noted to be activated rapidly in
reaction to many inducements such as seizures induction564, resulting in c-fos planned
use as a valuable indicator of neuronal activity562,565. It was documented that c-fos
activation was highly expressed in the hippocampus upon the development of tonicclonic convulsions (seizure 4-5) in both PTZ-acute and -chronic models but not with
less seizure scores209,566,567 implying that only high neuronal induction is needed to
boost c-fos expression in the hippocampus; c-fos high expression is a widely stated
phenomenon that highlights the molecular alternations occurring during the process of
epileptogenesis. Consequently, analysis of the expression of c-fos in the hippocampus
2 h after PTZ (60 mg/kg) acute administration in PTZ-acute model and 48 h after the
last PTZ injection in PTZ-chronic model was used to examine hippocampal neuronal
activity. The c-fos expression was studied 2 h after PTZ-acute model because it was
documented earlier that the expression of c-fos protein reached its highest levels,
nearly around 2 h after PTZ injection567. The results indicated that c-fos was highly
expressed in the hippocampus following both PTZ-acute and -chronic models,
indicating hippocampal neuronal excitation (Figures 34, 35, 44, & 45). The previous
findings were supported in numerous previous experiments in which c-fos was highly

182
activated in the hippocampus 2h after PTZ-acute administration in rodents567-569 and
zebrafish570. In addition, it was documented that c-fos was highly expressed in the
hippocampus in PTZ kindled rats395,566,568,571. As noted earlier, PTZ-induced seizures
effect is related to activation of excitatory amino acid receptors, which also contribute
to the induction of c-fos both in vitro and in vivo572-574. According to the abovementioned findings of the essential role of the hippocampus in learning and memory
process, and the noted memory-enhancement effect associated with decreasing
hippocampal c-fos expression in earlier study568. The PTZ-induced hippocampal
excitability can be correlated to the associated memory deficits. Moreover, seizureinduced c-fos expression has been at least partially related to increased release of GLU
in the brain575,576. Likewise, the use of NMDA receptor antagonist decreased the
seizure-induced c-fos expression when used with the convulsant agent but not alone577,
indicating the correlation between the hippocampal abnormal GLU releases and c-fos
expression observed in this study. Furthermore, attenuating of c-fos mRNA expression
is related to the drug alleviated effects on seizures, epileptogenesis, and/or epilepsy563.
It can be suggested the c-fos high expression is correlated with seizures development,
kindling procedure, and its associated memory-impairment.
Treatment with H3R antagonist 4 (5 and 10 mg/kg) 30-45 minutes before PTZ
injection mitigated hippocampal c-fos expression in both PTZ-acute and -chronic
models (Figures 34, 35, 44, & 45). The observed finding was previously noted,
showing that ciproxifan alleviated the stress‐evoked increase of cortical c-fos
expression in mice and attenuated the associated memory deficits578. Besides, it was
documented that thioperamide mitigated haloperidol-evoked striatum c-fos expression
in rats579. However, the aforementioned result is contrary to an earlier study which
noted that ciproxifan increased c-fos expression when administered alone536. This can
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be justified by conflicting H3R antagonist effects on c-fos expression under healthy
and stimulated conditions similar to the abovementioned finding on GLU. The
modulated effect of H3R antagonist 4 (5 mg/kg) in PTZ-kindling model was reversed
with RAM co-injection indicating the involvement of the histaminergic system in the
provided neuroprotective effect. Based on the earlier observations, it was suggested
that the neuroprotective effect of H3R antagonist 4 in PTZ-acute model can be related
to the H3R antagonist 4 inhibition of seizures. The anticonvulsant effect of H3R
antagonist 4 was indicated earlier in this study, and this is not to be reversed with RAM
co-injection. Suggesting the involvement of other neurotransmitters in the provided
effect, e.g., GLU, which also was indicated to be related to c-fos expression
increase580. While in PTZ-chronic models, the neuroprotective effect of H3R
antagonist 4 on c-fos expression can be related to its antiepileptic and memoryenhancing effect through antagonizing the H3Rs resulting in increased HA release and
lowered the excitatory neurotransmission GLU levels. The results indicated that VPA
acute and chronic treatment (300 mg/kg) significantly reduced hippocampal c-fos
expression following PTZ systemic administration (Figures 34, 35, 44, & 45). As noted
earlier, VPA attenuated flurothyl-induced hippocampal c-fos expression in male
Wistar rats581, indicating the neuroprotective effect of VPA.
Findings from this part of the study showed that chronic treatment with H3R
antagonists (H3R antagonist 4) displayed high protection against PTZ-induced
kindling, behavioral alternations, oxidative stress, neurochemical modifications, and
neuronal activation. All these results highly propose that the anticonvulsant and
memory-enhancing effects are owed to oxidative stress mitigation, reduction of AChE
activity, enhancement of HA and ACh release, decrease of GLU abnormal levels, and
attenuation of hippocampal c-fos expression through auto- and hetero-H3Rs inhibition
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(Figure 50). Even though ordinary AEDs inhibited seizures, they usually do not
provide memory-enhancing and neuroprotective effects. Numerous treatment
approaches have been established for epilepsy therapy; however, they are not
protective against epilepsy-induced cognitive impairments582. Further investigations
are needed in preclinical and clinical developments to provide superior scientific
support for developing H3R antagonist 4 as a therapeutic approach for epilepsy
treatment and attenuation of epilepsy-associated comorbidities.
SE is a life-threatening condition of continuing seizure activity related to cognitive
dysfunction, elevated mortality rate, and comorbidities, necessitating instantaneous
involvement with appropriate pharmacological treatments583-586. SE is classified as an
ongoing seizure for more than 30 min or numerous seizures without complete
recuperation of consciousness in any of them587. Initial pathophysiological insults of
SE in rodents contain severe neuroinflammation, excessive oxidative stress, selective
neuronal degeneration, and interruption of the brain-blood barrier, resulting in
consequent memory deficiencies588,589. In the last part of this study and as a
continuation of the above-mentioned investigations, the protective effect of the nonimidazole based H3R antagonist 4 was examined in the PLC-induced SE model.
Furthermore, the effect of H3R antagonist 4 on the hippocampal oxidative stress
markers as well as AChE activity of tested animals was assessed. PLC-induced seizure
model characterized by electroencephalographic waves as well as oral and
morphological results that imitate the one observed in TLE. Thus, the PLC-induced
seizure model has been accepted as an animal model with resemblance in features to
TLE129,590. The results indicated that all treated rats with PLC (400 mg/kg) exhibited
behavioral modifications and seizures, which were developed within 30 min to SE
(Figure 46). These findings were endorsed by earlier studies591-593. PLC is a muscarinic
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cholinergic agonist that induced seizures through stimulation of the M1 muscarinic
receptor subtype. As noted earlier, M1 receptors knocked out rodents that failed to
exhibit convulsion in reaction to PLC190. Moreover, several cholinomimetics
compounds were documented to provoke convulsions and once systemically
administered or directly injected into the brain594,595. Furthermore, treatment with
atropine, a muscarinic antagonist, inhibited PLC-induced SE191. Likewise, invitro
experiments

indicated that PLC application resulted in an imbalance between

inhibitory and excitatory transmission in cultured hippocampal neurons, causing the
initiation of SE192. Similarly, in vivo experiments supported hippocampal GLU release
after PLC administration193. Considerable evidence currently endorsed the proposal
that seizures are initiated by M1 receptors and are maintained by NMDA receptor
stimulation193,194. In this study, scopolamine-methyl nitrate an antimuscarinic
compound was used to minimize the peripheral cholinergic PLC-induced symptoms,
including tremor, salivation, piloerection, and diarrhea. As previously noted, this
compound was used to reduce the peripheral cholinergic evoked signs with no effect
of seizures induction596,597. Treatment with H3R antagonist 4 (5 and 10 mg/kg i.p) 3045 minutes before PLC injection mitigated PLC-evoked SE (Figure 46). Nevertheless,
H3R antagonist 4 (2.5 and 15 mg/kg) failed to provide any protective effect against
PLC-induced SE, suggesting a dose-dependent effect of H3R antagonist 4 in PLCinduced seizure model. This was previously remarked in this study in both electrically
and chemically induced seizure models. Another important point is that H3R
antagonist 4 (5 and 10 mg/kg i.p) anticonvulsant provided effect in the PLC-induced
seizure model was considerably higher compared to the upper dose (15 mg/kg, i.p.) or
the lower dose (2.5 mg/kg, i.p.), indicating that the optimal protection was detected
when the H3R antagonist 4 was applied at the doses 5 or 10 mg/kg: The highest
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protection remarkable effect showed at 10 mg/kg, and the effect of H3R antagonist 4
(15 mg/kg) was off target. Nevertheless, unsatisfactory antagonistic of H3R antagonist
4 with H3Rs was noted with the lower dose (2.5 mg/kg). The dose-dependency effect
observed for H3R antagonist 4 was indicated earlier, applying different acute seizure
models374. The aforementioned findings of dose-dependency are in line with former
experimental outcomes performed on several rodents305,443,598,599. In addition, the
anticonvulsant protective effect of H3R antagonist 4 (10 mg/kg) was abolished when
rats were co-injected with RAM or ZOL but not with PYR, indicating that the
anticonvulsant H3R antagonist 4 provided effect is facilitated through alternation of
the central histaminergic neurotransmission and to some level with interaction of the
released HA with post-synaptically located H2Rs but not H1Rs (Figure 47). The
previous implied mechanism underlying the anticonvulsant effect of H3R antagonist
4 is also in agreement with former preclinical observations in censoriously ill and polymedicated patient in which high doses of several centrally acting H2R antagonists
drugs promoted the development of convulsions600-602, indicating the involvement of
H2R antagonism, and, consequently, brain histaminergic neurotransmission in the
seizure promotion in PLC-evoked SE model. It is notable that RAM and ZOL, when
administered alone with PLC, did not provide significant changes when compared to
PLC-treated rats. According to our information, no previous experiment investigated
the effect of H3R antagonists in PLC-induced seizure model; however, the protective
effect of H3R antagonists had previously been endorsed in different acute and chronic
models603. Thus, inhibition of H3Rs by the test compound H3R antagonist 4 would
increase the neuronal release of brain histamine and modulate other neurotransmitters
releases, including GLU supplying the anticonvulsant protective effect in the PLCinduced seizure model. Interestingly, systemic pretreatment with the traditional
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antiepileptic drug DZP (10 mg/kg, i.p.) 30 minutes before PLC administration
inhibited the convulsions and SE occurrence evoked by PLC (Figure 46), and this
outcome was in agreement with former experimental observations

604-606

. DZP is a

traditional antiepileptic drug that mainly produces its antiepileptic effect due to the
pharmacological activities of modifying the GABAA–benzodiazepine receptor
complex facilitating GABA-mediated inhibitory neurotransmission in the CNS607-609.
Several preclinical studies have documented that oxidative stress was associated with
PLC-induced SE, which resulted in elevated ROS brain levels and neuronal injury
81,399,488,610

. Consequently, and according to the above-mentioned contribution of

oxidative stress in the initiation and development of epilepsy, assessment of
hippocampal numerous oxidative stress markers (e.g., MDA, GSH, CAT, and SOD)
in treated animals was essential to investigate the alleviating effect of the potential and
centrally acting compound H3R antagonist 4. Once again, the hippocampus has earned
the attention in the PLC-evoked SE model as it contains abundant prominent neuronal
circuits connected to seizure genesis, and it is exceptionally vulnerable to PLC-induced
neuronal damage. Besides, the hippocampal neuronal damage is considered the
hallmark of TLE611. The results indicated that PLC acute treatment is associated with
hippocampal elevated MDA levels and reduced GSH levels 1 h after PLC-induced SE
in tested rats, and these findings are in line with earlier preclinical experiments
conducted on different rodents (Figures 48A & C)398,612-614. On the other hand, CAT
and SOD, the natural antioxidant enzymes levels in the hippocampus, were not altered
1 h after PLC-evoked seizures, and this finding is inconsistent with an earlier
observation (Figures 48E & F)615. However, several previous outcomes were contrary
to the previous results in which CAT levels were reduced 6 h following seizure
induction with no change in SOD levels399,614 . Also, different studies exhibited
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reduced levels of CAT and SOD in the hippocampus 24 h following seizures593,613.
This can be explained by different brain collection time, indicating that an enhanced
metabolic requirement can be showed during the epileptic seizure, and CAT and SOD
activities are not modified during this acute phase of PLC-induced seizure. It is
interesting to note that acute treatment with H3R antagonist 4 (5, 10, and 15 mg/kg)
mitigated oxidative stress in the hippocampus of tested animals (Figures 48A & C),
demonstrating the antioxidant potential of H3R antagonist 4. Nonetheless, the
remarked antioxidant effect of H3R antagonist 4 was dose-independent at 5, 10, and
15 mg/kg provided effects were statistically not different. The latter finding of dose
independence is in agreement with an aforementioned indication in which the H3R
antagonist DL77 (10 or 15 mg/kg, i.p.) delivered equivalent antioxidant effects in the
hippocampus of VPA-induced autism-like behaviors in mice454. Surprisingly, H3R
antagonist 4 (15 mg/kg) exhibited a protective effect against hippocampal oxidative
stress caused by PLC-induced seizures despite its failure in inhibiting PLC-induced
SE. But the antioxidant provided effect with H3R antagonist 4 (10 mg/kg) was
reversed when rats were co-injected with RAM, implying the participation of H3R
histaminergic neurotransmission in the presented alleviating effects on the levels of
MDA and GSH (Figures 48B & D). The latter outcome is in line with a recent study
in which RAM co-injection abrogated DL77 modulated effect on oxidative stress in
VPA-induced autism-like paradigm in mice454. However, RAM injection with PLC
alone failed to provide any remarkable alternation on MDA and GSH levels in
comparison to the PLC group. Another point is that DZP acute pretreatment mitigated
PLC-induced oxidative stress in the hippocampus. The latter observation is in
agreement with earlier studies in which DZP mitigated stress-induced oxidative stress
in male Wistar rats616 and attenuated PLC-induced oxidative stress in animal model617.
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Thus, a strong relationship was documented among the cholinergic neurotransmission
and epilepsy. The contribution of cholinergic neurotransmission to the PLC-induced
seizure model has been well recognized592,618. Elevated hippocampal cholinergic
levels due to neuronal hyperactivity were noted in PLC-induced seizure model619,
which could result in neuronal damage during PLC-induced seizures620. Consequently,
hippocampal AChE activity levels were investigated in PLC-treated rats following SE.
The results indicated low levels of AChE activity in the hippocampus 1 h following
PLC-induced SE in treated rats, signifying probable high acetylcholine levels in the
hippocampus (Figure 49). The latter observation is in line with several experiments
indicating hippocampal reduced levels of AChE activity following PLC administration
indicating a critical association of hippocampal AChE activity and pathogenesis of
PLC-induced SE397,621,622. It was suggested that reduced levels of AChE activity could
be due to the regulation of the abnormally elevated levels of the ACh in the cholinergic
synapses during SE, which cause extreme stimulation and activation of muscarinic and
nicotinic receptors107,397. Moreover, brain decreased AChE activity were detected in
several chemically and electrically acute-induced seizure models131,133,623. However,
the elevated ACh levels will be reduced at delayed time points as documented earlier
in a previous study, in which DOZ had augmented the neuronal damage and memory
deficits associated with PLC-induced SE when administered before PLC injection.
Nevertheless, DOZ mitigated the neuronal destruction and cognitive deficiencies when
administered 3 weeks after PLC-induced repetitive seziures624, confirming the critical
role of the modulated cholinergic neurotransmission in the initiation and progression
of the PLC-evoked SE model.
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However, pretreatment with H3R antagonist 4 failed to alter the hippocampal AChE
activity in treated rats, indicating the lack of influence of acute treatment of H3R
antagonist 4 on the abnormal ACh levels in the hippocampus during PLC-induced SE.
Altogether, the observed results of PLC-induced SE model demonstrate that the novel
non-imidazole-based H3R antagonist 4 inhibited PLC-induced convulsions, SE, and
mortality in the tested animals which were partially reversed with the CNS-penetrant
RAM and ZOL, signifying a connection between the brain histaminergic
neurotransmission and the H3R antagonist 4 provided effect. Moreover, the detected
finding indicated the significant involvement of oxidative stress in the progression
and/or maintenance of seizure activity, and H3R antagonist 4 significantly decreased
the susceptibility of tested animals to PLC-induced SE. But a series of further seizure
test models with distinct species is still necessitated to further comprehend the present
outcomes noted for H3R antagonist 4, and to improve the translational value of its
prospective applicability in the therapeutic management of SE.
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Chapter 6: Conclusion

In conclusion acute systemic administration of novel and highly affine H3R
antagonists (1-16) exhibited various anticonvulsant effects in a range of acute induced
seizure models via brain histaminergic neurotransmission. H3R antagonist 4 dosedependently showed the most promising anticonvulsant activity in MES- and PTZinduced seizure models. Furthermore, acute systemic administration of H3R
antagonist 4 dose-dependently displayed a procognitive effect in DIZ-induced amnesic
effect applying both IAP and NOR behavioural tests without modulating locomotion
and anxiety-like behaviors of tested animals. These findings enhance further the
potential efficacy of H3R antagonists in the treatment of epilepsy and other
neuropsychiatric diseases characterized by cognitive deficits.
Acute H3R antagonist 4 significantly provided simultaneous anticonvulsant and
procognitive effect by alleviating the memory impairment associated with PTZ acute
model, and displayed antioxidant and procognitive effect.
Chronic H3R antagonist 4 significantly mitigated the kindling development and
attenuated the memory impairment associated with PTZ chronic treatment. Also,
chronic H3R antagonist 4 modulated oxidative stress and neurochemical levels in
PTZ-kindled rats. Moreover, chronic H3R antagonist 4 showed neuroprotective effect
by reducing c-fos protein expression in PTZ-kindled rats However, further
investigations are needed in preclinical and clinical developments to provide superior
scientific support for developing H3R antagonist 4 as a therapeutic approach for
epilepsy treatment and attenuation of epilepsy-associated comorbidities (Figure 50).
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Furthermore, H3R antagonist 4 inhibited PLC-evoked SE, and also exhibited
antioxidant effect. However, a series of further seizure test models with distinct species
is still necessitated to further comprehend the present outcomes noted for H3R
antagonist 4, and to improve the translational value of its prospective applicability in
the therapeutic management of SE.

Figure 50: Schematic graph describing the effect of H3R antagonist 4 in PTZkindling model.

6.1 Limitation of the study
•

Further experiments are essential to clarify the other probable mechanisms by
which H3R antagonist 4 elicited its anticonvulsant effect in PTZ-induced
seizures.

•

Additional abrogative studies are needed to explain the mechanisms behind the
provided procognitive, antioxidant, and neuroprotection effects of H3R
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antagonist 4 observed in acute PTZ-induced seizure as its anticonvulsant effect
was not facilitated through the histaminergic neurotransmission.
•

The available ELISA/colorimetric assay was utilized to detect the overall
content of hippocampal levels for several neurotransmitters of interest.
However, other techniques, e.g. microdialysis technique, should be developed
as it measures the instant levels of released neurotransmitters, and therefore, is
considered to be a more reliable and accurate technique.

•

Memory functions post SE seizures should be studied, as the current study
examined only the anticonvulsant effect of H3R antagonist 4 in PLC-induced
SE and its ability to mitigate SE incidence.

6.2 Future direction
Future studies are essential to investigate the anticonvulsant protective effect of H3R
antagonist 4 when administrated to fully kindled rats or to PLC-epileptic rats, and to
evaluate the procognitive effect of H3R antagonist 4 when treated post seizures
incidence. Altogether the obtained results opened a novel therapeutic window for
managing memory deficits associated with epilepsy. However, the examination of the
anticonvulsant effect of H3R antagonist 4 on spontaneous unprovoked seizures
occurrence in epileptic transgenic rodents, and the estimation of protective effect of
H3R antagonist 4 on other associated comorbidities with epilepsy.
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